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ABSTRACT 
Coronary angiography (CA) is a common interventional diagnostic procedure that is 
used to diagnose cardiovascular conditions such as heart attack, heart failure and angina. 
Breast dose in CA is conventionally believed to be low and breast cancers arising from CA 
procedures are not considered to be a high risk outcome.  
Recent changes in the International Commission on Radiological Protection (ICRP) 
recommendations suggest the radiosensitivity of the breast was greater than previously 
perceived. This was based on epidemiological, biological and physical evidence from data 
accumulated since 1990. This prompted the ICRP to increase the tissue weighting factor (wT) 
for the breast.   
During a CA procedure the primary X-ray beam may be intercepted by the breasts 
depending on the tube angulation chosen. However most of the primary X-ray beam is 
attenuated by tissue in the torso before reaching the breasts. Thus it is the scattered radiation 
that is more likely to be absorbed in the breast. The purpose of the study is to quantify breast 
dose to reassure patients and staff that these understandings still apply. 
A combination of measurements and simulations were used to estimate absorbed 
breast dose. Gafchromic® XR-QA2 film was used to measure breast dose placed inside the 
RANDO® phantom in a series of controlled experiments. The RANDO® is an 
anthropomorphic phantom commonly used for dosimetry investigations. Gafchromic® 
XR-QA2 film is a radiochromic film that changes colour when irradiated.  
Simulation is commonly used and readily available. The PCXMC software was used 
in this study to perform the simulations. It uses a mathematical phantom and the Monte 
Carlo method. 
The results achieved indicate the XR-QA2 film is a suitable method for measuring 
breast dose provided the accumulated dose is above the minimum measurable dose for the 
XR-QA2 film. The experiments yield additional information regarding left-right asymmetry 
of breast dose in CA procedure. The Gafchromic® film was able to provide two-dimensional 
spatial distribution and demonstrate the asymmetric dose distribution to the breasts. This 
was an advantage over TLDs, which only provide a single data point used to infer breast 
dose as per other experiments from the literature. PCXMC simulation also gives no spatial 
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dose information, assigning a breast dose with no distinction from left and right breast. It 
also enabled us to evaluate the quality of results predicted by simulation by direct 
comparison with measurement.  
The experiments revealed two contributing factors to breast dose 1) the fraction of 
breast intercepted by the primary X-ray beam and 2) the radiological beam path from the X-
ray tube focus to the breasts. Thus, the breast dose is sensitive to the tube angulation. At 
large angles, where the physical path length and radiological path are greatest, the radiation 
dose from a direct beam is similar to that from scattered radiation. The distinction of breast 
dose behaviour between LAO-RAO axis and CAU-CRA axis can be explained by the 
differences in radiological path length and anatomy of RANDO®. For combined tube 
angulations, this study showed LAO-RAO dependence when used in conjunction with a 
CRA component but not those with a CAU component. 
Normalised breast dose conversion coefficients were determined in a series of single 
and combined tube angulations. The application of a set of clinical tube angulations from 
those determined in the experiment showed the normalised breast dose was 0.12 mGy/ 
Gy.cm2.  
This investigation also showed the complexity of dose contribution to the breasts and 
the posterior skin in the Gafchromic® film analysis for a mock CA procedure. The mock CA 
procedure provided a net dose to the breasts and was used to verify the suitability of the 
breast dose conversion coefficients from the experimental results for the combined tube 
angulations. The breast dose from a mock CA procedure was measured to be 1.7 mGy and 
the normalised breast dose per mock CA procedure was 0.12 mGy/ Gy.cm2. This agreed 
with the results from the series of single and combined tube angulation experiment. 
Predictions from the simulation showed that in about 50% of cases it underestimates 
the breast dose compared to measured dose. Predictions are convenient but differences in 
geometry can lead to dose differences. Users of simulation software need to take care of 
geometry and patient size differences to avoid gross underestimates or overestimates. 
The variations in breast dose from the experiment, simulations and mock CA 
procedure can be interpreted as possible variations in real patients. This is because the 
geometric and anatomical differences between these three gave an indication of these 
variations. 
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Overall, the asymmetry of breast dose distribution depends on the geometry of the 
setup. From the experiment, the right breast dose was always greater than the left, whereas 
for the mock CA procedure it was vice versa. This highlights the importance of the fraction 
of breast intercepted by the X-ray beam in relation to the patient setup relative to the heart.  
From a radiation protection prospective, a breast dose of less than 1 mGy is very 
small and the actual risk from such a small breast dose is extremely low. This study provides 
a method to assess breast dose in CA for a given tube angulation. Staff can simply apply the 
normalised breast dose conversion coefficients from this study and multiply by the DAP to 
estimate breast dose. A simple model was developed that can be used to convert 
measurements from the Gafchromic® XR-QA2 film into absorbed dose for clinical 
applications. Institutional medical physicists could adopt the process described in this study 
to investigate breast dose or other organs of interest.  
It is hoped that this study will promotes awareness to clinicians in relation to the 
effects of geometric variations to breast dose and help those interested in breast dose in the 
cardiac catheterisation laboratory use this method to assess radiation dose.  
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ABBREVIATIONS 
ABC    Automatic Brightness Control 
CA   Coronary Angiography or Coronary Angiogram 
BSF   Back Scatter Factor CAUD /CAU   Caudal CRAN /CRA  Cranial  
CT   Computed Tomography 
DA   Digital Acquisition mode 
DAP   Dose Area Product 
ESD   Entrance Skin Dose 
FPD   Flat Panel Detector 
FSD   Focus to Skin Distance 
ICRP   International Commission on Radiological Protection 
ICRU    International Commission on Radiation Units and Measurements 
KVP   Peak Kilovoltage 
LAO    Left Anterior Oblique 
LET   Linear Energy Transfer 
MBH    Multi-Beam Hardening filter 
MESD    Maximum Entrance Skin Dose 
PA   Posterior Anterior 
RAO    Right Anterior Oblique 
ROI    Region of Interest 
SID   Source to Image receptor Distance 
TLD   Thermo Luminescent Dosimeter   
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1. INTRODUCTION 
The leading cause of death in Australia is cardiovascular disease. Every year many 
Australians are diagnosed and treated for cardiovascular conditions such as heart attack, 
heart failure, and angina. According to the Australian Institute of Health and Welfare 
(AIHW) report published in 2011, heart problems affected 3.5 million Australians. In 
2007-08, a total of 110,611 coronary angiography procedures were performed in Australian 
hospitals, of which 66% are males and 34% are females [1].  
Coronary angiography (CA) is an interventional diagnostic procedure that allows the 
cardiologist to use X-rays to visualise and identify normal, narrowed or obstructed blood 
vessels to the heart muscle. It involves inserting a thin hollow tube called a catheter into the 
femoral artery of the groin to navigate the blood vessels to the coronary artery. This 
procedure is performed under fluoroscopy, where the cardiologist views a continuous 
image of the motion of internal structures while the X-ray tube is energized [2]. A 
radio-opaque contrast agent is injected into the vessel, and any blockage or stenosis will be 
revealed on the X-ray image. If a blockage is located, the cardiologist will proceed to the 
therapeutic intervention procedure known as an angioplasty. This may involve the use of 
intravenous balloons to expand the clogged vessel and allow blood flow or stents to hold the 
vessel open. Restenosis is when the treated vessel becomes blocked again. The chance of a 
restenosis with balloon angioplasty alone is 40% and for stents it is reduced to 25% [3]. Both 
CA and angioplasty are becoming the norm as they are less dangerous and require shorter 
patient recovery times when compared to open heart coronary bypass-surgery [4].  
As with any ionising radiation, X-rays have sufficient energy to ionise atoms and 
molecules potentially causing damage to cells when absorbed by biological material. This 
may lead to cell death, cell mutations, carcinogenesis and hereditary effects [5]. The CA is a 
procedure where the thoracic is being irradiated by ionising radiation and the breast tissue 
is nearby, which is known to be radiosensitive.  
The aim of this thesis is to measure the breast dose as a function of tube angulation 
and estimate the radiation-induced cancer risks for the irradiated breast tissue during a 
typical CA. This study was motivated by the revised international recommendations for 
radiation protection in particular the radiation detriment to the breast tissue based on the 
latest available scientific information of the biology and physics of radiation exposure.  
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1.1. RATIONALE 
The International Commission on Radiological Protection (ICRP) provides 
recommendations on how to assess and interpret risk associated with ionising radiation 
from artificial and naturally occurring sources [6].  
In recent years, the ICRP has updated and revised its recommendations to some of 
the factors used in calculating biological effects of ionising radiation. This change was based 
on epidemiological, biological and physical evidence from new published data and 
accumulated studies since 1990, such as the Life Span Study of the Japanese atomic bomb 
survivor cohort, studies of the Chernobyl nuclear accident, and medical radiation studies. In 
its 1990 recommendations, the ICRP used the quantity effective dose, defined by the 
International Commission on Radiation Units and Measurements (ICRU) [7] for radiation 
risk assessment. It is a gender and age-averaged term, incorporating the radiation weighting 
factors (wR) and the tissue weighting factors (wT) for estimating risk to a general population 
from different types of radiation and to account for varying radiosensitivity of different 
tissue types. 
One of the most significant changes made in the new ICRP recommendation is the 
revised value of the wT for the breast tissue [8]. This decision was based on derived data on 
the risks of cancer induction and heritable disease. The revised value for wT (breast) was 
increased from 0.05 to 0.12. This means that the estimated risk from radiation to the breast 
tissue is now 2.4 times higher than previously estimated.  
It is generally perceived that breast dose in CA is sufficiently low as to be negligible. 
However, the ICRP has raised the risk factors because of evidence-based correlation 
between radiation exposure and breast cancer. A causal relationship was found between 
ionising radiation and breast cancer in the case of female patients who were treated for 
pulmonary (lung) tuberculosis using repeated fluoroscopy (artificial pneumothorax 
treatment), where the breasts were directly irradiated during treatment.  It was also found 
that the relative breast cancer risk is dependent on the age at exposure and the breast size 
[9].  
Usually radiation dose to the breasts is associated with mean glandular dose from a 
mammogram. However the mean glandular dose is not the same as the absorbed dose to the 
breast tissue as portrayed in this thesis and is explained in section 2.3.1.   
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Although the breasts are in the primary beam during a CA procedure, it passes 
through the torso before reaching the breasts, with substantial attenuation from the 
structures inside the torso. Given the proximity of the heart in relation to the breast, it is 
worth investigating the dose received to the breast tissue from a CA procedure particularly 
in light of the increased ICRP risk factors. Therefore measurement of dose to the breast was 
of interest at the Austin Hospital where this study was conducted. The Austin Hospital is a 
major teaching hospital in Melbourne, Australia, where approximately 1,135 CA procedures 
are performed annually. 1.2. OBJECTIVE 
As procedures involving ionising radiation become more common, the need for 
dosimetric measurements has also increased. The aim of this thesis is to measure the 
absorbed dose to the breast as a function of the various tube angulations used to acquire 
different views of the heart and blood vessels in CA.  
A self-developing radiochromic film is now available to aid with this type of 
measurement. The advantage of radiochromic film over traditional film dosimetry such as 
radiographic film and thermoluminescence dosimeter (TLD) is the elimination of post 
exposure development. International Specialty Products Inc (ISP) developed a range of 
products called Gafchromic® films for different energy and dose ranges that do not require 
any post exposure processing. The product XR-QA2 from ISP was designed for use with 
diagnostic procedures at kV energies and low dose range typical of a diagnostic procedure.  
The primary objective of this thesis is to directly measure breast dose and assess 
whether breast dose is reliably and accurately detectable during a diagnostic coronary 
angiogram using Gafchromic® XR-QA2 film. Secondary objectives included are: 
1) Determine breast dose conversion coefficients as a function of tube angulation for a 
typical CA procedure. 
2) Compare breast dose measurements with established Monte Carlo simulations such 
as PCXMC software. 
3) Determine the breast dose for a typical CA procedure.  
4) Determine the risk estimate for breast cancer for a typical CA procedure using Monte 
Carlo simulation with inputs from experimental procedure parameters.  
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1.3. SUMMARY OF APPROACH 
Measurements of breast dose were made using Gafchromic® film for various tube 
angulations typical to a CA procedure. The XR-QA2 film provided spatial dose distribution 
and dose at different depths inside the breast slices of an anthropomorphic phantom. The 
exposed film then needs to be interpreted as dose. 
In order to assess the breast dose with Gafchromic® XR-QA2 film, the film itself 
needs to be calibrated. The equipment used for imaging CA procedures are complex and 
mostly automated, making it easy to use in clinical application, but extremely difficult to 
manually set parameters for experiments. Automatic Brightness Control (ABC) is usually 
utilised to maintain good image quality in conjunction with beam hardening filters to reduce 
radiation dose to the patient that does not contribute to image formation. The beam 
hardening filter is also automated to change according to the mode of fluoroscopy used, 
with each mode producing a different X-ray spectrum.  
Due to the energy dependent nature of the film, it was decided that calibrations of 
the Gafchromic® XR-QA2 film will be performed using the fluoroscopy system used for CA 
procedures at the Austin Hospital. A method to overcome the limited control of setting 
parameters for the calibration will be discussed in chapter 3. Details of the fluoroscopy 
system used for the calibration and the experiment will be discussed in chapter 4. 1.4. OUTLINE OF THESIS 
Chapter 2 introduces background knowledge on radiation, radiobiology, the clinical 
procedure, and a literature review on radiation doses in interventional cardiology. Basic 
knowledge of the equipment and explanations of the terms introduced in sections 1.1 – 1.3 
will be discussed in chapter 2. Gafchromic® film and in particular the XR-QA2 film used for 
the experiment is introduced in chapter 3. This chapter also contains the method and the 
results of the film calibration. 
Chapter 4 outlines the experimental design, including information on the RANDO® 
phantom used to simulate patient attenuation, the Monte Carlo simulation program and 
technical details of the fluoroscopy unit used to perform the experiment. Chapter 5 presents 
the experimental and simulation results and chapter 6 is the discussion comparing the 
results from the experiment, the simulation and the literature. Finally, the summary and 
conclusion are presented in chapter 7.  
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2. BACKGROUND 
The fundamental principles of radiation physics can be found in most textbooks, thus 
a brief summary is included in the appendix A1. A short introduction to radiobiology is in 
section 2.1 followed by the concepts and dose quantities used for quantifying radiation 
measurements as defined by ICRP publication 103 [6] and ICRU report 74 [7] are in section 
2.2. The breast composition, measuring dose to the breast in mammography and breast 
cancer risks are presented in section 2.3. Section 2.4 describes the cardiac catheterisation 
laboratory, including descriptions of the common procedures performed, the equipment and 
its technology, and the nomenclature used for positioning the equipment. The final section is 
a literature review on radiation dose in interventional radiology. The dosimetry quantities 
adopted in sections 2.3 and 2.5 are from the ICRU report 74 [7].  2.1. RADIOBIOLOGY 
Ionising radiation may interact with biological material at the cellular level, causing 
cell damage, mutations and cell death. All charged particles are considered directly ionising 
as they can disrupt the atomic structure of the absorber and produce chemical and biological 
changes. X-rays and gamma rays are considered indirectly ionising as they do not produce 
chemical and biologic damage themselves. They impart their energy to produce fast-moving 
charged particles that in turn are able to cause damage.  2.1.1 RADIATION DAMAGE 
As radiation traverses through the body, it induces excitations and ionisation in the 
atoms and molecules of biological material. Cellular damage may occur via two 
mechanisms: 
1) Direct action. Radiation interacting directly with a DNA molecule, where it may be 
ionised or excited, initiating the chain of events leading to a biological change as 
shown in figure 2-1. Direct action of radiation is the dominant process for radiations 
with high linear energy transfer, such as neutrons or alpha-particles. 
2) Indirect action. A free radical is produced by interactions between radiation and other 
atoms or molecules in the cell, particularly water. A free radical is an unstable 
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chemical species that is able to diffuse far enough to reach and damage DNA 
molecule.  
 
Figure 2-1: Direct and Indirect actions to tissue damage, reproduced from source [10] 
Linear energy transfer (LET) is the liberated energy, from both ionisation and 
excitation that is released per unit length of medium along the track of an ionising particle. 
A slow moving, highly charged particle has a substantially higher LET than a fast, single 
charged particle. High LET radiation is densely ionising, meaning it transfers most of its 
energy to a localised region. X-rays used at diagnostic energy levels are considered as low 
LET radiation and are sparsely ionising, transferring their energy over greater distances.  
LET is an important measure in the evaluation of relative biological effectiveness (RBE). 
The RBE is an expression used to compare the effectiveness of the different radiations with 
respect to stochastic effects in radiobiology. The higher the RBE for a type of radiation, the 
more damaging is the type of radiation, per unit of energy deposited in biological tissues. 
RBE values are given as the ratio of the absorbed doses of two types of radiation producing 
the same specified biological effect in identical irradiation conditions. For example, 1 Gray of 
alpha particle radiation delivers twenty times more biologic damage as the same absorbed 
dose delivered by X-rays. The RBE is dependent on LET, dose, dose rate, fractionation, and 
the cells or tissues in which the effect is being assessed [11]. The LET and RBE are used to 
determine the radiation weighting factor, which will be discussed in section 2.2. 
Free radicals are atoms or molecules with a single unpaired electron in the outer 
shell. This makes them very chemically reactive as they attempt to achieve stability by 
pairing their unpaired electron with orbital electrons of neighbouring molecules. Chain 
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reactions can occur whereby a free radical creates a secondary free radical in the process of 
becoming chemically stable. 
 
Figure 2-2: Classic paradigm of radiation injury, reproduced from source [10].  
The time taken from the absorption of the incident photon to the final observed 
expression of detriment through the various events may vary from seconds to years or 
generations as illustration in figure 2-2.  2.1.2 MECHANISM OF CELL KILLING  
It is believed that DNA is the principle target for the biologic effects of radiation, 
including cell killing, carcinogenesis, and mutation. A brief description of DNA and the 
effects of radiation interacting with DNA are discussed in this section.  
2.1.2.1.  DNA damage 
Deoxyribonucleic acid (DNA) is a large organic molecule with a well-known double 
helix structure containing the genetic material of most living organisms. The “backbone” of 
each strand consists of alternating sugar and phosphate groups with four nitrogenous bases 
(adenine, thymine, cytosine, and guanine) attached. The two anti-parallel strands are held 
together by hydrogen bonds between adenine-thymine and cytosine-guanine base pairs. 
When cells are irradiated with a radiation dose of 1 Gray, approximately 1000 single-strand 
breaks are produced per cell. Single-strand breaks have little biologic consequence as these 
are readily repaired using the opposite DNA strand as a template, however if the repair is 
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incorrect, mutation may occur. Breaks in both strands, if well separated, are also readily 
repaired because they are handled as independent breaks.  
Double-strand breaks are produced when breaks in both strands are opposite or 
separated by only a few base pairs, i.e. the piece of chromatin completely breaks apart. 
Energy from X-rays is deposited unevenly in events termed “spurs” and “blobs” that 
contain a number of ion pairs in an area of a few nanometres in diameter. These spurs and 
blobs have dimensions similar to the DNA double helix and may lead to locally multiplied 
damaged sites, which are combinations of double-strand breaks and base damage. Generally 
it is the double-strand breaks rather than single-strand breaks that are most relevant in cell 
killing, carcinogenesis and mutations because they can lead to aberrations. An illustration of 
the different ways the DNA strand may break is shown in figure 2-3.  
 
Figure 2-3: Diagrams of single- and double-strand DNA breaks caused by radiation. A: 2D representation of the 
normal DNA helix. B: Single-strand  break. C: Breaks in both strands, if well separated, are repaired as 
independent breaks. D: Double-strand break, reproduced from source [12]. 
The DNA double helix is organised in a series of complex folds and looped domains, 
packed tightly into a chromosome. The cell cycle for mammalian cells can be divided into 
four phases: mitosis (M), followed by Gap 1 (G1), followed by the DNA synthesis phase (S), 
then Gap 2 (G2), and into mitosis again. In general, cells are most radiosensitive in the M and 
G2 phases and most resistant in late S phase. Radiation-induced breakage and incorrect 
rejoining in the pre-replication (G1) chromosomes can cause chromosome aberrations while 
chromatid aberrations are caused in post-replication (late S or G2) chromosomes. Main 
examples of radiation-induced aberrations include dicentrics, rings and anaphase bridges 
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which are considered lethal while symmetric translocations and small deletions are 
non-lethal. The incidence of most radiation-induced aberrations is a linear-quadratic 
function of dose [12, 13]. 
2.1.2.2.  The bystander effect 
Previously, radiobiology has taught that hereditary biologic effects required direct 
damage to DNA, however evidence in the last decade has demonstrated the existence of a 
“bystander effect”[14]. This is defined as the induction of biologic effects in cells that are not 
directly involved in the interaction, but are in close proximity to the cells that are. Its 
importance is primarily at low doses, where not all cells are irradiated and it may have 
important implications in risk estimation [14]. 
2.1.2.3.  Apoptotic and mitotic death 
After exposure to radiation cells may die either undergoing the next or a subsequent 
mitosis (mitotic death), or they may die from normal end of life cell deaths (apoptotic death). 
There is generally a correlation between the importance of apoptosis and radiosensitivity. If 
apoptosis is dominant, cells are radiosensitive; if apoptosis is absent, cells are radioresistant 
[14].  2.1.3 STOCHASTIC AND DETERMINISTIC EFFECTS  
Radiation detriment can be classified into two groups, deterministic effects and 
stochastic effects. Deterministic effects, also termed as “tissue reactions” describe the situation 
where large numbers of cells in an organ or tissue are killed or prevented from reproducing 
and functioning normally. Once a threshold dose is reached, the severity increases with dose 
and the damage becomes observable such as erythema, epilation and ulceration. This 
threshold dose is at a level substantially higher than doses from natural radiation or 
occupational exposure at normal operation.  
Stochastic effects are probabilistic, such as cancer induction and heritable effects 
caused by mutation of somatic cells and germ cells. For radiation protection purposes, it is 
assumed that there is no threshold dose below which cancer induction can be ruled as 
absent and an increase in frequency is proportional to dose, but not the severity. Thus a 
“linear-no-threshold” dose-response model is used, however at lower doses the assumption 
is an extrapolation. It can also be termed late effects, because cancer or heritable effects do not 
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express themselves until a later stage of the individual’s life or in the next generation [6]. 
Figure 2-4 below illustrates the dose-response curves for the two classifications.  
In interventional cardiology, skin injury is a well documented deterministic effect for 
fluoroscopically guided interventions [15]. Given the increased frequency of procedures per 
patient, the accumulative radiation dose may also lead to increased risk of stochastic effects, 
such as cancer.   
  
Figure 2-4: Dose-response curves. Curve (a) represents the relationship between dose and deterministic effects. 
Curve (b) represents the relationship between dose and stochastic effects. Interventional cardiology procedures 
can result in radiation doses that are high enough to cause radiation injury and an increased risk of cancer.  2.2. RADIATION PROTECTION – ICRP & ICRU 
To investigate radiation risk, an international body for radiation protection was 
established in the 1920s. The International Commission on Radiological Protection (ICRP) is 
the organisation dedicated to the advancement of radiological protection of human beings 
and biota. They provide recommendations and guidance on protection against the risks 
associated with ionising radiation from artificial and naturally occurring sources. The ICRP 
is comprised of a Main Commission and five standing Committees on radiation effects, 
doses from radiation exposure, protection in medicine, the application of ICRP 
recommendations, and the protection of the environment [6]. The Commission’s three 
fundamental principles for radiological protection are justification, optimisation and the 
application of dose limits to radiation sources delivering exposure and to individuals 
receiving exposure. Most regulatory authorities around the world including Australia have 
adopted the ICRP philosophy and recommendations.  
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The ICRP developed special dosimetric quantities for the assessment of doses from 
radiation exposures.  The concept of effective dose (E) relates radiation dose to cancer risk 
taking into consideration the differences in the effect of various radiations in causing 
stochastic effects and the variations in radiation sensitivity of different organs and tissues to 
the induction of stochastic effects.  
Working closely with ICRP is the International Commission on Radiation Units 
(ICRU) whose main objective is to develop a coherent system of radiological quantities and 
units. The ICRU also provides recommendations on how to measure radiation-related 
quantities, providing harmonization in the concepts and the methods used to describe and 
apply these quantities in all fields where ionizing radiation is used. The following 
subsections describe the dose quantities used in patient dosimetry as defined in the ICRU 
report 74 [7].  2.2.1 KERMA, ABSORBED DOSE & ORGAN DOSE 
The kerma (K) is the kinetic energy released per mass, measured in J/kg. The special 
name for the unit of kerma is gray (Gy). It is the sum of the initial kinetic energies of all the 
charged particles (dEtr) liberated by uncharged particles in a mass of material (dm), thus: 
dm
dEK tr=   (1) 
The absorbed dose, D, is the mean energy (dε) per unit mass deposited into a 
medium (dm), measured in J/kg and shares the same units as kerma, gray (Gy).  
dm
dD ε=   (2) 
The organ dose (DT) is defined as the mean energy (εT) deposited in a specified tissue 
or organ of mass (mT), thus 
T
T
T m
D ε=   (3). 
2.2.2 EQUIVALENT DOSE & EFFECTIVE DOSE  
In radiation protection, the radiation weighting factor, wR allows for differences in 
the relative biological effectiveness (RBE) of the incident radiation in producing stochastic 
effects at low doses in tissues or organs. This arises because a difference in RBE exists for 
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different LET radiation as they transfer their energy to the tissue in different ways. Table 2-1 
shows the radiation weighting factors currently used for estimating detriment. 
 
Table 2-1: Recommended radiation weighting factors, reproduced from source [6]. 
Radiation type Radiation weighting factor, wR 
Photons, electrons and muons 
Protons and charged pions  
Alpha particles, fission fragments, heavy ions 
Neutrons 
1 
2 
20 
A continuous function of neutron energy 
  
The equivalent dose (HT) is the absorbed dose (DT) multiplied by the radiation 
weighting factor (wR) to account for the effects of different types of radiation on the human 
body. In this thesis, only X-rays are being dealt with, which has a wR of 1, making equivalent 
dose the same as the absorbed dose.  
TRT DwH ×=  (4) 
The effective dose (E) is the whole body weighted average dose, it is the sum of the 
equivalent doses multiplied by the tissue weighting factor (wT). Table 2-2 shows the tissue 
weighting factors currently used for calculating radiation exposure.  
∑ ×=
T
TT HwE  (5) 
Table 2-2: Recommended tissue weighting factors, reproduced from source [6]. 
Tissue Tissue weighting factor, wT Sum of wT values 
Bone-marrow (red), colon, lung, 
stomach, breast, remainder tissues* 
0.12 0.72 
Gonads 0.08 0.08 
Bladder, oesophagus, liver, thyroid 0.04 0.16 
Bone surface, brain, salivary glands, skin 0.01 0.04 
Total  1 
*Remainder tissues: Adrenals, extrathoracic (ET) region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, 
pancreas, prostate (♂), small intestine, spleen, thymus, uterus/ cervix (♀). 
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These wT values are chosen to represent the contributions of individual organs and 
tissues to overall radiation detriment from stochastic effects and apply to a population of all 
ages and both sexes. 
As shown in table 2-2, the weighting factor for breast is one of the highest amongst 
the listed tissue. This implies an increased risk of radiation detriment to the breast tissue 
from exposure to ionising radiation relative to the previous ICRP 60 factor of 0.05. This 
heightened risk factor provides the motivation for the present study. 
The application of effective dose is mainly in radiological protection for occupational 
workers and the general public as a means of assessing exposure and controlling stochastic 
effects for regulatory purposes. The effective dose is calculated on the basis of reference 
values for a Reference Person [6]. The ICRP emphasises that the effective dose provides a 
measure of radiation detriment for protection purposes only. It does not provide an 
individual-specific dose however they do provide a basis for estimating the probability of 
stochastic effects for absorbed doses well below the thresholds for deterministic effects [8].  2.2.3 AIR KERMA-AREA PRODUCT (KAP) AND DOSE-AREA PRODUCT (DAP)  
Patient dosimetry is usually assessed indirectly by monitoring the output of an X-ray 
tube with a large-area transmission ionization chamber. The chamber is mounted on the 
collimator unit and is positioned to intercept the beam entirely before reaching the patient. 
The signal of the chamber is calibrated in terms of air kerma-area product (KAP) at a 
specified distance free-in-air. The air kerma-area product (also known as dose-area-product, 
DAP) is the integral air kerma (Ka) over the area of the beam (A) perpendicular to the beam 
axis [7]:  
PKA = ∫A Ka ∙ dA= Ka A   (6). 
The terms PKA, KAP and DAP are used interchangeably in this thesis as is common in 
conventional practice. 2.3. BREAST COMPOSITION, MEAN GLANDULAR DOSE AND BREAST CANCER 
The mammary glands are composed of adipose (fatty) tissue, ducts and glandular 
structures called lobules. As the female ages, the breast content in fat, fibrous and glandular 
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tissue varies. During pregnancy, there are structural changes within the breast and a 
significant increase in the amount of glandular components. As the female grows older, 
most of the glandular tissue is once again replaced by fat and fibrous tissue. Figure 2-5 is a 
schematic of the breast. 
 
Figure 2-5: Composition of the breast. 40% of the breast is considered to be comprised of glandular tissue and  
the remaining 60% is adipose tissue [6, 16]. This proportion changes as the female grows older.  
Glandular tissue is more sensitive to radiation than fatty tissue; therefore there exists 
a higher risk of breast cancer for females exposed at a younger age. Glandular tissue 
attenuates more radiation than fatty tissue, thus depositing energy into the breasts where 
radiation induced damage may take place. Whereas fatty tissue is less attenuating, meaning 
X-rays will pass through with less interaction with the breast tissue. 
The ICRP publication 89 report titled “Basic anatomical and physiological data for 
use in radiological protection: reference values” presents detailed information on age- and 
gender-related reference values for anatomical and physiological characteristics of reference 
individuals for dosimetric purposes. The reference value for the mass of both breasts in the 
adult female is 500g. The mass of glandular tissue is about 40% of the total mass of the breast 
and the average glandular fraction is 42.9% with a median value of 39%. Assuming the adult 
female mass of both breasts is 500 g and the glandular fraction is 40%, a glandular mass of 
100 g is indicated for each breast [17].   2.3.1 MEAN GLANDULAR DOSE 
The most commonly used term for estimating detriment to the breast tissue can be 
found in mammography. The mean dose to the glandular tissue was deemed appropriate 
Breast profile: 
A – ducts, B – lobules, C - dilated section 
of duct to hold milk, D – nipple, E – fat, F - 
pectoralis major muscle, G - chest wall/rib 
cage 
Enlargement: 
A – normal duct cells, B - basement 
membrane, C - lumen (center of duct) 
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because it was believed that the glandular tissue is most sensitive to radiation-induced 
damage. The term glandular tissue includes the acinar and ductal epithelium and associated 
stroma and it is the glandular tissue which is believed to be the most sensitive to 
radiation-induced carcinogenesis [18-20].  
In mammography, the X-ray spectrum mainly consists of low energy photons and 
the absorbed dose within the breast decreases rapidly with increasing tissue penetration. 
The main interaction process at this level is the photoelectric effect, thus the absorbed dose is 
localised. The absorbed dose will also be affected by the size and composition of the breast 
which can vary between populations and throughout the life of the woman. The diversity of 
breast dimensions and composition makes dose comparisons very difficult and it is 
important for such purposes that doses be specified for a standard breast and in a standard 
method [21].  
For dose comparisons to be possible, it was necessary to define a standard breast 
with standard composition. The standard breast is 4.5 cm thick, has a central region 
comprising a 50:50 mixture by weight of adipose and glandular tissues and a superficial 
region of adipose tissue, 0.5 cm thick. The compositions of these tissues are given by 
Hammerstien et al, [18] and White [22, 23]. It has a semi-circular cross-section in the 
horizontal plane of diameter 16 cm, giving a cross-sectional area of approximately 100 cm2. 
The dimensions of the standard breast are typical of those of a firmly compressed breast. In 
mammography it is essential to have good breast compression because it ensures a near 
uniform layer of breast tissue for diagnosis and reduces motion artefacts as well as minimise 
patient dose.    
The mean glandular dose for the standard breast and similar phantoms has been 
measured experimentally [18] and calculated using Monte Carlo techniques [24, 25]. In a 
practical setting, a phantom constructed according to the above prescription may not be 
available, thus Dance [26] suggested a method for estimating the mean glandular dose using 
a 4 cm thick Perspex phantom and measuring the absorbed dose free in air at the skin 
surface by recourse to published tables [27-30] which have been specially calculated to 
account for the breast type and thickness and beam quality.  
This involves determining the current product (mAs) and exposure time for the 
relevant kV under automatic exposure control (AEC) with the Perspex phantom on the 
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breast support. Record the focus-to-skin distance (ds), then measure the incident air kerma 
K0 with the phantom removed using the same parameters recorded for the AEC exposure.  
The estimated incident air kerma at the skin entrance, Ks, can be inferred using the 
inverse square law and assuming output linearity, 
Ks = K0 × (mAs/100) × (d0/ds) 2   (7). 
Refer to tabulations of Wu et al, Klein et al, Boone or Dance et al [27-30] to obtain the 
normalised mean glandular dose (DgN) which take into account the breast composition, 
thickness, kV, beam quality (HVL) and anode/filter type. Thus the mean glandular dose 
(Dg) for the standard breast can then be estimated using the relationship: 
Dg = DgN × Ks  (8). 
As demonstrated by equations 6 and 7, the mean glandular dose cannot be applied to 
the determination of breast dose in fluoroscopy due to difference in energy, the DgN term 
and the location of Ks. Mammography operates under much lower energy range (24 – 35 
kVp) than fluoroscopy (70 – 120 kVp) therefore the kV, beam quality and anode/filter type 
components of the DgN are not applicable. There are no conversion factors available in the 
literature that can translate the DgN term in mammography to fluoroscopy application. The 
Ks used here refers to the skin on the breast as the X-ray beam enters from the patient 
anterior. In fluoroscopy, the X-ray beam enters from that patient posterior, thus the Ks term 
is also not transferable.  
This thesis will be measuring the absorbed dose to the breast tissue in a setup that 
differs greatly from mammography. Therefore mean glandular dose should not be 
compared with the breast dose obtained in this thesis.  2.3.2 BREAST CANCER AND RADIATION  
There is clear evidence linking direct radiation exposure to the breasts with the 
consequences of developing breast cancer. The dose-response for breast cancer increases 
linearly with dose and the excess relative risk decreases as a function of age at exposure 
[31-37]. Many authors have demonstrated [38-42] that female patients who underwent 
treatment using radiation for tuberculosis and thymic enlargement had a higher incidence of 
breast cancer. Other studies including the Life Span Study (LLS) of Japanese atomic bomb 
survivors [43-46], radium luminisers [47] and women with scoliosis [48] exposed to multiple 
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diagnostic radiographic examinations during childhood and adolescence have also shown 
support for this.  
A basic comparison used in radiation epidemiology is to measure the rate of a 
specific disease among persons who have been exposed to radiation and among persons 
who have not. The relative risk is the ratio of the rate of disease among groups having some 
risk factor, such as radiation, divided by the rate among a group not having that factor. 
Relative risk has no units and the excess relative risk (ERR) is the relative risk minus 1 (the 
excess risk is expressed relative to the background risk). The absolute risk is the simple rate 
of disease among a population and has the units of the rates being compared. Excess 
absolute risk (EAR) is the difference between two absolute risks. Either ERR or EAR may be 
used in modelling the relation between radiation exposure and disease [37]. 
The age at exposure plays a critical role in the development of breast cancer. In the 
most recent report from the LSS cohort study, the ERR of breast cancer exposed at age 0-4 
years is 3.94 per Sv compared with exposure age at 20-39 years is 1.33 per Sv [46]. Tokumaga 
et al found a 13-fold ERR at 1 Sv for breast cancer occurring before age 35, compared to a 
2-fold excess after age 35, among survivors exposed before age 20 [44]. Using the EAR 
model, where a single mammographic examination with two views per breast, delivering 
3.7 mGy to both breasts, Yaffe and Mainprize [49] found the radiation-induced breast cancer 
from a single screening mammogram exposed at age 35 is 3.02 per mGy compared with 
exposure at age 50 is 1.03 per mGy in a cohort of 100,000 women.  
Thus it is worthwhile to investigate whether there is an increased risk of developing 
breast cancer from coronary angiography. This study seeks to estimate the associated doses 
for correlation to outcomes when those studies are performed.  2.4. THE CARDIAC CATHETERISATION LAB 
The cardiac catheterisation lab is a department specialising in the diagnosis and 
treatment to a range of heart conditions without open heart surgery. Procedures performed 
at a catheterisation lab can be quite varied, including intravascular ultrasound, 
electrophysiology study, pacemaker implantation, and angiography procedures. For most 
angiography the first 4-5 minutes is the diagnostic part known as the standard coronary 
angiogram (CA) to evaluate or confirm the presence of coronary artery disease, valve 
disease, and heart muscle function. If no blockage is found, no further investigation is 
22 | P a g e  
 
required. In cases where an issue is found, several types of interventions may be performed 
to open the artery. A brief description of each type of intervention is listed below [50]. 
Balloon angioplasty/Percutaneous transluminal coronary angioplasty (PTCA): A small 
balloon at the tip of the catheter is inserted near the blocked area of the coronary artery. The 
balloon is inflated, the fatty plaque or blockage is compressed against the artery walls and 
the diameter of the blood vessel is widened to increase blood flow to the heart.  
Balloon angioplasty with stent placement: A stent is a small metal mesh tube that acts as a 
scaffold to provide support inside the artery. A balloon catheter is used to insert the stent 
into the narrowed artery. Once in place, the balloon is inflated and the stent expands to the 
size of the artery and holds it open. The balloon is deflated and removed while the stent 
stays in place permanently. After a few weeks, the artery heals around the stent.   
Drug-eluting stents: Theses are stents that have a thin surface of medication that is actively 
released at the stent implantation site. The medication is to reduce the risk of restenosis. 
Rotablation (atherectomy): A special catheter, with an acorn-shaped, diamond-coated tip, is 
guided to the point of narrowing the coronary artery. The tip spins around at a high speed 
and grinds away the plaque on the arterial walls. This process is repeated as needed to treat 
the blockage and improve blood flow.  
Cutting balloon: This is a balloon tip with small blades attached. When the balloon is 
inflated, the blades are activated. These small blades score the plaque, and then the balloon 
compresses the fatty plaque into the arterial wall.    
Coronary angiography (CA) is the imaging of vessels of the heart to obtain specific 
information about the blood supply to identify blockages or valve deficiencies. The 
following is a brief description of a typical procedure [51]. 
1) A guide wire is inserted into the patient’s peripheral artery most commonly the right 
femoral artery. 
2) A flexible plastic sheath is advanced over the guide wire and placed in the artery. 
This serves as a passage-way for the insertion of catheters and to prevent blood loss. 
3) A thin hollow tube called a catheter is inserted through the sheath and guided 
intravenously to the heart under low dose fluoroscopy called screening. The 
cardiologist will navigate the catheter to the opening of the coronary artery.  
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4) Contrast agent or ‘dye’ is injected through the catheter and the flow is recorded 
using high dose, high frame rate digital fluoroscopy known as acquisitions. This is 
usually performed using a 6-inch field of view to magnify the heart vessels on the 
image. 
5) The C-arm is rotated around the patient table at various angles required to view the 
intricate system of vessels around the heart muscle and further acquisitions are made 
until the cardiologist is satisfied with the information collected. The C-arm 
orientation is also called a tube angulation. An example of the orientation of the C-arm 
is shown via several diagrams in section 2.4.2.   
6) In some cases it is easier to move the patient floating tabletop rather than the C-arm 
gantry for better visualisation of a particular artery.  
7) An acquisition of the left ventricle to assess its functionality is routinely performed at 
the end of a CA. This is performed on a 9 inch field of view to enable a full view of 
the left ventricle.  
A screenshot of an angiogram showing a 99% stenosis of the dominant right 
coronary artery is shown in figure 2-6. Following a stent insertion, the right coronary artery 
is shown to have returned to normal capacity.  
   
Figure 2-6: An angiogram of the right coronary artery (left), the white arrow indicates a blockage of the artery. 
An angiogram of the same right coronary artery after stent insertion (right), the artery has recovered its blood 
flow [52]. 
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2.4.1 THE C-ARM SYSTEM  
An essential part of the catheterisation lab is the X-ray fluoroscopy (also known as 
C-arm system) used to image the patient. This piece of equipment is responsible for 
generating X-rays and acquiring quality images for diagnostics and interventions. Cardiac 
C-arm systems are generally set up with the X-ray tube located under the patient table and 
the image receptor is connected to the X-ray tube with a C shaped arc. To reduce the 
operator dose, lead drapes hanging from the patient table are utilised. This setting allows for 
complex angulations in the frontal, oblique, and lateral planes while, at the same time, 
permitting cranial and caudal positioning of the supine patient. Angulations of the X-ray 
projection are important because they provide flexibility for the operator in searching for 
blockages hidden by overlapping vessels. The patient table is on a floating tabletop, which 
allows the operator to move the patient easily while the C-arm remains fixed.  
A team of skilled professionals are required to operate a catheterisation lab, 
consisting of cardiologists, radiographers, nurses, and cardiac technicians. Figure 2-7 shows 
the setup of a typical catheterisation lab in a major hospital. 
 
Figure 2-7: Typical layout of a catheterisation lab with a Shimadzu BRANSIST Safire (direct conversion 
technology) cardiovascular system installation and key features identified [53].  
There are several types of image receptor technology for producing fluoroscopy, the 
image intensifier, and the indirect and direct conversion flat panel detector. Essentially they 
all serve one purpose, converting X-rays into electric signals that can be digitally stored for 
easy manipulation, presentation and archiving of information. Figure 2-8 demonstrates the 
C-arm 
Flat panel detector 
X-ray tube 
Patient Table 
Display monitors 
Staff  
Lead glass shield 
Lead drape shield 
Operator controls –     
foot switch, hand control 
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key differences between the three methods, followed by a brief description of the flat panel 
detector technology. Since image intensifiers are gradually being replaced by flat panel 
detectors, their details are located in the appendix A2.   
 
Figure 2-8: The three methods for producing  fluoroscopic images, the traditional image intensifier, indirect 
conversion and direct conversion, adapted from source [54]. 
2.4.1.1.  Flat panel detectors  
Flat panel detectors (FPD) are quickly replacing image intensifiers as the image 
receptor in fluoroscopy systems. With the removal of the bulky television camera imaging 
chain and vacuum tube, it is more compact and allows for more flexible movement during 
examination. The FPD consists of an array of solid-state detector elements (DELs) that 
produce a digital electronic signal representing the intensity of the X-rays that impinge on 
each DEL and displays this distribution as a visible image. In the indirect conversion 
systems, the X-ray energy is first converted to light by a scintillation layer usually composed 
of thallium-activated cesium iodide (CsI) in a needle-like structure. This structure is 
designed to direct light towards the photodiode located below, which acts as a switch for the 
DELs to quantify the light into a digital signal.  
In direct conversion systems, the scintillation layer and photodiode are absent and 
the X-ray energy is converted directly into a signal received by the DEL array through a 
semiconducting layer of amorphous selenium (a-Se). Both indirect and direct FPD are more 
efficient at converting X-rays into an image because there is less energy loss through the 
process and tend to require less radiation than image intensifier systems. Generally the FPD 
systems have better stability, lower radiation dose rates, and improved dynamic range. 
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However, they have lower spatial resolution with very small and very large field of views 
and a different appearance of the displayed image compared with that of images from 
image intensifier systems [55]. 
2.4.1.2.  Automatic brightness control and multi-beam hardening 
In modern angiographic imaging, the Automatic Brightness Control (ABC) mode of 
operation is the use of a set of rules (algorithms) that control the system's response to 
dynamic changes in imaging conditions. Usually these control algorithms maintain the 
absorbed energy fluence per pixel at the imaging detector's X-ray capture layer, resulting in 
a reasonably constant average signal level from the detector for a given detector field of 
view (FOV). The absorbed energy fluence is maintained by controlling the exposure 
parameters of the X-ray generator such that a constant, pre-defined detector signal level is 
achieved. These parameters are kV, mA, pulse width and filtration. In pulsed fluoroscopy, 
the exposure is pulsed rather than continuous and the pulse width is the exposure time of 
each pulse in milliseconds. One of five methods commonly employed are: (1) a change in 
kVp with a fixed mA, (2) a change in mA with fixed kVp, (3) a change in the kVp and the 
mA simultaneously (4) a change in pulsed width adjunct to the three methods mentioned 
and (5) a change in filtration. Usually a central area on the imager receptor is utilised to 
sample the signal intensity as the input signal for the ABC [56].  
One of the unwanted properties of the Bremsstrahlung spectrum is the amount of 
low-energy photons in the beam. These low-energy photons do not have sufficient energy to 
penetrate the patient and reach the image receptor to form a useful image. However, they 
will be attenuated by the patient, thus depositing dose to the patient that does not contribute 
to a diagnosis. To remove these unwanted low-energy X-rays (also known as soft X-rays) 
filter materials may be added at the X-ray beam output to reduce the amount of soft X-rays, 
yet allow the higher-energy photons (or hard X-rays) to pass through. The multi-beam 
hardening (MBH) functions as a spectral shaping filter to exclude soft X-rays that do not 
contribute to the image, but contribute to patient dose. In some modern angiography units 
the MBH is capable of automatically selecting the appropriate beam filtration for a given 
type of examination. More details on the MBH will be revealed in chapter 4.  
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2.4.2 NOMENCLATURE FOR TUBE ORIENTATION 
The X-ray tube and flat panel detector must be mounted on an apparatus that allows 
complex angulations in the frontal, oblique, and lateral planes while, at the same time, 
permitting cranial and caudal positioning around the supine patient. Each patient has a 
unique anatomy and cardiac configuration that require individualisation of the study. The 
nomenclature for tube orientation used in interventional radiology is derived from the 
position of the patient anatomy relative to the imaging panel. It indicates the location of the 
flat panel detector face with respect to the patient. RAO is shorthand for Right Anterior 
Oblique view, LAO is shorthand for Left Anterior Oblique view, CAU or CAUD is shorthand 
for caudal and CRA is shorthand for cranial. Some tube angulations give better anatomic 
definition because it avoids overlapping or foreshortening particular arteries. For example 
cardiologists would use a RAO (0° – 10°) – CRA (25° – 40°) to view the middle and distal left 
anterior descending artery, without overlap of the septal and diagonal branches [51].   
Tables A-2 and A-3 listing the common tube angulations used to view the left and 
right coronary artery are located in appendix A3. The following series of figures depict the 
same orientation viewed from different positions around the patient table and the 
nomenclature used in the catheterisation lab. Figure 2-9 is the display monitor showing a 
RAO 20° / CAU 25° tube angulation and the nomenclature in a schematic format, RAO 20 
means the flat panel detector is located 20° over the patient’s right anterior chest wall and 
CAUD 25 means the flat panel detector is 25° caudally to the patient. Figure 2-10 is a view 
from the foot of the patient table and figure 2-11 is a side view from the patient's left.  
 
Figure 2-9: This is a display monitor located inside the catheterisation lab showing the position of the X-ray  
beam through the patient and the nomenclature used to define their orientation. Also displayed on the monitor 
are the heat units of the X-ray tube (bottom left) and the fluoroscopy time (bottom right).  
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Figure 2-10: Physical appearance of  the same orientation as described in figure 2-10 looking from the end of  the 
patient table. The image receptor is tilted towards the right side of the phantom and caudally to the phantom. 
 
Figure 2-11: This is a side view of the same orientation as described in the figures above (RAO 20, CAUD 25). 
The image receptor is tilted away from the head (caudal) and towards the right side of the phantom.  2.5. RADIATION DOSE IN INTERVENTIONAL RADIOLOGY  
Much of the research conducted in the field of interventional cardiology involves 
assessing radiation-induced injuries. Radiation induced skin damage is a well-documented 
L R 
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side effect of prolonged radiation exposure. Radiation induced cancer is also a 
well-documented potential outcome from exposure to radiation. 
Literature on radiation doses in interventional radiology are mostly concerned with 
entrance skin dose (ESD), which is the absorbed dose to the skin surface from radiation. ESD 
is often used as an indicator for deterministic effects such as skin erythema and can be 
derived using a dose-area product (DAP) meter, the cumulative air kerma (CAK) measured 
at the interventional reference point (Ka,r), software simulation or measured using 
thermoluminsecent dosimeters (TLDs), or film dosimetry[57, 58]. Several authors have 
investigated effective dose (E) as well [59, 60]. Tube angulations or projections and their 
relationship to patient dose and operator dose have also been investigated [61, 62].  2.5.1 CUMULATIVE AIR KERMA (CAK) AND DOSE AREA PRODUCT (DAP)  
Most modern fluoroscopy systems are capable of recording the cumulative values of 
CAK and DAP for a procedure. The CAK at the interventional reference point (Ka,r) may be 
measured or calculated [63]. The interventional reference point is located 15cm from the 
isocentre, towards the X-ray focal spot as defined by the IEC [64]. Both Ka,r and DAP do not 
include backscatter from the patient’s posterior. While Ka,r  is preferred over the use of DAP 
[63], the fluoroscopy unit used in this thesis was not equipped with Ka,r. Thus it will not be 
mentioned any further.   
The DAP was introduced in section 2.2.3 and it measures the product of incident air 
kerma and the area of the X-ray beam. The unit commonly used is Gy.cm2, and because 
radiation intensity decreases as the square of the distance from the source and the area 
irradiated increases by the same factor, thus DAP is independent of distance from the 
source. Provided the beam area is known the accumulated air kerma can be calculated at 
any other distances [65]. Two methods of DAP meter calibration have been adopted by the 
IAEA depending on the type of installation (over couch or under couch) [66]. Generally for 
patient exposures, table attenuation needs to be accounted for in skin dose estimations.  
McParland [67] experimentally determined conversion factors that correlate a DAP 
value with entrance skin dose with a nominal geometry for various interventional 
radiological procedures. However ESD is dependent upon distance from the source when all 
other factors remain unchanged. Also a new area of skin is irradiated when tube angulation 
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is incorporated and the DAP does not take into account this change in area of irradiated skin 
surface. A sketch demonstrating this effect is shown in figure 2-12.  
 
Figure 2-12: Effect on irradiated skin surface when the projection is angulated, adapted from Blair [68].   
Another useful dose quantity is the maximum entrance skin dose (MESD), also 
termed as peak skin dose or maximum skin dose in the literature. Hansson [69], van de 
Putte [70], Vano et al [71,72], Quai et al [73], Karambatsakidou [74], Iqeilan [75], Domienik et 
al [76] and Bogaert et al [77] investigated MESD correlation with DAP measurements. Most 
authors reported a relatively good correlation or conversion factors [69, 72-77].  
Leung and Martin [78], Betsou et al [79], Neofotistou et al [80],  Hansson [69], 
Lobotessi et al [81], Morrish et al [82], Compagnone et al [83] and Seierstad et al [84] 
conducted studies on conversion factors from DAP measurements to effective dose (E) using 
patient data or experimental data. Schultz and Zoetelief [59] warns that specific exposure 
conditions have an influence on the dose conversion coefficients and published dose 
conversion coefficients should only be used if all the conditions are matched. Kuon et al [61] 
and Smith et al [62] evaluated patient dose and operator dose in interventional cardiology as 
a function of tube angulations or projections. With regards to operator dose, Morrish et al 
[82] was interested in dose distribution of scatter from oblique projections.  2.5.2 THERMOLUMINESCENT DOSIMETERS 
Thermoluminescent dosimeters (TLD) employ inorganic crystals that can store the 
energy absorbed during X-ray exposure in the form of electron traps in high-energy 
imperfections in the crystal. When heat is applied to the TLD, the stored energy is released 
as the emission of visible light. The light output is proportional to the radiation air kerma 
X-ray source 
X-ray source 
P.A. view Angulated view 
New exposed 
area of skin  
Exposed area 
of skin  
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incident on the material. A majority of authors used this method to acquire measurements of 
ESD in interventional cardiology [69-72, 77, 79, 80, 84]. Some authors acquired E using TLDs 
placed inside an anthropomorphic phantom [69, 79, 84]. Mustafa and Janeczek [85] 
performed a similar experiment to this thesis in 1989 with a limited number of organ doses 
investigated, including breast dose using an anthropomorphic phantom but with TLDs.  2.5.3 SOFTWARE SIMULATION AND FILM DOSIMETRY 
There are software simulations available that can calculate the skin dose, organ dose 
and effective dose using the Monte Carlo radiation transport calculations. The Monte Carlo 
technique is a computational method based on the mathematical simulation of physical 
processes. Harrison et al [86] used the software XDOSE (NRBP, Oxon, UK) and Delichas et 
al [87] used the ODS-60 software (Rados Technolgy, Turku, Finland) to determine E from 
DAP measurements. Schultz and Zoetelief [59] and Bogaert et al [88], determined 
hospital-specific dose conversion coefficients for DAP to E, generated by the Monte Carlo 
simulation code PCXMC. Compagnone [83] used the NRPB model [89] and Bozkurt model 
[90] to generate E from DAP. Morrell et al [91] developed a mathematical model to calculate 
skin dose distribution using exposure and projection data from DICOM headers off patient 
data. 
Schlattl et al [92] derived new organ dose conversion coefficients for coronary 
angiographic interventions using Monte Carlo based simulations and voxel models of the 
human anatomy. In addition to the dose conversion coefficients, the dependence of the 
patient dose on the projection has been estimated, showing that the patient doses are highest 
for left anterior oblique views with strong caudal or cranial orientation.  
Film dosimetry is the use of radiographic (slow film) or radiochromic film as a 
medium to detect, measure and record radiation dose. Many studies have been conducted 
using the Gafchromic® XR or Kodak EDR2 film to investigate entrance skin dose and 
comparing them with TLDs, DAP measurements or mathematical models [71, 72, 74-76, 80, 
84, 93]. Film dosimetry is used in this thesis and will be discussed further in chapter 3.  2.5.4 DISCUSSION 
Literature concerning breast dose is normally related to CT angiography [94-98] or 
mammography, but not necessarily in coronary angiography. Keeping in mind that the 
mean glandular dose used in mammography is different from the breast dose discussed in 
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this thesis. Many authors have investigated doses in coronary angiography procedures. 
Their main focus has always been on deterministic effects such as the likelihood of skin 
burns, threshold doses for erythema, ESD, dose reference levels (DRL) or operator doses [57, 
58, 61, 62, 67-77, 82, 91, 94]. This is because the main concern in interventional cardiology is 
the prolonged exposure time and high dose rates due to the complexity of cardiac cases that 
could increase the probability of deterministic effects. In effect, this would also increase 
operator doses for complex cases.  
Some authors have researched on stochastic effects by correlating DAP values with 
effective dose [59, 60, 78-84, 86-90, 92]. This is because multiple procedures and cumulative 
dose adds radiation burden to patients. The radiation burden can be in the form of 
deterministic effects or stochastic effects. 
A few authors have explored organ doses, including breast dose in cardiac 
procedures like Mustafa and Janeczek [85], which was performed 23 years when 
fluoroscopy technology was different to today. More recent works by Schlattl et al [92] and 
Seierstad et al [84] revisited breast dose, showing the importance in breast dose in light of 
advanced fluoroscopy technology and radiosensitivity of breast tissue. This reinforces the 
motivation for this study. Kuon et al [61] found some tube angulations provided minimal 
radiation exposure to patients and operators while Smith et al [62] developed an algorithm 
that identified a core set of angiographic views that optimized the information yield and 
minimized radiation risk in coronary angiography.   
From the literature review, there is insufficient published information on breast dose 
in interventional cardiology being reported. With the assessment of breast tissue becoming a 
highlighted issue after the revised ICRP recommendation was published, this was a good 
opportunity to provide breast dose analysis. A summary table of the findings from all the 
mentioned authors in this chapter can be found in section 6.5. 2.5.5 CONCLUSION 
DAP, CAK and ESD are key indicators for deterministic effects from interventional 
cardiology procedures. However, with the increased tissue weighting factor for breast tissue 
signaling an increase in estimated radiation risk to the breast, it was deemed important in 
this hospital to investigate this more closely.  
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Due to the large scope of interventional cardiology procedures, this thesis 
investigated only the most common procedure performed in the cardiac catheterisation lab, 
which is coronary angiography (CA). It is also common for patients to have multiple CAs, 
thus increasing their potential lifetime radiation dose which may lead to an increase in their 
lifetime attribute risk from radiation.  
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3. FILM DOSIMETRY 
In the previous chapter, film dosimetry was introduced as a method used for data 
collection in interventional cardiology procedures. Traditionally, the most commonly used 
film in medical imaging and dosimetry field is radiographic film. As radiographic film 
became obsolete, it is being replaced by radiochromic (self developing) film in the dosimetry 
field.   
Before the radiochromic film can be used for any dosimetry analysis, a dose response 
calibration needs to be performed. The dose response of the radiochromic film was 
calibrated using two methods. The two methods are identical in process with the exception 
that the fluoroscopy system was on automatic mode in the earlier calibration and then on 
manual mode in the later calibration. This was because the fluoroscopy system could not 
switch to manual control at the time when this study began. Thus a technique was devised 
to overcome the automated issue.  
Two years into this study, the fluoroscopy system had an upgrade and the manual 
control became available. The X-ray beam quality between the two calibrations is quite 
different because in the automatic mode, attenuators were placed in the beam to allow the 
author to adjust the kilovoltage (kVp) and dose rate, thus it was deemed important by the 
author to make a second set of calibrations in the manual mode. However, experiments 
performed before the upgrade will continue to use the earlier calibration for which the same 
batch of film was used. 
In this chapter section 3.1 presents an overview of radiochromic film followed by 
section 3.2 on a particular type of radiochromic film, the Gafchromic® XR-QA2 used in this 
study. Section 3.3 details the dose response calibrations including sub-sections covering 
materials, methods, results and uncertainty analysis for each calibration. Lastly section 3.4 
and 3.5 are the discussion and conclusion. For completeness an overview of radiographic 
film can be found in appendix B1.  
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3.1. RADIOCHROMIC FILM OVERVIEW 
Radiochromic film has been widely used for dosimetry and beam alignment in 
radiotherapy applications, since it was commercially available in the late 1990s as an 
alternative to the traditional radiographic film method. Radiochromic film is better suited to 
dosimetry due to the absence of a chemical bath development phase which can alter the 
dose-response relationship. 
In 1998 the first comprehensive guideline on the use and calibration of radiochromic 
film was released by The American Association of Physicists in Medicine (AAPM) [99]. This 
was primarily to meet the demands of hospital physicists in utilising radiochromic films for 
medical applications, since there were no such guidelines at that point in time. The 
radiochromic effect was first observed by Niepce in 1826, but it was McLaughlin et al and 
Lewis et al who were the early pioneers in the use of the radiochromic effect in medical 
applications [100-103].   
In the past decade, the use of radiochromic films has evolved and has expanded into 
applications in diagnostic radiology.  The energy range used in radiotherapy applications is 
in the MeV range while in diagnostic radiology it is a hundred times less (in the keV range). 
This fundamental difference has a significant impact on film sensitivity and energy 
response.  
The radiochromic effect is the direct coloration of a material through the absorption 
of energetic radiation, without the aid of latent chemical, optical or thermal development or 
amplification [99]. Radiochromic films are capable of measuring qualitative and quantitative 
dosimetry as well as being a visual display record and a medium for archiving. 
Traditionally, the most commonly used film in the medical imaging field is radiographic 
film, which is designed for imaging rather than dosimetry.  
Gafchromic® film developed by International Specialty Products (Wayne, NJ, USA) 
is a type of radiochromic film which does not require any chemical processing. It consists of 
a radiosensitive layer of monomers sandwiched between an opaque support material and a 
yellow coloured filter dye material. When irradiated the radiosensitive monomers will 
undergo a chemical reaction where the monomer molecules link together to form polymer 
chains in a process known as polymerisation. This will produce a visible colour darkening in 
the film and the amount of darkening is proportional to the dose delivered (figure 3-1)  
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Figure 3-1: A piece of Gafchromic® film after exposure to X-rays, taken from manufacturer brochure [104]. The 
darker brown area in the centre of the film is the area exposed to X-rays while the lighter orange section is the 
original colour of the film which is unexposed.  
This film is also relatively unaffected by visible light, easy to handle and very 
versatile compared with radiographic film which is very light sensitive and requires 
handling in a light-tight environment (dark room), thus resulting in increased complexity in 
film processing and film handling.   
A range of different Gafchromic® film products is available on the market 
depending on the application. The composition for the active material varies from type to 
type, however the method for extracting dose in clinical use utilises the same approach. The 
Gafchromic® film used for this experiment is the XR-QA2 film, an upgraded version of the 
XR-QA product. Both these products are more sensitive to low energy radiation designed 
for diagnostic procedures within the kilovoltage range [104].  3.2. GAFCHROMIC ® XR-QA2 CHARACTERISTICS  
The Gafchromic® XR-QA2 dosimetry film is designed for measuring the absorbed 
dose of low energy photons within a diagnostic energy range of 80-140 kVp and has a dose 
sensitivity range of 1–200 mGy [105, 106]. Its predecessor, the XR-QA film was investigated 
by Butson et al [107], Chiu-Tsao et al [108], Rampado [109], and Alnawaf [110, 111]. More 
recently works by Tingey [112] and Giaddui [113] have investigated the characteristics of the 
XR-QA2 film in radiographic settings and cone beam computed tomography (CBCT) 
imaging respectively. Its performance was found to be very similar to the XR-QA product 
[114]. Compared with the other Gafchromic® products, both types of film contain added 
elements with high atomic number to absorb extra kilo-voltage X-rays that are capable of 
37 | P a g e  
 
generating photoelectrons and subsequently increase the energy absorption of the 
diacetylene monomers to initiate the polymerisation process at diagnostic energies.  
The Gafchromic® films come in boxes of 10 sheets, each sheet being 25.4 cm x 30.48 
cm (10” x 12”) in size and each able to be easily cut into pieces to fit the experimental setup. 
As shown in figure 3-2, each film consists of a 25 micron active layer sandwiched between a 
surface layer of 3 micron and a 25 micron pressure sensitive adhesive layer.  
The base polyester is a white opaque 97 micron coating, which acts to reflect the 
active layer colour change for visual inspection. The top coating is clear yellow polyester 
which acts to protect the active layer and provides an enhanced visible colour change for the 
film upon radiation [104]. The active component is a micro-particulate, radiation sensitive 
monomer dispersed in a polymer matrix. This active layer nominally consists of H, C, N, O, 
Li, Br and Cs with several other high atomic number elements.  
Upon exposure to ionising radiation, the active diacetylenes undergo a solid-state 
polymerisation reaction producing a dye polymer referred to as a polydiacetylene. The 
colour of the dye darkens from yellow to brown in proportion to the radiation exposure and 
is enhanced as a result of the nano-particle dispersion in the composition [115]. Illustrated in 
figure 3-3 is the chemical reaction that takes place at the molecular level upon irradiation. 
The triple carbon bonds are broken so that polymer chains can be formed. 
 
Figure 3-2: Cross section of the XR-QA2 Gafchromic® film and composition layers from the manufacturer 
brochure [104]. The active layer contains some high Z elements to boost absorbance of kV photons. Upon 
irradiation, the active component will polymerise to produce a dye. The degree of coloration of this dye polymer 
is proportional to the amount of radiation dose. 
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Figure 3-3: Illustration of the diacetylene monomers in action, the molecules need to be in an ordered  form to be 
active. When they interact with photons, polymerisation occurs. The original active component was 
Pentacosa-10, 12-diynoic acid (PCDA). Current active component is lithium pentacosa-10, 12-diynoate 
(LiPCDA). Image reproduced from Lewis [116].  
A typical behaviour of Gafchromic® films is post irradiation growth. This effect 
manifests itself as a significant increase in opacity in the first 24 hours after exposure. This is 
due to the kinetics of the polymerisation reaction when the active component forms a dye 
polymer corresponding to an increased concentration of polymer within the active layer. But 
the rate of change of absorption diminishes rapidly with time [99]. Rampado et al [109] 
found that the variation of the film response for a given dose from post irradiation growth 
was about 10% in the first 24 hours after the exposure and up to 4% in the next three days.  
It is recommended by the manufacturer to maintain the same temperatures during 
irradiation, storage and readout. Films should be handled with care, avoiding contact with 
dust, fingerprints or excessive bending. Although the films are not required to be kept in a 
light-tight environment, they should be stored in a dry, dim environment and prolonged 
exposure to normal light, UV light and heat should be avoided. At temperatures above 70°C 
the dye material in the film will deactivate rendering the film un-useable. Scanning 
protocols should be kept consistent and each batch of film should be calibrated to account 
for film response variations as a result of the manufacturing process [103]. 
The dose response of XR-QA2 film is photon energy dependent, and was reported by 
Giaddui et al [113] to vary around 10% between 100 and 120 kVp. Thus a dose response 
curve is required for a range of photon energies, considering that during a real coronary 
angiogram (CA) the automatic brightness control (ABC) will automatically adjust the 
energy.  
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3.3. DOSE RESPONSE CALIBRATION  
The X-ray apparatus used for the calibration is the Shimadzu BRANSIST Safire HF9 
(Shimadzu Corporation, Japan). This system is also used routinely for interventional 
cardiology cases at the Austin Hospital. This system was fitted with ABC and does not 
permit manual exposures, i.e. parameters such as kVp and milliamperage cannot be set to 
particular values during a digital acquisition. A method is described in section 3.3.3 (ABC 
enabled calibration) for exposing calibration films at controlled, known beam energies under 
ABC mode. In 2013 the fluoroscopy system was upgraded by the Shimadzu engineers to 
allow manual control of kVp and milliamperage settings (ABC disabled). Thus a second set 
of calibrations were completed in 2013. The methods and results of this second calibration, 
termed ABC disabled calibration (manual mode) are described in section 3.3.4. The method 
used for both calibrations are identical, except one was performed in ABC mode and the 
other in manual mode. Experimental works performed prior to 2013 will use the ABC 
enabled calibrations while experiments performed in 2013 will use the ABC disabled 
calibrations. This is because the XR-QA2 films used prior to 2013 belonged to the same batch 
of film used for the calibrations performed in the ABC mode and the two approaches were 
compared. 
A total of three boxes were used for the entire experiment (Lot A10071002B is box 1 
and Lot A10121203 is box 2 and box 3). Each batch of new film should be calibrated and 
subsequent boxes with the same batch number should be cross-checked at a few dose points 
to obtain a correction factor when the same dose response curve is used. The box with batch 
number Lot A10071002B was used in the mock CA experiment. The two boxes with batch 
number Lot A10121203 were used in the controlled experiments. A cross check was 
performed between the two boxes of Gafchromic® film with batch number lot A10121203 in 
manual mode and can be found in appendix B4. This was unavoidable due to the amount of 
Gafchromic® film required for the experiment and the time span of this study.  
Although the X-ray spectrum differs in the screening and digital acquisition modes, 
the calibrations were performed in digital acquisition mode (DA) because the contribution 
from screening to the dose deposition on the film is relatively less than the acquisition mode 
during a CA procedure [117]. This is because screening mode is a low dose rate technique 
used for positioning the catheter and not used for image acquisitions.  
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Section 3.3.1 is a brief description of the apparatus used for the calibration and 
section 3.3.2 is on scanning of the calibrated film. Section 3.3.3 is the setup, results and 
uncertainty analysis for the calibration with ABC enabled. Section 3.3.4 is the setup, results, 
uncertainty analysis of the calibration with ABC disabled. Sections 3.4 and 3.5 are the 
discussion and conclusion. 3.3.1 MATERIALS & APPARATUS 
The two key apparatus used in performing the calibration were the Piranha external 
dose probe (RTI Electronics, Sweden) and beam attenuators comprising polymethyl 
methacrylates (PMMA), aluminium sheets and copper sheets.  
The Piranha is a multi-purpose meter capable of measuring the kVp, HVL, exposure 
time, dose and dose rate of an X-ray beam. It is suitable for use with radiography, 
fluoroscopy, dental and mammography equipment. Figure 3-4 shows the Piranha base unit 
with the external dose probe R100B. The dose probe R100B is a solid-state detector that 
connects to the Piranha base unit. The active detector area is 10 mm x 10 mm and is capable 
of detecting very low dose rates, such as those from a pulsed fluoroscopy system. It has a 3% 
inaccuracy when measuring the dose and was last calibrated in 2009. The calibration 
certificate and more detail on the dosimeter is located appendix B2. The dose probe R100B 
was used to measure the reference dose delivered to the XR-QA2 film.  
 
Figure 3-4: Piranha base unit and external dose probe (R100B). The dose probe was used during calibration of  
the Gafchromic® XR-QA2 film with a known dose. The physical size of the dose probe is 20 mm x  45 mm x 7.4  
mm and weighs 85g.  
This detector was cross-calibrated in 2012 with the same detector owned by the 
Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) to ensure that the 
Piranha Base Unit 
Piranha  
Dose Probe 
Active 
detector 
area  
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values had not drifted significantly. The results of the cross-calibration revealed a 0.2% 
difference between the two detectors, therefore no further correction factors were necessary 
to compensate for any possible deviations over the time period between the film calibration 
and experimental data collection. The cross-calibration is presented in appendix B3. While 
the cross calibration was performed in primary radiation, the consistency is expected to 
follow for in-phantom exposure where the energy spectrum is different. This follows from 
the fact that even the primary beam is largely made up of low energy photons.  
Beam attenuators were required to manipulate the ABC of the fluoroscopy system. 
PMMA is a clear plastic material that is approximately tissue equivalent for diagnostic X-ray 
energies. Aluminum and copper are common elements used as beam attenuators at 
diagnostic X-ray energies.  
Solid-state detectors (SD) tend to underestimate the dose in phantom or ESD 
measurements because they are less sensitive to scatter radiation from backscatter and the 
surroundings compared to ionisation chambers (IC). This effect has been observed and 
confirmed by Martin [118], who recommends a correction factor of 1.25 when using SD 
under such settings. This was based on experiments with 4 different types of SD with 
different numbers of silicon diode elements within the detector probe and filters in front of 
the diodes.  
Due to the unconventional setup of this study, a correction factor was directly 
measured with our solid-state detector and an ionisation chamber. This was performed 
because the Gafchromic® film was believed to respond in a similar manner as an ionisation 
chamber i.e. having little directional dependence. Our SD sat side by side with the IC in an 
identical setup as the two calibration setups shown in figure 3-5 and the results are listed in 
table 3-1.  
Table 3-1: Correction factor to compensate for SD response to match IC response. 
Setup Ratio (SD / IC) Correction factor (1 / Ratio) 
ABC enabled 0.5 (± 2%) 2 
ABC disabled (manual) 0.7 (± 2%) 1.4 
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Figure 3-5: Cross-check between SD and IC. (a) ABC enabled setup, (b) ABC disabled setup and (c) SD and IC 
positioned side by side in the X-ray beam as displayed on the monitor screen. 
Fifteen measurements were averaged over the energy range (71, 84 and 97kVp) and 
the correction factor was applied in all calibrations between our solid-state detector and the 
Gafchromic® film. The dose uncertainty from the IC is 4% and the calculated total 
uncertainty from the ratio is 2%. 3.3.2 FILM SCANNING PROTOCOL 
The colour change of the XR-QA2 film needed to be quantified to the corresponding 
radiation dose. Film uniformity was assessed by scanning various sizes of the film (from 1 
cm × 2 cm to 10 cm × 11 cm) and was found to be less than 3% by Giaddui et al. This implies 
XR-QA2 film has good uniformity. Net reflectance variation on a flatbed scanner (intra) was 
found to be 4% at a dose of 13 mGy and 2% at a dose of 90 mGy by Giaddui et al [113]. Thus 
the effect of scanner uniformity is dose dependent and decreases with increasing dose. This 
was caused from light scattering effects by the light source used by a desktop scanner, as the 
central section of the scanner normally produces a high source of light uniformity as oppose 
to the peripheral. Film scanning orientation was reported by both Giaddui et al (XR-QA2) 
[113] and Alnawaf et al (XR-QA) [110] to affect the net reflectance and net optical density by 
around 2%. This was caused from analysing the film with a partially or fully polarised light 
source such as a flatbed scanner. 
For this study an Epson V7000 Photo dual lens system flatbed scanner was used to 
scan the XR-QA2 film into a digital format. The following protocol was used throughout the 
calibration. A reflective scanning mode was used with 48-bit colour, 300 dpi resolution, no 
(a) (b) (c) 
SD & IC 
SD 
IC 
SD & IC 
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correction or colour control selected and digitized as a tagged image file format (tiff) file. 
Prior to scanning any irradiated films, scans without film on the scanner bed were made in 
order to warm up the scanner lamp. All of the films were placed in the top right corner of 
the flatbed scanner for reproducibility and an area was selected to fit the entire film to be 
scanned. Very small calibration films (1 cm × 1.5 cm) are minimally affected by the scanner 
non-uniformity and were used. For large films used in the experiment, the 4% uncertainty 
has been accounted for as per Giaddui et al above. All films were scanned 3 days after being 
exposed and were kept in a cool, dry environment for storage when not in use, to remove 
post-irradiation growth related uncertainty. 
Mean pixel value was chosen as the corresponding dose unit instead of optical 
density (OD). For image processing, a free software ImageJ (National Institute of Health, 
Bethesda, MD) version 1.45s [119] was used to acquire the mean pixel value in the red colour 
channel. A region of interest (ROI) was selected to measure the mean pixel value. The results 
were plotted using MS Excel (Microsoft Corporation, USA) and a dose response curve was 
fitted using MATLAB R2010a (Math Works, Natick, MA). 3.3.3 CALIBRATION WITH ABC ENABLED 
To generate a dose-response curve for the XR-QA2 film (Lot# A10071002B – box 1) a 
set of seven, 1 cm × 1.5 cm rectangles were exposed to doses from 1 – 140 mGy at 71, 84 and 
97 kVp.  
The C-arm system operates under pulsed fluoroscopy and ABC which restricts the 
operator from manually choosing parameters such as kVp. To overcome this limitation, the 
following setup was necessary to ensure a reference dose at a given kVp could be measured. 
A combination of PMMA, aluminum and copper sheets were used as beam attenuators to 
manipulate the system to fix a kVp station. By placing the beam attenuators in the beam, 
they force the ABC feedback system of the C-arm to produce the kVp most commonly seen 
in clinical work. The brightness level at the image receptor remains consistent. Three dose 
response curves at 71, 84 and 97 kVp were taken and the selected kVp stations were 
considered to be within the normal clinical range based on observation of clinical cases. Due 
to the high dose rate in some conditions PMMA was placed in front of the dose probe 
R100B, so the X-ray spectrum was altered. 
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The setup for the calibration is shown in figure 3-6 and the beam attenuators used to 
set up the 3 calibration energies are listed in table 3-2. The source-to-image receptor distance 
(SID) was set to 100 cm and table to floor height was 100 cm.  
The dose rate was measured using the Piranha dose probe R100B to determine the 
exposure time needed to acquire seven dose points from 1 mGy to 140 mGy. Once the dose 
rate was measured, the film was placed side by side with the dose probe and was exposed 
until the requisite dose was deposited. The dose probe and film were placed on top of 12.5 
cm of PMMA so that the requisite dose rate was achieved. This was important because if the 
film had been placed too close to the X-ray tube (i.e. on the patient table), resulting in a dose 
rate greater than 1 mGy/s, then it would have been difficult to calibrate the film at 1 mGy 
without a timer that could measure in intervals of less than one second. This approach also 
exposes the film to a photon spectrum that more closely resembles that inside a phantom. 
The fluoroscopy system has an automatic maximum digital acquisition timer, where 
the X-ray will stop exposing in digital acquisition (DA) mode after 10 seconds regardless of 
whether the foot pedal control is still activated. This exposure time limit was verified by the 
Dose Probe R100B. This in effect became a method of measuring exposures in intervals of 10 
seconds. A mechanical timer was used to keep track of exposure times less than 10 seconds. 
In some instances, multiple exposures were made to the film to accumulate the requisite 
dose. For example, to deposit 8 mGy to the film at 71 kVp, an exposure of 38 seconds was 
required. The foot pedal was pressed down until the X-ray terminated itself. This action was 
repeated two more times to achieve an accumulative exposure of 30 seconds. The remaining 
of the 8 seconds needed for the exposure was measured by the mechanical timer.  
 
Table 3-2: Attenuating material combinations used to achieve the 3 different energies for the Gafchromic® 
XR-QA2 film calibration and their dose rates at the corresponding reference point. 
Energy (kVp) Attenuating material combination Dose rates at detector & film 
reference point (mGy/min) 
71 7 mm Aluminium 12.6 
84 1 mm Copper 38.2 
97 1.5 mm Copper + 0.3 mm Aluminium 56.4 
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Figure 3-6: ABC enabled calibration setup. The beam attenuating materials are in the beam to force the 
fluoroscopy system’s feedback mechanism to set a desired kilovoltage. The reference point was a location that 
received a dose rate of 1mGy/s at 97 kVp.  
A total of 63 pieces of film were used to calibrate a dose range of 1 mGy to 140 mGy 
across the three kilovoltages. Three pieces of film were used to calibrate each dose point. The 
accumulated dose was measured by the Piranha dose probe and recorded for each piece of 
calibrated film. The exposed films then needed to be digitised to obtain a mean pixel value 
that could be converted into a measurement of dose as described in section 3.3.2.  
3.3.3.1.  Results  
The dose response curves from the calibration performed in DA mode are presented 
below in figure 3-7, with figure 3-8 showing the subsets of the same data with finer detail. 
Exponential curves were fitted to the measured data for the purpose of allowing later 
interpolation between measured calibration points.  
Using a kVp specific calibration curve for dose analysis is cumbersome in a clinical 
setting where kVp is not necessarily constant and time constraints will restrict the 
practicality of the approach. The three calibration curves can be approximated by a single 
curve model. This simple model can be used without the details of knowing the kVp used 
per acquisition. Thus the calibration data from the three different energies were combined to 
Reference 
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and XR-
QA2 film 
Flat panel 
detector (FPD) 
Beam 
attenuating 
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fit a single calibration curve, given in figure 3-9. The prediction bound curves (dotted 
curves) are the 95% uncertainty of the fitted curve from the ABC enabled calibration data 
points. This is an indicator for how well the fitted curve will perform for predictions.  
Given the ease of scanning the film into a digital format using a flatbed scanner, and 
using software to extract the mean pixel value of the film and using an equation to convert 
mean pixel values into dose values, this makes it more practical for clinical application. 
Figure 3-10 is the residual plot of the fitted curve. For a MPV of 40000 
(approximately equivalent to a measured dose of 15 mGy), the deviation from the measured 
dose and the fitted curve is approximately 27%. The calibration data is tabulated in 
appendix B5. 
  
Figure 3-7: Calibration curves for 71 kVp, 84 kVp and 97 kVp with Gafchromic® XR-QA2 film. The 
uncertainty of the dose delivered is 4% and the uncertainty for the scanned mean pixel value is 3.5%. This is a 
controlled environment; therefore no flatbed scanner uniformity, film uniformity and film scanning orientation 
uncertainties are included.  
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Figure 3-8: Insets (a) - (c) are close ups of figure 3-7 showing the error bars more clearly. The uncertainty of the dose delivered is 4% and the uncertainty for the scanned 
mean pixel value is 3.5%. Note the horizontal (Mean Pixel Value) and vertical axes (Dose) are different for each inset.  
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Figure 3-9: Known dose versus mean pixel values (MPV) in digital acquisition (DA) mode fitted  to an 
exponential model.  Pred bnds is the prediction bounds and  are the 95% uncertainty of  the fitted curve from the 
calibration data points. They indicate how well the fitted curve will perform for predictions. 
 
 
Figure 3-10: Residual plot for ABC enabled fitted curve. Maximum deviation from the fitted curve is 
approximately 10 mGy. 
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The exponential curve was fitted to measured data using the following model in 
MATLAB’s curve fitting tool: 
normnorm dxbx eceaD ⋅+⋅=   (9) 
The xnorm is the normalised mean pixel value (MPV) measured from scanned film 
using the ImageJ software and a, b, c and d are the fitting coefficients. The fitting coefficients 
are tabulated in table 3-3 and the evaluation of the fitted data with this model is tabulated in 
table 3-4. MATLAB used the following equation to determine xnorm, where x is the mean of 
the x data points and σ is the standard deviation of the x data points.   
σ
)( xxxnorm
−
=  (10) 
The mean x data points was 36080 and standard deviation was 9797 for the ABC 
enabled calibration curve.  
 
Table 3-3: Coefficients resulting from curve fitting application in MATLAB of the fitted calibration curves 
 a b c d 
Coefficients -0.05174 3.12 19.38 -1.189 
95% confidence 
bounds 
(-0.459, 0.3556) (-3.408, 9.647) (18.06, 20.69) (-1.234, -1.144) 
     
 
Table 3-4: Goodness of fits – Evaluation of the fitted data with this model 
Sum of squares due to error (SSE) R-squared Adjusted R-squared 
707.5 0.995 0.994 
   
 
The coefficient of determination (R-squared) of the model appears to fit well with the 
experimental data (table 3-4). As demonstrated in figures 3-7, 3-8 and 3-9 the dose response 
of the XR-QA2 film is energy dependent and non-linear. This is consistent with findings 
from the literature [106, 108, 109, 113].  
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3.3.3.2.  Uncertainty analysis 
With any experimental work, there will be many sources of uncertainty. When a 
result is found by a calculation from a collection of measurements without any cross 
correlation terms, a Gaussian propagation of error can be used to calculate the variance in a 
measured dose by,  
2
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where i is the number of parameters (x) in the dose equation (D) with each parameter having 
a variance of xi2 [120]. The uncertainties can be separated into those associated with the 
fitting process in MATLAB and those associated with experimental uncertainties.  
Therefore, given a dose response of 
dxbx eceaD ⋅+⋅=  (12), 
where x is the mean pixel value, the Gaussian propagation yields: 
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Splitting the expression above into its components between the fitting process and 
film calibration, the uncertainty associated with the fitting process (fit) is: 
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The uncertainty associated with film calibration (cal) is: 
( )
100(%)
22
×
⋅+⋅
⋅+⋅
= dxbx
x
dxbx
cal ecea
ecdeab σ
σ  (17), 
1×⋅
⋅+⋅
⋅+⋅
= xd xb x
d xb x
ecea
ec dea b σ  (18). 
The measurable uncertainty (x) is a combination of scanner, film and digitisation 
uncertainties which can be summed in quadrature: 
222(%) digitalfilmscannerx σσσσ ++=  (19). 
Other sources of uncertainty include scanner warm up time, post exposure growth, 
and size of the film. However these are minimized to become negligible by following the 
film scanning protocol presented in section 3.3.2. Table 3-5 is a summary of the components 
for the measurable uncertainty x of equation 19. 
 
Table 3-5: Source of uncertainty for x for film calibration 
Source of uncertainty for x Uncertainty 
Scanner variability [113] 4 % 
Scanning orientation [113, 110] 2 % 
Film uniformity (pixel value) 3.5% 
  
Figure 3-11 shows the uncertainty in dose conversion (D) as a function of measured 
dose. At the lower doses, the uncertainty of the measured dose was greatest at 
approximately 200% for a measured dose of 5 mGy. This improves as the dose increases. For 
a reasonable interpretation of the mean pixel value from the Gafchromic® XR-QA2 film with 
an uncertainty of 16%, it should be exposed to at least a dose of 10 mGy. It is important to 
remember that although efforts were made to maintain the ABC of the equipment at a static 
kVp, each calibrated kilo-voltage curve represents a polychromatic energy curve with a 
different X-ray spectrum. The energy dependence has implications for dosimetry of 
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fluoroscopy beams conducted in this thesis. In a typical fluoroscopic system the beam 
energy is automatically modulated to achieve sufficient patient penetration based on patient 
attenuation. As a consequence any single film may be exposed to a range of energies 
typically varying from 70 to 110 kVp. Thus, the variation in film response at different 
energies will be considered as a contribution to uncertainty in the measured dose. This gives 
rise to an uncertainty that cannot be avoided and makes up a large portion of the 
uncertainty. 
 
Figure 3-11: The uncertainty  from fitting  process and  measuring  process by a Gaussian propagation of error as 
expressed in equation 15 for the fitted curve.  3.3.4 CALIBRATION WITH ABC DISABLED  
To generate a dose-response curve for the film (Lot# A10071002B – box 2) three sets 
of thirty-seven, 1.5 cm × 1 cm rectangles were exposed to doses from 0–300 mGy at 71, 84 
and 97 kVp. Under this configuration the C-arm system operated under pulsed fluoroscopy 
and ABC was disabled to allow for manual settings for an exposure. The brightness level at 
the image receptor was not of concern during the calibration (manual mode). To protect the 
image receptor from potentially high doses from the manual setting, a piece of 4 mm thick 
lead sheet was placed in front of the flat panel detector.  
Three dose response curves at 71, 84 and 97 kVp were taken and the selected kVp 
stations were considered to be within the normal clinical range. The setup for this calibration 
in manual mode is shown in figure 3-12. It shows 15 cm PMMA as part of the stand used to 
support the lead sheet to protect the flat panel detector from over exposure. The air gap 
between the PMMA blocks and the dose probes placed on the tabletop is sufficient to avoid 
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detecting backscatter radiation from the PMMA blocks. Backscatter radiation from the 
PMMA blocks would result in a higher measured reference dose. This setup also meant the 
X-ray spectrum is close to free in air (the table attenuation would have a minimal effect on 
the X-ray spectrum) and is different to the ABC enabled calibration. 
 
 
Figure 3-12: ABC disabled calibration setup. The PMMA is there only as a support for the lead sheet to protect 
the system’s flat panel detector from over-exposure. 
The procedure is identical to section 3.3.3 with the exception that the ABC is now 
disabled and there is no need for attenuators to be placed in the beam to force the system to 
produce a suitable kilovoltage for the calibration. The kVp and mA for each exposure was 
set manually. The SID was set to 100 cm and table to floor height at 100 cm.  
A total of 111 pieces of film were used to calibrate a dose range of 0–300 mGy across 
the three kilovoltages. Each dose point calibrated was repeated three times and a single 
unexposed piece of film was used as zero dose point for each kilovoltage. The accumulated 
dose was measured by the Piranha dose probe and recorded for each piece of calibrated 
film. The exposed films were then digitised to obtain a mean pixel value that could be 
converted into a measurement of dose as described in section 3.3.2.  
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3.3.4.1.  Results  
The dose response curves for the calibration performed with manual X-ray generator 
controls in DA mode are presented below in figure 3-13, with  
figure 3-14 showing the subsets of the same data in finer detail. Exponential curve 
was fitted to the measured data for the purpose of allowing later interpolation between 
measured calibration points. The curve fitting result is presented in figure 3-15. Figure 3-16 
is the residual plot of the fitted curve. For a MPV of 40000 (approximately equivalent to a 
measured dose of 10 mGy), the deviation from the measured dose and the fitted curve is 
approximately 10%. The calibration data is tabulated in appendix B5. 
 
Figure 3-13: Calibration curves for 71 kVp, 84 kVp and  97 kVp with  Gafchromic® XR-QA2 film. The 
uncertainty of the dose delivered is 4% and the uncertainty for the scanned mean pixel value is 3.5%. This is a 
controlled environment, therefore no flatbed scanner uniformity, film size difference, scanning orientation 
uncertainties are included.  
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Figure 3-14: Insets (a) - (c) are close ups of figure 3-13 showing the error bars more clearly. The uncertainty of the dose delivered is 4% and the uncertainty for the scanned 
mean pixel value is 3.5%. Note the horizontal (Mean Pixel Value) and vertical axes (Dose) are different for each inset.   
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Figure 3-15: Known dose versus mean pixel values (MPV) for digital acquisition (DA) mode fitted to an 
exponential model.  Pred bnds is the prediction bounds and  are the 95% uncertainty of  the fitted curve from the 
calibration data points. They indicate how well the fitted curve will perform for predictions.   
 
 
Figure 3-16: Residual plot for the ABC disabled fitted curve. Maximum deviation from the fitted curve is 
approximately 20 mGy.   
Using the same equations as in section 3.3.3.1, the exponential curve was fitted 
(normalized and centered) with the measured data using MATLAB’s curve fitting tool. The 
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fitting coefficients are tabulated in table 3-6 and the evaluation of the fitted data with this 
model is tabulated in table 3-7. The mean x data points was 30760 and standard deviation 
was 9807 for the ABC disabled calibration curve.  
 
Table 3-6: Coefficients resulting from curve fitting application in MATLAB of the fitted calibration curves 
 a b c d 
Coefficients -0.001806 4.289  32.54 -1.437 
95% confidence 
bounds 
(-0.05127, 
0.04766) 
(-12.02, 20.6) (30.49, 34.59) (-1.493, -1.382) 
     
 
Table 3-7: Goodness of fits – Evaluation of the fitted data with this model 
Sum of squares due to error (SSE) R-squared Adjusted R-squared 
2421 0.994 0.993 
 
 
  
3.3.4.2.  Uncertainty analysis 
Using the same equations from section 3.3.3.2 and table 3-6, the propagation of error 
for the ABC disabled calibration curve can be computed. The σx component here is the same 
as those from table 3-5. Figure 3-17 shows the uncertainty in dose conversion σD as a 
function of measured dose. At the lower doses, the uncertainty of the measured dose was 
greatest at approximately 190% for a measured dose of 5.4 mGy. This improves as the dose 
increases. Compared to the fitted curve for ABC enabled calibration, this fitted curve has a 
similar uncertainty range.  
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Figure 3-17: Propagation of error from dose conversion using MPV from XR-QA2 film for ABC disabled 
calibration.  3.4. DISCUSSION 
The angiography system was fixed in the ABC mode previously when this project 
first began, thus an alternative method was devised to counter the issue using attenuators in 
the beam to force the ABC to select clinical kilovoltages. However, two years later after a 
system upgrade, the unit is now capable of manual selection of X-ray generator parameters. 
Since a new batch of film arrived, the author felt that a second calibration should be 
performed in manual mode. As long as the corresponding calibration curve was used on the 
same batch of film it was calibrated for, there should be no ill effect. As shown in sections 
3.3.3.2 and 3.3.4.2 the uncertainty for σD was lower for the ABC disabled (manual mode) 
calibration curve.  
The two calibration curves start to diverge from around 75 mGy and their differences 
increase as the dose increases as shown in figure 3-18. At doses less than 75 mGy the two 
calibration curves behave similarly with or without the ABC mode in operation. The dose 
range encountered in this study would in the order of 10 mGy, since the investigation is on 
breast dose, which primarily will be exposed to scatter dose. 
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Figure 3-18: The curve fits for the ABC enabled (red) and ABC disabled (blue) dose calibration curves. The 
dotted lines are the 95% confidence bounds on the fitted curves. At low doses (<75 mGy), the two calibration 
curves behave in a similar manner. 
The difference between the two calibration curves at higher dose may be attributed 
to their effective energy of the beam since the XR-QA2 film is sensitive to the beam energy. 
In the ABC enabled calibration setup, PMMA was placed in front of the Gafchromic XR-QA2 
film. This in effect changed the X-ray spectrum to the film compared to the ABC disabled 
calibration performed on the table in manual mode. The software Xertex 5.0 (University of 
Sydney, Australia) [121] was used to generate X-ray spectra matching those from the two 
calibrations. For the ABC disabled calibration (manual mode), 4 mm of Aluminium was 
used to depict its X-ray spectrum and for the ABC enabled spectrum an additional 125 mm 
of Lucite was used. The PMMA material was not available on the software; however the 
closest approximate would be the Lucite material. The X-ray spectra are illustrated in figure 
3-19 comparing the ABC enabled spectrum (red curve) and the ABC disabled spectrum (blue 
curve). The ABC enabled spectrum (red curve) was normalised for comparison. 
The two spectra exhibit similar peaks, with the ABC enabled spectrum absorbing 
more low energy photons than the ABC disabled spectrum. At higher photon energies, the 
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ABC disabled spectrum absorbs photons. The HVL values for the ABC enabled and manual 
calibrations were 7.44 mmAl and 4.69 mmAl respectively. 
 
Figure 3-19: X-ray spectrum between the two calibration methods at 100 kVp. Red curve is the ABC enabled  
calibration (HVL 7.44 mm Al) and blue is the ABC disabled (in manual mode) curve (HVL 4.69 mm Al). 
Computed using Xertex software [121] and reproduced in MS Excel.  
The scatter incident on the detector and film is limited to table scatter in the manual 
calibration, while the ABC enabled calibration included backscatter from the PMMA placed 
behind the detector and film. A cross check was performed between two boxes of 
Gafchromic® XR-QA2 film with same batch number A10121203 (box 2 and 3). The standard 
deviation between the mean pixel values for the two boxes of film was around 8%. This 
suggests that these two batches behave very similarly. A correction factor was derived to 
correct for this and then the same calibration curve was used for analysis (ABC disabled 
curve). The cross check results are plotted and tabulated in appendix B4. 3.5. CONCLUSION   
In this chapter the characteristics of Gafchromic® XR-QA2 and film scanning 
protocol have been discussed. The manufacturer claims the XR-QA2 film is sensitive to 
doses as low as 1 mGy when read using the red channel. However, in practice it would be 
wise to ensure a dose of at least 10 mGy is exposed to the film for an uncertainty within 15%. 
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As the dose increases, the energy dependence of the film becomes less noticeable. Constancy 
in scanning protocol and avoiding prolonged exposure to light were key considerations 
when using the XR-QA2 film for dosimetry measurements. The uncertainty for the ABC 
enabled calibration curve was 16% at a dose of 10 mGy and for the ABC disabled calibration 
curve was 8% at a dose of 10 mGy.  
The ABC enabled calibration curve was used for a clinical CA imitation procedure 
performed prior to 2013. Measurements for breast dose and posterior entrance skin dose 
from a clinical – like CA procedure are expected to lie between 1 – 40 mGy and 20 – 140 mGy 
respectively. Thus the uncertainty ranges between 3 – 200% using the ABC enabled 
calibration curve. 
For the remaining experiments which were performed in 2013, the ABC disabled 
calibration curve was used and it is expected that the dose range for breast dose 
measurements lie between 5 – 30 mGy. The uncertainty ranges between 1.8 to 190% when 
using the ABC disabled calibration curve. One strategy to improve the uncertainties in low 
dose range is to perform multiple exposures and then divide per procedure.  
The scanning protocol and dose response curve presented in this chapter were used 
to calculate breast dose from exposed sheets of Gafchromic® XR-QA2 film placed in 
RANDO’s breasts and the results are presented in chapter 5. 
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4. EXPERIMENTAL DESIGN  
The objective of this thesis is to investigate the relationship between breast dose and 
tube angulation in coronary angiography (CA). To assess the breast dose in CA, sheets of 
Gafchromic® XR-QA2 film were positioned between the breast slices and on the chest wall 
of an anthropomorphic phantom. The phantom was exposed to individual beam 
angulations typically used in CA procedures, and the dose distribution analysed from the 
film. In addition, an imitation CA procedure (mock CA) was conducted on the phantom 
consisting of typical combinations of tube angulations and exposures. Breast dose and 
effective dose were also calculated using a simulation program.  
Section 4.1 is the materials and apparatus, including the specifications of the 
anthropomorphic phantom, set up of the Gafchromic® XR-QA2 film, and technical 
information on the fluoroscopy system. Section 4.2 describes the controlled conditions of the 
experiment and the mock CA procedure. Section 4.3 describes the steps for dose analysis 
and the conversion from mean pixel values extracted from Gafchromic® XR-QA2 film to 
breast dose. Section 4.4 describes a well established Monte Carlo program used for 
dosimetry in X-ray energies. This program was used to compare breast dose from 
experimental results.  4.1. MATERIALS AND APPARATUS 4.1.1 RANDO® - ANTHROPOMORPHIC PHANTOM 
The RANDO® is an anthropomorphic phantom product from The Phantom 
Laboratory. RANDO® man represents a 175 cm (5’9’’) tall and 73.5 kg (162 lb) male with no 
arms or legs. It consists of 70 slices, each 2.5 mm thick, constructed with two 
tissue-simulating materials: the RANDO® soft tissue material and the RANDO® lung 
material and a natural human skeleton. Both tissue materials are designed to have the same 
absorption as human tissue at normal radiotherapy photon energies [122]. Diagnostic X-ray 
photon energies are much lower than those used in radiotherapy but this should not have an 
impact on the measurements made using RANDO®. Further communication by email with 
a representative from The Phantom Laboratory confirmed that no correction factors are 
required when performing procedures using RANDO® at kilovoltage energies and 
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RANDO® is equivalent to human tissue at diagnostic photon energies [123]. The soft tissue 
material is manufactured with a proprietary urethane formulation. It has an effective atomic 
number and mass density which simulate muscle tissue with randomly distributed fat. The 
lung material has the same effective atomic number as the soft tissue material but with a 
density which simulate lungs in a median respiratory state. The molded lungs are 
hand-shaped and fitted to naturally fill the rib cage.  
Various breast sizes are available, and in this experiment size B cups were used. The 
breast shapes are not natural. The male RANDO® phantom has adaptor bases for matching 
breasts to the male’s chest contours. Human breasts are not symmetrical and RANDO® also 
has asymmetrical breasts as indicated by the measurements in table 4-1 and in the 
manufacturer’s brochure [122]. The size B cup breasts are made up of 3 slices, each slice is 
approximately 2.5 cm thick, resulting in a total thickness of 7.5 cm. The left breast weighed 
0.45 kg while the right breast weighed 0.55 kg. It is worth noting that the left breast appears 
significantly smaller than the right breast, although the thicknesses are the same.  
 
Table 4-1: Measurements and sizes of the breast components used for the experiment in conjunction with  the 
RANDO® torso 
 Left breast  Right breast  
Slice 1  Slice 2 Slice 3  Slice 1  Slice 2 Slice 3  
Length (cm) 12.3 11 9 12.5 11 9.2 
Width (cm) 11.7 10.5 8.8 11.9 10.5 9 
Height (cm) 2.5 2.5 2.5 2.5 2.5 2.5 
Weight (kg) 0.2 0.18 0.07 0.25 0.18 0.12 
Total weight (measured) 0.45 kg (± 5%) 0.55 kg (± 5%) 
 
The size B cups were selected to represent the equivalent thickness overlying the 
chest for a patient with large breasts lying supine, which is approximately 5 – 7 cm. 
Although the RANDO® breast slices are upright and rigid, they approximated the scenarios 
used clinically in terms of proximity to patient’s chest. It is anticipated that due to gravity, 
majority of the breast tissue would fall to the patient’s side regardless of additional breast 
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size. Thus the experiment with RANDO® is intended to be indicative of a typical patient 
while recognising that considerable variation will exist within the patient population.  
Compared to human breasts, the RANDO® breasts are very rigid as shown in figure 
4-1. Under normal circumstances, when a person lays supine, the breast tissue will fall away 
from the chest as demonstrated in the CT image (figure 4-2). This suggests that the size of 
the breasts in terms of cup size does not have much influence as they will drop to a certain 
degree when the patient is lying supine. Therefore measurements at even greater distances 
from the chest wall are not important. Figure 4-3 is a series of CT cross-sectional images 
(axial slices) of RANDO® with the breast slices sitting on the anterior chest wall. The images 
of RANDO® through the CT scanner clearly show the heart and other organs are absent in 
the phantom, thus during the experiment, the location of the heart was estimated.  
 
Figure 4-1: The RANDO® phantom with the B cup breasts sitting on the anterior chest wall. The breasts are 
very rigid and upright in shape. 
 
Figure 4-2: An axial slice of a chest CT scan. This image demonstrates how the breast tissue is displaced to the 
side of the patient when laying supine. 
Breasts 
Nipple 
Adipose tissue 
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Figure 4-3: Axial slices of a CT scan of RANDO®, from slice 11 to slice 25 (from left to right). Each slice 
represents a thickness of 2.5 cm along the z-axis. The breasts pieces are placed on the chest anterior and appear 
slightly asymmetric and are very rigid.   
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For our experiment, slice 14 to slice 25 (approximately from the sternal notch or 3rd 
thoracic vertebra to 2nd lumbar vertebra) of RANDO® were used, because a CA essentially 
observes the heart with predominantly the thoracic cavity being irradiated, while the rest of 
the body does not receive much direct or scatter radiation with the beam angulations used in 
this type of procedure. A table in the appendix C1 lists the dimensions of each slice. 4.1.2 GAFCHROMIC® XR-QA2 FILM 
A single sheet of the Gafchromic® XR-QA2 film was placed on the posterior surface 
of RANDO® to measure entrance skin dose for the mock CA procedure. Cut-outs of film 
were placed on the anterior chest wall and sandwiched between the breast slices to measure 
breast dose at three different depths as shown in figure 4-4. The results from the dose 
calibrations described in chapter 3 for the Gafchromic® XR-QA2 film were used to interpret 
the dose values recorded during exposures. 
 
Figure 4-4: Images of Gafchromic® XR-QA2 film placed on RANDO®’s chest (a) and the breast layers (b, c, d). 
The gaps where pegs were used to connect the slices were interpolated using MATLAB. 4.1.3 EQUIPMENT – SHIMADZU BRANSIST SAFIRE UNIT 
The apparatus used in this experiment was a Shimadzu BRANSIST Safire HF9 flat 
panel detector angiography unit. It employs direct conversion technology with flat panel 
detectors (FPD), a floating patient tabletop and has a maximum 9 × 9 inch field of view. It is 
configured with automatic brightness control (ABC) and multi-beam hardening (MBH).  
The automatic brightness control as described in section 2.4.1.2 automatically 
modulates the beam energy (kVp) and tube current (mA) to achieve sufficient patient 
penetration and photon flux at the detector based on patient attenuation, and displays an 
appropriate brightness on the viewing monitor. This gives the operator no manual control 
(a) (c) (d) (b) 
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over the generator parameters. The operator may change the source to image panel distance, 
table height, table translation, tube angulation, field size and collimation.   4.1.4 BEAM FILTRATION AND DAP METER 
Multi-beam hardening is an automated filter located inside the collimator unit. It is 
designed to select the optimum filter for an examination or operation mode so as to exclude 
soft X-rays that do not contribute to the image but would contribute to dose. This is because 
the soft X-rays are not energetic enough to reach the imaging panel to provide information 
but are subsequently attenuated in the patient, resulting in a dose deposition. The Shimadzu 
unit has four possible beam filtration (BH) settings installed on the system and they are 
listed below in table 4-2. A specific filter is assigned to each protocol and the filtration does 
not change with patient size. During the ABC enabled and manual calibrations, the BH 2 
filter was activated because it was associated with the selected clinical RAD-DA protocol. 
For the mock CA procedure, the BH 3 filter was activated for the screening mode, 
and the BH 2 filter for the acquisition mode (DA). The system will automatically switch 
between these two filters as the operator toggles between screening or acquisition mode 
with a foot switch. The sequence for the procedure was the same as would be conducted on 
a patient, with screening used initially to insert the guide wire and catheter, then a short 
amount of screening preceding each acquisition run. DA contribution is greater than 
screening [70, 74, 77, 117]. 
 
Table 4-2: Multi-beam hardening wheel setting on the Shimadzu Safire unit 
Protocol MBH Name Filter Material 
Cardiac-Fluoro 15H 
Abdo-Fluoro 15H 
BH 1 2mm of Aluminum + 0.1mm of Copper 
Rad- DA, RSM, DSA BH 2 1mm of Aluminum 
Cardiac-Fluoro 15N and 30H 
Abdo-Fluoro 15N 
Other-Fluoro 
BH 3 1.5mm of Aluminum + 0.3mm of Copper 
Other – All Fluoro BH 4 1.5 mm of Aluminum + 0.6 mm of Copper 
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The DAP meter as described in section 2.5.1 was recorded per acquisition during the 
experiment and mock CA procedure. This was so the breast dose could be normalised to 
DAP for analysis. The DAP meter was calibrated against the Piranha dose probe before 
commencing the experiments.  4.2. METHOD 
A set of controlled experiments were performed by the author to investigate the effect of 
tube angulation variation to the measured breast dose. A mock CA procedure was 
performed by an experienced cardiologist who worked at the Austin Hospital. This was 
because we wanted to compare the difference between a simulated procedure performed by 
a cardiologist and the experiment and simulations. Sections 4.2.1 and 4.2.2 are descriptions 
of these procedures respectively.  4.2.1 CONTROLLED CONDITIONS – TUBE ANGULATIONS 
Table 4-3 lists out the tube angulations used for the experiment, they were selected 
based on typical tube angulations for a CA procedure [124,125]. As described in section 
2.4.2, certain tube angulations provide better anatomic definition because it avoids 
overlapping or foreshortening critical arteries that the cardiologist needs to access to assess 
the functionality of the heart. 
At each tube angulation, manual exposure setting was used. The X-ray generator 
parameters were fixed to 84 kVp, 400 mA and 20 ms in DA mode at a source-to-image 
receptor distance (SID) of 100 cm, table height at 90 cm from the floor and a 6” field of view. 
A total of 6 x 10 second exposures were made per tube angulation, this was to expose the 
film with enough radiation to obtain a measurable dose with small uncertainty.  
The tube angulations used in the experiment are defined into two configurations, 
single and combined. A single tube angulation is when only one angle is changed in either the 
transverse or sagittal plane and a combined tube angulation is when the angle changes in 
both transverse and sagittal planes. These configurations represent those typically used in 
CA procedures.  
The patient floating tabletop remained in the same location for each of the single tube 
angulation, thus at some larger angles (e.g. CRAN 40º and CAUD 40º) the SID was changed 
to 101 cm to avoid the flat panel detector crashing into the RANDO® phantom. 
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Accompanying illustrations of the tube angulations are shown in figures 4-5 and 4-6. Note 
that the tube angulation is named according to the position of the flat panel detector with 
respect to the patient and not the direction of the X-ray beam being directed at. 
 The combined tube angulations are the same as those used in the mock CA 
procedure performed by a cardiologist (section 4.2.2). These were taken as a comparison 
between single tube angulations as it is more common to use combined tube angulations to 
view the heart.  
The breast dose conversion coefficients for the combined tube angulations were 
determined to assess whether they followed the trends and findings derived from the single 
tube angulations and to compare with the mock CA procedure.  
 
Table 4-3: Tube projections used for this experiment 
LAO 10º RAO 10º CRAN 10º CAUD 10º 
LAO 30º RAO 30º CRAN 30º CAUD 30º 
LAO 40º RAO 40º CRAN 40º CAUD 40º 
PA (straight) LAO 34º / CAUD 6º LAO 35º / CRAN 31º LAO 42º / CAUD 27º 
RAO 2º / CRAN 30º RAO 6º / CRAN 40º RAO 33º / CRAN 4º RAO 31º/ CAUD 28º 
 
70 | P a g e  
 
 
Figure 4-5: Visual representations of the single tube angulation configurations. The C-arm gantry rotates 
around the isocentre located at 65 cm from the focus when positioned in a PA position.  
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Figure 4-6: Visual representations of the combined tube angulations. These angles are more complex, but allow 
better anatomic definition of particular arteries by avoiding overlap and foreshortening particular vessels. They  
are frequently used in clinical cases.  4.2.2 MOCK CORONARY ANGIOGRAPHY PROCEDURE 
The mock CA procedure was performed by an experienced cardiologist who worked 
at the Austin Hospital. The parameters that were controllable by the operator were tube 
angulation, field of view, table height, patient positioning, screening time and acquisition 
time. Screening and acquisition are two modes of fluoroscopy the operator may select 
during a CA procedure. Table 4-4 lists the typical parameters used during screening and 
acquisition mode from patient data. Screening mode is a comparatively low dose mode used 
for patient positioning and alignment. Acquisition (DA) mode is a high dose rate 
fluoroscopy mode used for taking high quality diagnostic images of the anatomy of interest. 
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Table 4-4: Typical parameters used for each of the fluoroscopy modes during a CA procedure from patient data. 
Mode MBH kVp mA Approximate dose rate at 
FPD (µGy/min) 
Screening BH 3 60 – 80 7 – 20 18 
Acquisition BH 2 70 – 120 600 – 800 150 
 
A benefit from combining patient positioning and tube angulation is to reduce the 
entrance skin dose to the patient’s posterior as any overlapping fields as well as prolonged 
exposure time will result in a higher chance of deterministic effects occurring at that 
location. The posterior entrance skin dose was measured during the CA mock procedure to 
compare with values from the literature. The breast dose was measured by accumulating 14 
mock CA procedures to ensure a substantial dose was delivered to the breast layers and 
minimise the uncertainty associated with extracting low dose measurement from the 
Gafchromic® film. .  
The 15 cm x 15 cm (6 inch) field of view was used for all acquisitions except for 
acquisition #9 (table 4-5), which used a 23 cm x 23 cm (9 inch) field of view at the end of each 
mock CA procedure. This was because the usual last acquisition is used to assess the 
functionality of the left ventricle and it requires a larger field of view to ensure full coverage 
of the ventricle [124, 125]. This LV view was only performed during the mock CA procedure 
and not during the experiment. 
The source to image receptor distance (SID) was varied slightly for the different tube 
angulations because otherwise the FPD would crash into RANDO®. The X-ray parameters 
were automatically adjusted under the system’s automatic brightness control (ABC mode). 
Table 4-5 shows the recorded parameters used for each acquisition of the mock CA 
procedure, including tube angulation, SID, kVp, mA, pulse width, number of frames, 
exposure time and DAP. Compared with the values in table 4-4, the mock CA procedure 
values are similar to those from patient data. The tube angulations used in the mock CA 
procedure will be collectively known as clinical tube angulations as they are a combination of 
single and combined tube angulations.  
All acquisitions were performed with pulsed fluoroscopy at 15 frames per second, 
except for acquisition #9 which was performed at 30 frames per second. Acquisition #9 is 
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the LV view, which uses a 9 inch FOV and requires a faster frame rate to capture the left 
ventricular function. The sum of the 9 acquisitions gave a total DAP of 14.06 Gy.cm2.  
 
Table 4-5: Parameters recorded during the mock CA procedures. 
Acquisition Tube angulations SID 
(cm) 
Tube factors Number 
of  
frames 
Time (s) Gy.cm2 
kV mA ms 
#1 LAO31 / CAU28 101 79 596 5 35 4.7 1.22 
#2 CAU39 96 79 590 5 27 3.6 0.94 
#3 RAO6 / CRA40 102 99 610 8 34 4.5 1.19 
#4 LAO35 / CRA31 104 101 585 9 42 5.6 1.46 
#5 LAO42 / CAU27 98 87 628 5 32 4.3 1.12 
#6 LAO34 / CAU6 96 83 634 6 31 4.1 1.08 
#7 RAO2 / CRA30 99 80 604 5 39 5.2 1.36 
#8 RAO33 / CRA4 99 77 572 5 32 4.3 1.12 
#9 RAO33 / CRA4 99 71 518 3 131 8.7 4.57 
      Total DAP 14.06 
         4.3. DOSE ANALYSIS   
After the experiments were performed, the Gafchromic® films were taken to a 
flatbed scanner to be scanned into image files for analysis. The following steps were taken to 
extract dose information: 
1) Scan film according to protocol in chapter 3 (with slight adjustments in cases where 
the film sizes were non-identical). 
2) Extract mean pixel value (MPV) of film using ImageJ. 
3) Convert MPV into dose values in Excel using the calibration equation from chapter 3. 
4) The ABC disabled calibration curve was used for the controlled tube angulations 
data analysis. 
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5) The ABC enabled calibration curve was used for the mock CA procedure data 
analysis.  
6) Use MATLAB to interpolate the data gaps where pegs were used to connect the 
breast slices.  
7) Arrange dose values into a distribution map in MATLAB for the mock CA procedure 
only. 
The following subsections provide a brief description of each step taken to produce the 
graphs and dose values presented in the results chapter.  4.3.1 FLATBED SCANNER, IMAGEJ, MS EXCEL AND MATLAB 
The same flatbed scanner and scanner settings used for the calibration described in 
section 3.3.2 was used to digitise all the Gafchromic® XR-QA2 film exposed to radiation 
during the experiments and mock CA procedure. Each scanned Gafchromic® XR-QA2 film 
collage was digitised as a tagged image file format (tiff) file and ImageJ (National Institute of 
Health, Bethesda, MD) version 1.45s was used to extract the MPV from the image file. The 
extracted MPV was converted into a dose value in Microsoft Excel (2007) using the 
calibration curves obtained from chapter 3.  
Each dose value was then divided by the number of exposures performed to ensure 
substantial dose was deposited to the XR-QA2 film in the breasts for analysis. For the 
experiments, this was repeated 6 times per tube angulation and for the mock CA procedure 
this was repeated 14 times per acquisition.  
MATLAB 7.10.0 R2010a (MathWorks) was used to interpolate the gaps where 
Gafchromic® XR-QA2 film was not placed within a slice, i.e. where there were pegs to 
connect breast pieces together. After that was completed, dose distribution maps for the 
posterior skin entrance and breast layers were displayed using MATLAB functions. The few 
lines of code used for the interpolation can be found in the appendix C2. 
For both experiment and mock CA procedures the breast dose were normalised to 
DAP as a breast dose conversion coefficient.  
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4.3.2 BREAST DOSE AND POSTERIOR ENTRANCE SKIN DOSE 
Gafchromic® XR-QA2 film was placed in the breast slices to collect absorbed dose. A 
circular mask was used to ensure that only exposure within the breast slice was extracted 
from the film to be included in calculating the absorbed breast dose. The Gafchromic® 
XR-QA2 film placed on the chest anterior was fully covered by the breast layer 1, thus the 
entire piece of Gafchormic® film was used to compute as the dose for breast layer 1(figure 
4-4).  
Breast organ dose was calculated as the weighted mean dose value deposited on the 
XR-QA2 film located within the breast slices. Individual breast organ dose for each left and 
right breast were also calculated using a mass weighted average method as expressed in the 
equations below, where l1 stands for the mean dose measured at layer1 and so on: 

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The layer1 dose was taken as the average of the dose deposited to the base of breast 
layer 1 (anterior chest), thus breast layer 3 is actually the base of the last breast slice (figure 
4-4). It was difficult to correlate exact locations from above and below the slices. The surface 
area of the top and base of each breast slice are different, therefore it was determined 
impractical to average the dose deposited on the two surfaces as the average dose delivered 
to a breast slice, especially when the top of the last breast slice is a hemisphere. Instead the 
base of each breast slice was taken as the plane indicative of the average dose of that breast 
slice.  
In clinical settings, the posterior entrance skin dose is not measured. This is because 
it is deemed impractical to have detectors (TLDs, film etc.) to cover the entire posterior of the 
patient. Thus the posterior entrance skin dose is normally inferred from DAP value using 
the inverse square law principle as discussed in section 2.5.2 and a backscatter factor to 
account for scatter radiation from the posterior. This simplified equation is often used to 
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estimate patient entrance skin dose, where DAP is the accumulated DAP from the 
procedure, FSD is the focus-to-skin distance, SID is source-to-imaging panel distance, A is 
the area at the imaging panel and BSF is the nominal backscatter factor of 1.35 [5]. Equation 
23 does not take into account table attenuation. 
BSFASIDFSDDAPESD ××÷= )/(  (23), 
For the mock CA procedure, the posterior entrance skin dose (ESD) was recorded on 
a 10” x 12” single piece of Gafchromic® XR-QA2 film. The ESD was calculated as the mean 
dose value recorded on XR-QA2 film from the posterior of RANDO®. This was compared 
with the conventional method of inferring ESD from the DAP as outlined in equation 23.  
It was anticipated that one breast would record a higher absorbed dose as a 
consequence of varying tube angulations, where the primary beam will pass through one 
breast more frequently than the other due to the anatomical asymmetry. 
The posterior entrance skin dose (ESD) and maximum entrance skin dose (MESD) 
measured from the mock CA procedure were compared with those obtained by various 
studies in the literature quoted in section 2.4 to ensure that the mock CA procedures 
performed in this thesis are similar to those performed in the clinical setting. 4.4. PCXMC SIMULATION  
A well established simulation program, PCXMC was used to compare the 
experimental results from Gafchromic® film. This section provides an overview of the 
simulation software and describes the methodology for the analysis to follow in chapter 5. 4.4.1 PCXMC OVERVIEW 
PCXMC is a PC-based Monte Carlo program for calculating patient organ dose, 
effective dose and the risk of death from radiation induced cancers in medical X-ray 
examinations. The Monte Carlo method of photon transport calculation is based on 
stochastic mathematical simulation of interactions between photons and matter. Photons are 
emitted from a point source into the solid angle specified by the focal distance and the  
X-ray field dimensions, and followed. The photons will randomly interact with the phantom 
according to the probability distributions of the physical processes that they may undergo: 
photo-electric absorption, coherent scattering (Rayleigh) or incoherent scattering (Compton).  
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Other interactions are not considered in PCXMC because the maximum photon 
energy is limited to 150 keV. At each interaction point the energy deposition to the organ at 
that position is calculated and stored for dose calculation. This chain of interaction events 
forms a so-called history of an individual photon. A large number of independent photon 
histories is generated, and estimates of the mean values of energy depositions in the various 
organs of the phantom are used for calculating the doses in these organs [126]. 
Calculated organ doses can be used for the assessment of the risk of 
exposure-induced cancer. The risk estimates are based on the combined absolute and 
relative risk models of BEIR VII committee [37]. PCXMC calculates the risk of 
exposure-induced death (REID) for leukaemia, cancers in colon, stomach, lung, urinary 
bladder, prostate, uterus, ovaries, breast, liver, thyroid and for all other solid cancers 
combined. The user may use the risk calculation module for estimating the cancer risk 
resulting from a single exposure or multiple exposures simulated in PCXMC. The data 
calculated by PCXMC have been earlier compared to the organ dose conversion factors 
calculated in NRPB by Jones and Wall [127] and Hart et al [128] and were found to agree 
well [126]. Reasonable agreement of PCXMC results has also been found in many 
comparisons with dose measurements and calculations with other phantom models, e.g., 
Schmidt et al [127] and Schultz et al [130].  
PCXMC allows free adjustment of the X-ray beam projection (tube angulation) and 
other examination conditions of projection radiography and fluoroscopy. It uses anatomical 
data based on the mathematical hermaphrodite phantom models of Cristy and Eckerman 
[131], which describe patients of six different ages: new-born, 1, 5, 10, 15 year old and adult, 
with some modifications to make them more realistic for external irradiation conditions and 
to enable the calculation of the effective dose according to the new ICRP Publication 103 
tissue weighting factors.  
The phantom weight and height are user-adjustable. All organ doses calculated by 
this program are relative to the incident air kerma. The air kerma is the kinetic energy 
released in matter at the point where the central axis of the X-ray beam enters the patient. It 
is given in units of milligray (mGy), free-in-air and without backscatter. The user must 
supply the amount of radiation input as either the entrance exposure (mR, free-in-air, 
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without backscatter), air kerma-area product or dose-area product (mGy.cm2), or exposure-
area product (R.cm2) [132]. 
One of the quantities used in PCXMC for lifetime risk estimates is the term risk of 
exposure-induced death (REID). REID originates from cohort analysis techniques where 
death rates in the exposed and unexposed cohorts are compared. A positive REID value 
indicates excess deaths in the exposed cohort. In the risk assessment model of BEIR the 
REID-values of relative and absolute risk models are combined and are given the weights of 
0.7 and 0.3 respectively. For breast cancer only the absolute model is used [126]. The 
Euro-American mortality and cancer incidence data are from ICRP publication 103 [6]. 4.4.2 PERFORMING THE PCXMC DOSE CALCULATIONS 
A dose calculation using PCXMC involves three steps – (1) defining the examination 
conditions, (2) performing the Monte Carlo simulation, and (3) calculating the organ doses 
for a specified X-ray spectrum and patient input dose.  
In defining the examination, phantom data and geometric data for the X-ray beam is 
required. Phantom data includes selecting an age group (0, 1, 5, 10, 15, and adult), phantom 
height and mass and whether the arms are included. Geometric data includes FSD, beam 
width and height (as measured at the distance FSD from the focal spot and in the plane that 
is normal to the central axis of the X-ray beam), projection angle, cranio-caudal angle and a 
reference point inside the phantom (Xref, Yref, Zref).  
A phantom image and a radiograph image are available to assist with finding proper 
coordinates for the reference point inside the phantom, through which the central axis of the 
X-ray beam is directed. Figure 4-7 is a screenshot defining the PA examination in the 
PCXMC program [132].  
79 | P a g e  
 
 
Figure 4-7: A screenshot of PCXMC simulation. The bottom right is a radiograph of the anatomy selected by the 
X-ray beam geometry. 
When replicating the mock CA procedure in the simulation, the radiograph image 
was used because the software will centre in on the organ selected in the radiograph. So that, 
as the tube angulations changed in the mock CA procedure, the simulation was able to keep 
the X-ray beam centred on the target organ (the heart). 
However because the RANDO® phantom does not contain a well defined heart, the 
experiment was actually performed by positioning RANDO® with external markers rather 
than centring the heart. The author used the spine as a landmark to align the phantom along 
the x-y plane and the centre of the detachable breasts to align the z-axis. It was assumed that 
the heart resides between the RANDO® breasts. Once this was setup in the PA condition, 
the patient table remained stationary for all the other tube angulation exposures in the 
experiment. This meant the experiment did not fully replicate a cardiac procedure. Thus a 
simulation that replicated the experiment was also required for direct comparison.  
Therefore two sets of simulations were done, one that replicated a cardiac procedure 
with patient table movement and another simulation that replicated the experiment with the 
spine centred in the PA tube angulation and no further table movement for the rest of the 
tube angulations.  
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The PCXMC uses the FSD to determine dose, so the displacement from the midline 
needs to be corrected for to match what was actually occurring with the fluoroscopy unit. 
The FSD and beam size was corrected for each angle change because the isocentre for the 
fluoroscopy unit was at 65 cm from the focus, whereas the PCXMC simulation rotates the 
X-ray beam according to the point that enters the skin surface of the phantom. Using 
trigonometry, the displacement from the isocentre on the fluoroscopy system was translated 
to the displacement on the table top where the RANDO® phantom was. This was then 
entered into the PCXMC simulation.  
Figure 4-8 illustrates how to calculate and account for this displacement. A summary 
of the reference points, FSD and X-ray beam size adjustments used to perform all the 
simulations in PCXMC can be found in appendix C3. 
 After the definitions of each examination are set, the program will then simulate 
these conditions and the results of the simulation are automatically saved to be used for 
calculating organ doses for any X-ray spectrum and input dose. The X-ray spectrum selected 
to calculate the breast organ dose was chosen at 84kV, 8° target angle and 4 mm Al total 
filtration. The filtration remains unchanged during the simulation because it did not vary 
during the experiment.  
A DAP value from the experiment for the corresponding tube angulation from table 
4-3 were entered into the PCXMC simulation to calculate the breast dose. The result of the 
simulation is tabulated in chapter 5.  
 
Figure 4-8: Trigonometry used to correct for projection angle used in PCXMC versus on the fluoroscopy system.    
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4.5. UNCERTAINTY ANALYSIS  
In addition to the uncertainty calculated in sections 3.3.3.2 and 3.3.4.2, the 
uncertainties from the experimental work and the film size variability needs to be included. 
Table 4-6 below summarises the source of uncertainty in x, and table 4-7 lists the 
uncertainties in digitizing film (x), from experimental parameters (cal), from fitting the 
calibration curve (fit) and the total uncertainty in the measured dose (D).  
Note that the source of uncertainty in x is the same for both calibrations (ABC 
enabled and ABC disabled) because it is related to digitizing the film. The uncertainty in 
curve fitting (fit) and the experiment parameters (cal) are the main difference between the 
ABC enabled and ABC disabled (manual mode) calibrations. 
 
Table 4-6: The uncertainty in scanning protocol and in the measured dose for the experiment.  
Source of uncertainty for σx Uncertainty 
Bed scanner variability [113] 4% 
Film scanning orientation [113, 110] 2% 
Film uniformity [113] 3% 
Pixel value 3.5% 
  
Table 4-7: The uncertainty in the measured dose for the experiment and its components. 
 ABC enabled ABC disabled 
Uncertainty in digitising film (σx) 6.4% 6.4% 
Uncertainty in experiment parameters (σcal) 7% 8% 
Uncertainty in curve fitting (σ f it) 9% 14% 
Uncertainty in measured dose (σD) 13% 17% 
 
As previously mentioned in chapter 3, the Gafchromic® XR-QA2 film may be highly 
energy dependent. The ABC is utilised in the mock CA procedure and this modulates the 
beam energy and tube current. This variation will increase the polychromatic nature of the 
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X-rays contributing dose to the film. These energies cannot be distinguished and therefore 
the uncertainty of the measured dose is mainly due to the energy dependence of the 
XR-QA2 film and the varying nature of the X-ray system. 4.6. SUMMARY  
The relationship between breast organ dose and various tube angulations in CA was 
investigated in this study under a controlled experiment and a simulated CA procedure 
(mock CA). These were performed on an anthropomorphic phantom and Gafchromic® 
XR-QA2 films were used to record the exposure from both controlled and simulated 
procedures. The simulated CA procedure was based on clinical procedures but the 
measurements were not taken from patients, therefore it is termed a mock procedure in this 
thesis. The set up was designed to measure the breast dose using the RANDO® phantom.  
In addition, the dose distribution on the anterior chest wall and the posterior skin 
entrance were measured. The posterior entrance skin dose (ESD) measured is used as a 
verification to make sure the mock CA procedures are within the measured ESD from other 
CA procedures performed in the literature. The data gathered for the anterior chest wall 
would be something that hasn’t been investigated in the literature before and will also 
provide useful information on how the dose enters the breasts.  
When the patient is lying supine, the breast tissue tends to fall off towards the sides 
rather than stay in a rigid form like the breasts on the RANDO® phantom. It was estimated 
that for a patient with large breasts, the total breast thickness was approximately 7cm, thus 
the B cup breast size (approximately 7 - 7.5 cm) was selected for the RANDO® phantom.   
The PCXMC uses the Monte Carlo method to calculate absorbed organ dose and 
effective dose. The process involves tracking photon interactions such as photoelectric effect 
and Compton scattering in a mathematical phantom. In addition, the PCXMC software 
provides effective dose and risk estimates for a range of age groups, which are all very 
useful.   
83 | P a g e  
 
5. EXPERIMENTAL RESULTS  
The breast dose was measured for a set of single and combined tube angulations 
most commonly used in a CA procedure. A single tube angulation here means the FPD was 
moved in one axis only, e.g. LAO 10 where the FPD tilts 10° towards the patient’s left side. A 
combined tube angulation combines the FPD tilt in two axes, e.g. LAO 10 / CAU 20 where 
the FPD tilts 10° towards the patient’s left side and 20° caudally to the patient.  
Breast dose measurements were successfully extracted from the Gafchromic® 
XR-QA2 films and breast dose conversion coefficients were produced. PCXMC simulations 
were performed for the tube angulations used in the experiment. Breast dose, effective dose 
and risk estimates (only for mock CA procedure) were retrieved from the simulations.   
A mock CA procedure comprising an accumulation of clinical tube angulations on 
the Gafchromic® XR-QA2 film was performed. Dose measurements at 3 different planes in 
the breasts were collected and the posterior skin entrance and maximum skin dose were 
collected in the same mock CA procedure. Table 5-1 lists the terms used to describe the 
doses measured using the RANDO® phantom, their location and the beam direction.  
 
Table 5-1: Terminology used to describe doses measured within the RANDO® phantom 
Term Location and beam direction 
Posterior Entrance Skin Dose  At patient posterior (under-table X-ray tube) 
Breast Dose At patient anterior (the dose deposited within the breast organ) 
Breast slice or layer  The dose deposited on each of RANDO®‘s breast slices counting 
from 3 as the smallest piece (furthest from chest) and 1 as the largest 
piece (closest to chest)  
Exit Dose The dose deposited on breast slice 3 (the beam exiting the breast) 
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The outcome of the experiment indicated an asymmetic trend in breast dose as the 
tube angulation deviated from PA for both transverse and sagittal planes. PCXMC 
simulation agreed with the experimental result for movements in the sagittal plane. For the 
mock CA procedure, the results indicated a higher dose deposition to the left breast than the 
right, in contrast to findings from the single and combined tube angulation configurations 
from the experiment.  
In section 5.1 the breast dose conversion coefficients for single and combined tube 
angulations are presented in tables and histograms. In section 5.2 the PCXMC simulation 
results are presented. Section 5.3 presents the breast dose and the entrance skin dose from 
the mock CA procedure using clinical tube angulations as two-dimensional dose plots 
corresponding to the films placed in breast layers and skin posterior. Finally section 5.4 
presents the uncertainties from the results.  5.1. BREAST DOSE AS A FUNCTION OF TUBE ANGULATION 
The breast dose was measured at a range of tube angulations typical of a CA 
procedure (table 4-3). Table 5-2 summarizes the breast dose conversion coefficients 
measured in mGy per DAP for the single and combined tube angulation configurations. The 
dose conversion coefficients include the left and right breast dose and exit dose. The 
accompanying figures following the table 5-2 emphasize the relationship between the breast 
dose and the single tube angulations in the transverse plane (figure 5-1 and figure 5-3) and 
sagittal plane (figure 5-2 and figure 5-4). Note that cranial indicates the position of the flat 
panel detector (rather than the X-ray tube) is towards the patient’s head. Refer to section 
4.2.1 for definitions and illustrations of tube angulation.  
Combined tube angulation is more complex than the single tube angulation as 
displayed in figure 5-5 and figure 5-6. In general, the trend for the breast dose conversion 
coefficient decreases as the X-ray tube moves away from the PA position and the dose to the 
left breast is normally less than the right breast. The majority of the X-ray beam is attenuated 
by the soft tissue inside the RANDO® phantom, leaving very minimal primary beam 
reaching the breast layer #3 where the exit dose was measured. Therefore the exit dose 
measurements are indications of scattered radiation to the breast for various tube 
angulations.  
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To ensure a measurable dose was absorbed by the film at each tube angulation, six 
exposures were made at each position to the individual film. The reproducibility of the 
repeat exposures were such that the mean DAP for the single tube angulation experiment 
was 79.7 Gy.cm2 and a standard deviation of 4.5 Gy.cm2. The mean DAP for the combined 
tube angulation experiment was 83.8 Gy.cm2 and a standard deviation of 1.4 Gy.cm2. Thus 
the individual doses were higher than for standard CA procedures and the dose conversion 
coefficients have been normalized to DAP (Gy.cm2).  
The skin entrance area was calculated to be 98.1 cm2 at FSD of 65 cm for PA. Using 
the equation from section 4.3.2, this gave a posterior entrance skin dose of 1.1 Gy for the 
single tube angulations and 1.2 Gy for the combined tube angulations. 
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Table 5-2: Breast dose conversion coefficients (mGy / Gy.cm2) determined from measured dose using XR-QA2 
film and DAP values for LAO and RAO single tube angulations. The grayed row is the PA tube angulation.  
Dose conversion coefficients (mGy / Gy.cm2) 
Tube angulation Breast Left breast Right breast Left exit Right exit 
LAO 40° 0.11 0.12 0.11 0.04 0.01 
LAO 30° 0.13 0.13 0.14 0.05 0.02 
LAO 10° 0.17 0.16 0.18 0.06 0.03 
PA 0° 0.21 0.17 0.25 0.04 0.04 
RAO 10° 0.2 0.17 0.23 0.04 0.07 
RAO 30° 0.14 0.11 0.16 0.03 0.04 
RAO 40° 0.12 0.1 0.14 0.02 0.04 
CAUD 40° 0.12 0.09 0.14 0.02 0.03 
CAUD 30° 0.19 0.15 0.21 0.03 0.04 
CAUD 10° 0.2 0.16 0.24 0.04 0.06 
PA 0° 0.21 0.17 0.25 0.04 0.04 
CRAN 10° 0.21 0.16 0.25 0.03 0.06 
CRAN 30° 0.11 0.09 0.13 0.02 0.03 
CRAN 40° 0.06 0.06 0.07 0.02 0.02 
RAO 6° / CRA 40° 0.07 0.06 0.07 0.02 0.02 
RAO 2° / CRA 30° 0.11 0.1 0.11 0.03 0.03 
LAO 35° / CRA 31° 0.08 0.05 0.1 0.01 0.02 
RAO 33° / CRA 4° 0.15 0.13 0.16 0.02 0.03 
LAO 34° / CAU 6° 0.13 0.13 0.13 0.03 0.02 
LAO 42° / CAU 27° 0.1 0.09 0.1 0.02 0.01 
RAO 31° / CAU 28° 0.12 0.11 0.13 0.01 0.01 
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Figure 5-1 shows that the normalised breast dose would be at its greatest in a PA 
tube angulation. There is a minor difference in breast dose when comparing LAO and RAO 
at 30 and 40 degrees tube angulation. However at 10º there is a more significant asymmetry 
observed with the RAO 10 producing a higher dose. In the sagittal plane, the reverse trend is 
observed with the breast dose at CAU 10 and CRA 10 being quite symmetric, but beyond 10º 
the breast dose distribution is asymmetric. The CAU 30 and CAU 40 resulted in a greater 
dose than the CRA counterparts.  
 
Figure 5-1: Breast dose conversion coefficients as a function of tube angulation in the transverse plane. The 
uncertainties of these coefficients are ± 8.5%.The trend is that the breast dose falls as the X-ray tube moves away  
from a PA position.   
 
Figure 5-2: Breast dose conversion coefficients as a function of tube angulation in the sagittal plane. The 
uncertainties of these coefficients are ± 8.5%. The trend  is that the breast dose falls as the X-ray  tube moves 
away from a PA position with a steeper decline in the cranial direction. 
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In the PA tube angulation the XR-QA2 film in the left breast recorded 30% less dose 
than the right. This is attributed to two factors, the different sizes of the left and right 
breasts, and the fraction of the breast intersected by the beam. The breasts are not identical, 
thus the distribution of the breast on the chest would be uneven. This had an effect on the 
portion of the X-ray beam intersecting each breast. It is expected that one breast would 
receive more radiation than the other. Similar asymmetries are observable in real patient 
breasts and are discussed later in the section 6.2.  
Figure 5-3 shows the dose to the left breast was less than the right breast by 26 - 32% 
for the PA and RAO tube angulations. A similar trend is observed for the LAO tube 
angulations but with a smaller difference at approximately 9%, however there is an 
exception for LAO 40 where the measured dose to the left breast was slightly greater by 
10%. The uncertainty between the left and right breast dose in LAO 40 almost completely 
overlaps, so it’s difficult to distinguish their disparity. The variation in the right breast as the 
tube angulation varies in the transverse plane is more prominent than the left.  
 
Figure 5-3: Left and right breast dose conversion coefficients for single tube angulation in the transverse plane. 
The uncertainties of these coefficients are ± 8.5%. The trend is the right breast dose is always greater than the 
left breast. Even though for LAO40 the left breast is slightly higher, the uncertainties overlap. 
The left and right breast doses follow the same trend as the tube angulation varies in 
the sagittal plane as shown in figure 5-4. The difference between left and right breast dose 
ranges from 29 – 37% across the CAU-CRA tube angulations with the exception of CRA 40 
where the difference was 14%.  
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Figure 5-4: Left and right breast dose conversion coefficients for single tube angulation in the sagittal plane. The 
uncertainties for these coefficients are ± 8.5%.The trend is the right breast dose is always greater than the left 
breast.  
For more complex tube angulations, figure 5-5 shows a set of typical tube angulation 
combinations for a CA procedure. A combination of LAO–RAO in conjunction with 
CAU-CRA is used to observe particular veins and arteries in the heart. The RAO 33 /CRA 4 
tube angulation delivered the highest breast dose per DAP and the RAO 6 / CRA 40 
delivered the least.  
 
Figure 5-5: Breast dose conversion coefficients for combined  tube angulation. The uncertainties for these 
coefficients are ± 8.5%.The trend is not as obvious for complex tube angulations that are involved in clinical  
settings.  
 Figure 5-6 shows the left and right breast contributions to the breast dose. The 
variation ranged from 5 – 50% for the combined tube angulations. The largest variation was 
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from the LAO 35/ CRA 31 tube angulation and the smallest variation was from LAO 34/ 
CAU 6. This suggests the combined effects of LAO-RAO and CAU-CRA tube movements 
are very complex.   
 
Figure 5-6: Lef t and right breast dose conversion coefficients for combined tube angulation. The uncertainties 
for these coefficients are ± 8.5%. The trend is the right breast dose is always greater than the left breast, 
although their difference varies depending on the tube angulation. 
The only trend that could be established between the single and combined tube 
angulation was the behaviour for the CAU–CRA (sagittal plane) in the LAO direction. For 
example, RAO 6/ CRA 40, RAO 2/ CRA 30 and RAO 33/ CRA 4 exhibit an increasing dose 
trend as the CRA angle decreased. However LAO 35/ CRA 31 cannot be included in the 
sample because it is not in the same quadrant as RAO/CRA tube angulation. The same is 
true for LAO 42/ CAU 27 and LAO 34/ CAU 6 where an increase in dose is observed as the 
CAU angle decreased, but RAO 31/ CAU 28 cannot be included in the generalisation 
because it is situated in a different quadrant.  
There is a possibility that the combined effect of LAO-RAO and CAU-CRA tube 
angulation is more simply related to the quadrant and less strongly influenced by specific 
angle. Because only a limited number of combination tube angulations were performed, it is 
not possible to fully assess this notion in this thesis. In general, the combined tube 
angulation produced lower breast dose conversion coefficients than the single tube 
angulation. This is because combined tube angulations generally involve longer radiological 
path lengths.   
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5.2. BREAST DOSE FROM PCXMC SIMULATION  
The same parameters used in the experiment, such as tube angulation, DAP and kVp 
values were entered into the PCXMC simulation to calculate the absorbed dose to the breast 
and the effective dose. Table 5-3 summarises the breast dose coefficients calculated by 
PCXMC. All the coefficients have been normalized to DAP.  
The simulation allowed the user to position the X-ray beam by selecting a target 
organ in a radiograph. A simulation using the heart centred in the radiograph at all times 
even after a tube angulation change was performed. This scenario matches up with what 
occurs in a real CA procedure. However due to the absence of a definitive heart in the 
RANDO® phantom, the experiment was performed with no table movement after it was set 
up in PA position. The PA position was set up using external markers and the spine as 
indictors for alignment along the LAO-RAO axis and the detachable breasts to align the 
CAU-CRA axis. Because it was difficult to ascertain the location of the heart without 
exposing the film used to make the measurements, the most practical method was to 
perform the experiment without table movement once it has been set up in the PA position. 
This way, the experiment was reproducible because it eliminates guessing whether the heart 
was centred in the field of view after each tube angulation change. This meant a simulation 
of the experiment required positioning the mathematical phantom in PCXMC using the 
spine rather than the heart as the central pointer. Also the patient table was stationary for all 
the exposures in the experiment and a geometric correction used to account for the change 
in focus-to-skin distance at each tube angulation. Therefore two simulations were 
performed. One simulation that replicated a CA procedure with patient table movement and 
the other simulation that replicated the experiment performed with the Gafchromic® film 
inserts and no patient table movement. Refer to section 4.4.2.2 for illustrations.  
Unlike the breast dose conversion coefficients from section 5.1 the PCXMC program 
does not generate left and right breast doses. The accompanying figures following the table 
5-3 emphasize the relationship between the heart and the experimental simulations in the 
transverse (figure 5-7) and sagittal planes (figure 5-8) for single tube angulations, and 
combined tube angulation (figure 5-9). 
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Table 5-3: Breast dose conversion coefficients calculated from two PCXMC simulations for single and combined  
tube angulations. PA is shaded in gray. 
Breast dose conversion coefficients (mGy / Gy.cm2) 
Tube angulation Heart as the target organ Experimental set up 
LAO 40° 0.10 0.07 
LAO 30° 0.09 0.14 
LAO 10° 0.07 0.14 
PA  0.07 0.07 
RAO 10° 0.08 0.2 
RAO 30° 0.10 0.16 
RAO 40° 0.10 0.1 
CAUD 40° 0.05 0.05 
CAUD 30° 0.06 0.06 
CAUD 10° 0.07 0.07 
PA 0.07 0.07 
CRAN 10° 0.07 0.07 
CRAN 30° 0.06 0.05 
CRAN 40° 0.03 0.04 
RAO 6° / CRA 40° 0.04 0.04 
RAO 2° / CRA 30° 0.05 0.05 
LAO 35° / CRA 31° 0.06 0.06 
RAO 33° / CRA 4° 0.1 0.1 
LAO 34° / CAU 6° 0.1 0.09 
LAO 42° / CAU 27° 0.07 0.04 
RAO 31° / CAU 28° 0.08 0.05 
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Figures 5-7, 5-8 and 5-9 are histograms comparing the two PCXMC simulations in 
transverse and sagittal plane for single tube angulations and combined tube angulations. 
Note that the scale on the vertical axis (mGy/Gy.cm2) is different in figure 5-7 compared to 
figures 5-8 and 5-9.  
 
Figure 5-7: Breast dose conversion coefficients from two PCXMC simulations in the LAO-RAO axis. The 
statistical  uncertainty  is 5% for PCXMC-heart and 4.1% for PCXMC-experimental. The two simulations do 
not follow the same trends. 
 
Figure 5-8: Breast dose conversion coefficients from two PCXMC simulations in the CAU-CRA axis. The 
statistical uncertainty is 7.4% for PCXMC-heart and 5.1% for PCXMC-experimental. The two simulations 
follow the same trend. Note the vertical axis in figure 5-7 is different to this figure.  
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The CAU-CRA tube angulations yield much lower doses than the LAO-RAO tube 
angulations. The breast dose conversion coefficient in PA for the heart and experimental 
simulations are identical. The heart and experimental simulations behave very differently in 
the transverse plane, but the trend in the sagittal plane is similar.  
Figure 5-9 shows the trends for combined tube angulation. The difference between 
PCXMC-heart and PCXMC-experimental simulations are small for most combined tube 
angulation, with the exception of LAO 34/ CAU 6, LAO 42/ CAU 27 and RAO 31/ CAU 28. 
It doesn’t follow LAO-RAO nor CAU-CRA trends. So clearly the combined effect is a 
complex combination of these factors. Again, the influences in LAO-RAO and CAU-CRA 
configuration may be dependent on quadrant rather than specific angle.  
 
Figure 5-9: Breast dose conversion coefficients for combined tube angulation in PCXMC simulations. The 
statistical uncertainty is 4.8% for PCXMC-heart and 5.8% for PCXMC-experimental. The two simulations 
agree well in some configurations but disagree when CAU direction is involved. 
 The differences between the PCXMC-heart and PCXMC-experimental results arise 
from changes in the X-ray beam position with respect to the heart. With the aid of a 
simulated radiograph provided in the PCXMC software, the PCXMC-heart simulation was 
produced using the heart at the centre of the field of view at all tube angulations. 
The PCXMC simulation was also able to perform a few extra tasks that were not 
possible in the experiment. The whole body effective dose is available from the PCXMC 
simulation and in the context of breast dose contribution to whole body effective dose this 
can be used to compare with experimental values. The results of effective dose as a function 
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of tube angulation can be found in appendix D. The effective dose to the breast will be 
discussed and compared with measured breast dose later in the section 6.4. 
Risk estimates were also computed in PCXMC for a CA procedure and will be 
discussed in section 6.4. 5.3. BREAST DOSE AND ENTRANCE SKIN DOSE FROM MOCK CA PROCEDURE  
In addition to the single and combined tube angulation configuration experiments, a 
mock CA procedure was performed by an experienced cardiology resident. The mock CA 
procedure consists of an accumulation of the 9 acquisitions as outlined in table 4-5 in chapter 
4, which includes 7 combined tube angulations and 1 single tube angulation from section 
5.1, plus a RAO 33/ CAU 4 configuration with a 9 inch FOV. This is the same sequence of 
acquisitions performed during a routine CA procedure and is collectively called clinical tube 
angulations. The set up of the Gafchromic® XR-QA2 film covered parts of the chest beneath 
the breast slice, the base of each breast slice and the RANDO® posterior. A total of 14 mock 
CA procedures were recorded on the Gafchromic® film in the breasts to ensure substantial 
dose was received for analysis. But only one mock CA procedure was required to record the 
posterior entrance skin dose distribution.  
Figure 5-10 and insets are the two-dimensional dose plots from the mock CA 
procedure of the left and right breasts respectively. Each inset represents the dose deposited 
in the breast region at each plane with insets (a) and (b) being at the chest, insets (c) and (d) 
at breast slice 1 and insets (e) and (f) at breast slice 2. The central area where film placement 
was not possible due to the position of the pegs which hold the breast slices together were 
linearly interpolated for dose. The mean pixel values extracted from the Gafchromic® 
XR-QA2 films were converted to absorbed dose using the ABC enabled calibration curve 
from chapter 3. This calibration curve was chosen because the mock CA procedure was 
performed prior to 2013 using the same batch of film from the ABC enabled calibration.  
As anticipated, the film on each sequential layer towards the breast anterior received 
less radiation than the previous layer as the photons attenuate through the breast layers 
from the posterior. 
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Figure 5-10: Dose distribution of left chest layer (a), breast layer1(c) and breast layer2 (e) and right chest layer 
(b),breast layer1 (d) and breast layer2 (f) from the mock CA procedure. The film placed on the chest layer was 
completely covered by the breast slice. The film placed in the left breast measured more dose than the right.  
(a) (b) 
(d) (c)  
(e) (f) 
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The left breast received more radiation than the right breast in the mock CA 
procedure. This is contrary to the findings in section 5.1 where the right breast consistently 
received a greater dose. This is to do with the table translation movements and subsequently 
the fraction of breast exposed to the primary X-ray beam. Table 5-4 summarises the breast 
dose measurements made from the mock CA procedure.  
 
Table 5-4: Summary of breast measurements made from mock CA procedure 
 Dose per procedure (averaged over 14 
procedures) 
Normalised to DAP 
(mGy/Gy.cm2) 
DAP (Gy.cm2) 14.06 1 
Breast dose (mGy) 1.7 ± 6.5% 0.12 
Left breast dose (mGy) 2.3 ± 6.5% 0.16 
Right breast dose (mGy) 1.17 ± 6.5% 0.08 
 
The posterior entrance skin dose (ESD) was measured as the mean dose recorded on 
the Gafchromic® XR-QA2 film placed at the posterior. The peak skin dose was determined 
first by visually selecting the ROI of overlapped areas, then measuring these selected ROIs 
and finally selecting the ROI that yielded the lowest mean pixel value, which corresponded 
to the greatest colour change on the film. Table 5-5 compares the entrance skin dose (ESD) 
calculated using the conventional method described in section 4.3.2 and measurement made 
with Gafchromic® XR-QA2 film placed on the posterior of RANDO®.  
 
Table 5-5: Summary of entrance skin dose measurements and calculations from mock CA procedure. 
Beam area at skin entrance (cm2) 71.7 
Posterior ESD calculated (Gy) 0.26 
Total irradiated skin entrance area  689 
Posterior ESD measured (Gy) 0.04 ± 6.5% 
Peak skin dose measured (Gy) 0.08 ± 6.5% 
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Figure 5-11 is a reconstructed image of four quadrants of a single sheet of 
Gafchromic® XR-QA2 film after irradiation from the mock CA procedure. This figure 
represents the dose distribution to the posterior ESD. The darker the colouring, the greater 
the dose absorbed at that location. Overlapping of the X-ray fields can also be seen in this 
figure and is a consequence of varying tube angulation for the purpose of examining the 
heart from various angles during the procedure. Figure 5-12 is the dose distribution graph of 
figure 5-11. Areas of overlap that are darker in figure 5-11 are shown as areas of high 
absorbed dose in figure 5-12. 
 
Figure 5-11: mage of the posterior entrance skin dose recorded on Gafchromic® XR-QA2 film (30cm x 30cm). 
The shape of the X-ray  beam is clearly shown. The mock CA procedure performed on RANDO® indicated more 
acquisitions were made on the patient’s left posterior.  
                                                  
Figure 5-12: Corresponding dose distribution graph of figure 5-11 for the posterior entrance skin dose from the 
mock CA procedure. Overlapping fields show a greater absorbed dose to the film and the location most likely to 
exhibit deterministic effects. The skin dose to the posterior is not evenly distributed over the posterior, but 
depends on the tube angulations used in the examination.  
99 | P a g e  
 
From table 5-5 and figure 5-12, the irradiated posterior skin area and calculated beam 
area at skin entrance is very different. Conventional estimates using the method described in 
section 2.5.1 is a gross overestimate of skin dose and in turn deterministic effect. In clinical 
setting, Gafchromic® film is not always available, thus the use of DAP to correlate to skin 
dose is practical. However given the limited amount of information available during a 
procedure, using the inverse square law principle of X-ray beam divergence and geometry, 
inferring the skin dose from the DAP is the simplest approximation.  
Manufactures have adopted the use of an air kerma value at a reference point to 
improve the skin dose estimate in the clinical setting. From a radiation protection 
perspective the skin dose estimate is a threshold trigger for more detailed analysis if it is 
suspected that the dose delivered to the patient exceeds the skin dose limit for deterministic 
effects (2 Gy). The key to improved skin dose estimates is the tube angulations used during 
the procedure. By applying the total irradiated skin entrance area to the equation from 
section 4.3.2, the resultant skin dose is similar to the measured skin dose from the 
Gafchromic® film. Thus the theoretical principle applies, but a better estimate of the 
irradiated skin area is in order. As shown in figure 5-11 the irradiated skin area is dependent 
on tube angulation. The direction of the beam entering the skin posterior is important and so 
is overlapping areas of skin exposed to radiation. Peak skin dose is a better indicator 
compared to entrance skin dose for whether deterministic effects are likely to occur and 
where. 5.4. UNCERTAINTY 
The combination of the uncertainties for the experiment, mock CA procedure and 
simulation is summarised here. The uncertainties listed here include those previously 
described in chapter 3 arising from the film calibration, in chapter 4 from the experimental 
set up, and the total uncertainty applicable to the results.  
For each measurement extracted from the Gafchromic® XR-QA2 film, a sequence of 
processes is required. At each stage of the process, uncertainties are accumulated. Tables 5-6 
and 5-7 below are tallies of the uncertainties leading to the final dose calculation.  
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For the PCXMC simulations, uncertainties for the breast dose and effective dose 
calculations are listed in table 5-8. These arise from statistical methods using Monte Carlo 
simulation and were computed by the software per tube angulation. The number of photons 
per history used in the simulation was chosen to keep the uncertainty less than 10% [126]. 
 
Table 5-6: Contributions to the measurement uncertainty in digitising Gafchromic® XR-QA2 film in the film 
calibration. 
Factors contributing to measurable uncertainty (x) Uncertainty 
Scanner variability 
Scanning orientation 
Film uniformity (pixel value) 
Film net reflectance (film size) 
4% 
2% 
3.5% 
3% 
Total  6.4% 
 
 
 
Table 5-7: Contributions to the total uncertainty  in dose measurement extracted from Gafchromic® XR-QA2 
film for the experiment and the mock CA procedure and from the simulations.  
Uncertainty Experiment Mock CA procedure  
Film calibration 8% 7% 
Curve fitting 14% 9% 
Total uncertainty ±8.5%  ±6.5%  
 
 
  
Table 5-8: Uncertainties in dose calculations from PCXMC simulations. 
Uncertainty Experimental simulation Heart simulation 
Breast dose < 6% <8% 
Effective dose <1% <1% 
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6. DISCUSSION 
 To assess the breast dose in a CA procedure, a number of experiments and 
simulations were performed. Gafchromic® film placed inside RANDO®’s breasts was used 
to measure the absorbed dose at 3 different depth layers in the breasts. This was repeated for 
a series of single tube angulations in the LAO-RAO and CAU-CRA axes and some clinically 
relevant combinations of these. The film provided quantitative results as well as dose 
distributions, showing a relationship between breast dose and tube angulation and 
asymmetric dose distribution between the left and right breast.  
The PCXMC simulation is an easily available tool for estimating breast dose and 
effective dose. It requires the DAP and a few geometric and X-ray generator parameters to 
perform the simulation. The experiment was modelled in the simulation and a comparison 
was made between the measured and predicted results. This yielded some agreement for 
single tube angulations in the sagittal plane but disagreement in the transverse plane and 
combined tube angulations. A simulation of the same tube angulations as the experiment 
but with table movement similar to a CA procedure where the heart is kept at the centre of 
the FOV was also performed and compared with the experimental results.  
The mock CA procedure performed by an experienced cardiology resident, offered 
an example for analysis of the breast dose and entrance skin dose. This provided an 
opportunity to compare a typical CA procedure scenario with the simulations and the 
experiments. 6.1. BREAST DOSE FROM RANDO® USING GAFCHROMIC® FILM 
The trend observed for left and right breast doses as a function of tube angulation 
can be explained in terms of two influences, 1) the fraction of each breast being intersected 
by the beam, and 2) the radiological path length through the torso. This latter refers to the 
intensity attenuated by the materials the beam passes through and is made complex by the 
increasing physical path length with increasing angle, offset in some cases by a reduced 
radiological path length through lung tissue. The use of Gafchromic® film as an area 
dosimeter provides information related to each of these.  
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A collage of Gafchromic® film as depicted in figure 4-4 was placed at each breast 
slice on RANDO® to collect breast dose. Figure 6-1 shows the resultant dose distribution 
collected. The dotted circles show the edge of the posterior surface of each breast slice 
relatively to the edges of the film. Some areas of high dose exposure lie outside the breast 
boundary. Only dose deposited within the breast boundary was used in formulating the 
absorbed breast dose. A circular mask was used when extracting dose from the 
Gafchromic® film to exclude dose outside the breast boundary. The ROIs for each patch of 
film were averaged to obtain the mean pixel value for each layer. Panels (a) to (c) are the 
films on the left chest (beneath breast layer1), breast layer 1, and breast layer 2 respectively. 
Panel (d) to (f) are the films placed for measuring right breast dose.  
 
Figure 6 -1: Gafchromic® film in the left breast for PA tube angulation at chest (a), breast layer1 (b) and  breast 
layer2 (c). The corresponding panels are the films placed in the right breast at chest (d), breast layer1 (e) and  
breast layer2 (f) respectively. The primary X-ray beam path is clearly shown on each film and the dotted circle is 
the breast slice boundary. (Beam’s eye view). 
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Note that the breast slices are slightly elliptical and not identical for left and right 
breasts. The physical dimensions of each breast slice can be found in table 4-1. At each 
subsequent layer, the primary X-ray field diminishes.  
According to the histogram in figure 5-1, the LAO-RAO tube angulations show the 
breast dose is quite symmetric with the exception of 10º where the RAO tube angulation 
yields a greater dose than the LAO. This is evident in the Gafchromic® film at the chest layer 
and is demonstrated in figure 6-2 as dose distribution plots. The left column displays the 
film and the corresponding right column portrays the dose distribution recorded on the film 
for each of the single tube angulations. For large tube angulations such as LAO 30, LAO 40, 
RAO 30 and RAO 40, the primary X-ray beam is hardly visible on the film. In comparison, 
the PA, LAO 10 and RAO 10 show the primary beam clearly on the film. A greater fraction 
of the film is exposed to the primary beam on the right side in RAO 10 than the LAO 10. This 
is a consequence of the asymmetry of breast size and position. 
Although the primary X-ray beam cannot be seen on the films for the larger tube 
angulations, dose was still measured on the film. This would be attributed to scatter 
radiation. The Gafchromic® film gave intensity information on scattered radiation even 
when the breast was not in the primary X-ray beam path.  
The distinct banding effect visible in PA, LAO 10 and RAO 10 in figure 6-2 is an 
artefact. This was a result of the RANDO® slices having slight air gaps between adjacent 
slices, allowing direct X-ray beam to intercept the film.  
The dose decreases at each sequential layer away from the chest demonstrating the 
influence of the radiological path length through the breast slices figure 6-1). The primary 
beam moves outside of the breast as a function of tube angulation, as seen here by the 
fraction of the beam cross-section on the film (figure 6-2). 
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Figure 6-2: Gafchromic® film placed at the chest wall for PA, LAO and RAO tube angulations. Note that the 
two pieces of film are not adjacent to one another, but each lie beneath a breast slice sitting on the chest surface. 
Refer to figure 6-3.   
The film placed at the chest is not perpendicular to the X-ray beam as depicted in the 
CT images of RANDO®, but sits on a slightly curved surface. Figure 6-3 shows the 
placement of the film on the chest (panel a) and three CT images corresponding to 3 
consecutive slices along the z-axis, each at 2.5 cm intervals (panels b-d). The solid mass 
between the lungs is most likely an imitation of the heart as it clearly occupies a larger 
portion of the left lung. Considering the absence of a well defined heart compartment in 
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RANDO® it is assumed this mass is a close approximation of the heart. Although this mass 
seems to morph into the abdomen region as depicted in section 4.1.1 (figure 4-3). 
As you move inferior towards the abdomen, the proportions of lung tissue and soft 
tissue materials inside RANDO® change. In figure 6-3, the CT images show the different 
radiological beam path leading into the chest and then to the breasts. The locations A-F in 
panel (a) of figure 6-3 correspond to the same locations A-F in panels (b) to (d). Locations A 
and D are in a superior slice, B and E are in a central slice and C and F are in an inferior slice. 
Note that the physical beam path in locations A to F are the same, but their radiological 
beam path length varies depending on the material it intercepts. That is an increased 
radiological beam path as a result of more attenuating material.  
Through the progression of each CT image from panel b to d, there is a reduced 
radiological path length in the left side compared with the right side. A beam path through 
more material would result in less dose reaching the film placed at the chest and in the 
breast slices.  
The superior slice shows a greater portion of the radiological beam path being 
through the lung, thus the radiation dose reaching the breast will be more. In the central 
slice, the left breast receives less dose because the heart attenuates a greater portion of the 
X-ray beam whereas the right breast will receive relatively higher dose because of the 
reduced radiological path length from lung tissue. In the inferior slice, the dose to the left 
breast decreases even further as it is attenuated by a larger portion of the heart. The right 
breast is also affected slightly, thus it receives less dose than in the central slice.   
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Figure 6-3: The dose distribution recorded at the chest (a) as a effect of radiological path length leading to the 
RANDO® breasts (b)-(d ). Corresponding beam paths in the CT images are matched  with locations recorded  on 
the film at the chest.  
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The asymmetry between LAO 10 and RAO 10 shown in figure 6-4 could be explained 
by the illustration in figure 6-5. Relative to the PA tube angulation, both LAO 10 and RAO 
10 measured a lower breast dose due to a difference in radiological path length, even though 
the area of the beam intersecting the breasts is similar in each case. The radiological path is 
more attenuated for LAO 10 compared to RAO 10 for the part of the beam that intersects the 
breast, because of the heart sitting more to the left side. Thus LAO tube angulations produce 
lower breast dose than RAO tube angulations.  
In the PA tube angulation only a small portion of the left and right breasts are 
exposed but as the X-ray tube moves into LAO or RAO tube angulation, a larger portion of 
one breast is more exposed than the other. The yellow line representing the X-ray beam path 
in figure 6-5 clearly shows that the X-ray beam misses a large fraction of one breast for LAO 
10 and RAO 10.  
In the LAO 10 scenario a small fraction of the right breast is intercepted by the 
primary beam (figure 6-5), but the contribution to the overall breast dose from the right 
breast is slightly greater than the left (figure 6-4). The radiological beam path indicates that 
less dose will reach the left breast due to attenuation in the RANDO® phantom. These two 
influences, the small fraction of primary beam to the right breast and the increased 
radiological beam path to the left breast, lead to an overall breast dose that is less than the 
PA tube angulation.  
In the RAO 10 condition dose to the right breast has a greater contribution to the 
overall breast dose compounded by a reduced radiological beam path such that more dose 
will reach the right breast. Thus the overall breast dose relative to the PA condition is less, 
but greater than LAO 10.  
When each breast was analysed separately, the left breast dose changes only slightly 
moving from RAO 10 to PA to LAO 10 even though the fraction of left breast exposed to the 
primary X-ray beam clearly diminishes. This suggests that the soft tissue imitating the heart 
sitting slightly skewed to the left is contributing to the left breast dose as scattered radiation.  
In contrast, the right breast dose demonstrates a sharp decrease from PA to LAO 10. 
Looking at the CT images in figure 6-5, a smaller fraction of the right breast is exposed to the 
primary beam in LAO 10 compared to PA. The right breast dose decreases only slightly 
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from PA to RAO 10 even though half of the right breast is now exposed to the primary 
beam, because the radiological beam path has increased.  
 
Figure 6-4: Dose conversion coefficients for RAO 10, PA and LAO 10. The left breast dose does not vary as 
much as the right breast dose when the tube angulation changes. The change from PA to RAO 10 is relatively 
small when compared to the decline from PA to LAO 10.  
 
Figure 6-5: Radiological path length for RAO 10, PA, and LAO 10 tube angulations. The isocentre of the C-arm 
gantry is located  8 cm above the patient table. The X-ray beam path clearly shows the fraction of each breast 
exposed to the X-ray field.  
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A decline in breast dose is observed as the tube angle increases for the LAO tube 
angulations in figure 6-6. This is consistent with the theory that as the tube moves further 
away from a PA tube angulation one breast would be out of the primary beam, thus 
contributing less dose to the overall breast dose. Also an increase in radiological beam path 
would decrease the beam intensity reaching the in-field breast.  
The measured dose to the right breast was consistently higher than the left for all 
tube angulations with the exception of LAO 40. One possibility is the attenuation due to a 
decreased radiological beam path means more dose reaches the film in the right breast as a 
function of increasing tube angle. The percentage difference between left and right breast at 
LAO 40 is smaller than (9%) the uncertainty of the dose measurement which is 13%. The left 
breast measured 7% less dose than the right breast for LAO 30 and 11% less dose for LAO 
10.  
Although the right breast is completely outside of the X-ray beam path in panel (a) of 
figure 6-8 for LAO 30 and LAO 40, the film still recorded a measurable dose. This suggests 
that it could be attributed to scattered radiation from soft tissue inside RANDO®. The soft 
tissue imitating the heart lies in the X-ray beam path to the left breast attenuating a large 
fraction of the dose. Attenuation is due to both absorption and scattering, thus scattered 
radiation from this mass is being recorded on Gafchromic® film situated in the breast slices. 
The right breast is still receiving scattered radiation in addition to less attenuating material 
in the beam path. The scattered radiation to the right breast in LAO 40 is comparable to the 
direct transmission to the left breast which is in the beam.  
A trend was observed in figure 6-7 for the RAO tube angulations, where the breast 
dose decreases as the angle increases. The decline from RAO 10 to RAO 30 is more 
prominent than from RAO 30 and RAO 40. This is because the amount of soft tissue and 
lung tissue traversed by the two further tube angulations are similar as shown in panel (b) of 
figure 6-8.  
The left breast continues to receive less dose as the X-ray beam completely misses the 
left breast as illustrated in panel (b) of figure 6-8. Thus the dose to the left breast is attributed 
to scattered radiation. The percentage difference between left and right breast dose was 27%, 
32% and 26% for RAO 10, RAO 30 and RAO 40 respectively.  
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The scatter radiation contribution is comparable for LAO 40 and RAO 40, but the 
contribution from the primary radiation is slightly different as seen in the left breast dose 
and right breast dose differences.  
There is a greater percentage difference between left and right breast dose in RAO 
configuration compared to LAO. This is attributed to the different amounts of dense tissue 
in the radiological beam paths.  
 
Figure 6-6: Breast dose conversion coefficients for LAO tube angulations and the breakdown of  breast dose to 
left and right.  As the angle increases, the breast dose declines. 
 
Figure 6-7: Breast dose conversion coefficients for RAO tube angulations and the breakdown of  breast dose 
between left and right. As the angle increases, the breast dose declines. 
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Figure 6-8: The radiological path length for LAO (a) and RAO (b) tube angulations. Each tube angulation 
interacts with different material embedded inside RANDO®, producing different breast dose. 
Legend 
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The measured breast dose in the cranial tube angulations were less than the caudal. 
This was because in the cranial tube angulation, the X-ray beam was attenuated by soft 
tissue in the abdominal region before reaching the breasts. Whereas in the caudal tube 
angulation, the X-ray beam was attenuated by lung tissue, which is less dense, thus 
relatively more dose reached the breasts. Figure 6-9 below demonstrates the difference in 
anatomy the X-ray beam travels through for a CAU 40 (a) and a CRA 40 (b) position. 
 
Figure 6-9: X-ray beam path and direction (in yellow and red) through RANDO® for CAU (a) and CRA (b) 
positions. The difference in breast dose arises from the radiological path lengths for these two tube angulations.   
From table 5-2, the left and right breast dose conversion coefficients show 
asymmetry; in contrast to the left and right exit doses these are quite similar for single and 
combined tube angulations. This angular independence suggests the exit dose values are 
representative of scattered radiation collected at the furthest point on the breast on breast 
layer 3. This is because regardless of the radiological path length to the location where the 
exit dose was recorded or the tube angulation, majority of the X-ray beam has been 
attenuated by the torso and breast layers before it even reaches breast layer 3.   
For combined tube angulations, the trend is more difficult to quantify. A significant 
observation is that for combination tube angulations, either the CAU-CRA component or 
LAO-RAO component has dominance over the other. For example, when the combined tube 
angulations were sorted according to their CRA component in ascending order, the 
observation is a decrease in breast dose regardless of the LAO or RAO component as 
depicted in figure 6-10. This observation is also true for the left and right breast dose of the 
same tube angulations except for left breast component of LAO 35/ CRA 31.  
(a) (b) 
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Figure 6-10: Breast dose conversion coefficients for combined tube angulations with a CRA component and the 
breakdown of breast dose between left and right. As the CRA angle decrease, the overall breast dose increased.   
The LAO 35/ CRA 31 combination is somewhat different to the trend of the other 
tube angulations in figure 6-10, however this is easily explained by observing that LAO 35/ 
CRA 31 is in a different quadrant than the others. That is the tube angulations assessed in 
figure 6-10 are mainly in the LAO-CRA quadrant. Thus geometric asymmetry may have an 
effect on the results.  
When combined tube angulations were sorted according to their CAU component in 
ascending order (figure 6-11), it does not closely follow the same influence as observed for 
combination tube angulations with a CRA component. The LAO-RAO component 
dominates the breast dose behaviour in figure 6-11. This is consistent with the explanation of 
attenuating different fraction of the heart in the thoracic volume. The left-right dependence 
is important because of the slight asymmetric geometry of the heart. The X-ray beam 
traverses the lung tissue before reaching the breasts in CAU tube angulations.  
The LAO component would result in an increased radiological path length due to a 
greater fraction of the heart being in the beam. While the RAO component would result in a 
decreased radiological path length due to a smaller fraction of the heart being in the beam. 
This is evident between LAO 42/ CAU 27 and RAO 31/ CAU 28 where the CAU angle 
component is similar, but the breast dose is 23% less.  
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Figure 6 -11: Breast dose conversion coefficients for combined  tube angulations with  a CAU component and  the 
breakdown of breast dose between left and right. As the CAU angle decrease, no obvious trend is observed.   
Comparison with figures figure 6-10 and Figure 6-11 shows that for combined tube 
angulations with a CRA component, the CRA component dominates its behaviour, where an 
increase in CRA angle relates to a decrease in breast dose. This is consistent with the 
explanation of the increased radiological path length in CRA tube angulations. The left-right 
dependence becomes negligible when the X-ray beam traverses the soft tissue in the 
abdomen, followed by attenuating the heart and lung tissue before reaching the breast. 
However for combined tube angulations with a CAU component, the LAO-RAO 
component dominates. This is attributed to the difference in radiological path length in the 
LAO-RAO component, where the fraction of the heart intercepted by the X-ray beam has a 
dominate effect. There is only a limited number of combined tube angulations investigated 
in this thesis. The influence may simply be based on quadrant rather than specific angle.  6.2. BREAST DOSE FROM PCXMC SIMULATIONS COMPARED TO GAFCHROMIC® FILM   
The simulations differ from the experiment in that the X-ray beam is centred on the 
heart. In the experiments, RANDO® does not have a well defined heart; hence the 
experiment was conducted in a reproducible arrangement that placed the isocentre on the 
midline, anterior to the spine. The height and weight of the phantom used in the simulation 
was matched to RANDO specifications, however this doesn’t guarantee the same torso 
thickness and the torso thickness cannot be easily extracted from the simulation. The 
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experimental results from section 5.1 are combined with simulation results from section 5.2 
for comparison in figures 6-12, 6-14 and 6-15.   
PCXMC simulations predicted lower doses than measured, for most tube 
angulations in the transverse plane (figure 6-12). Comparing the experiment with the 
PCXMC-heart simulation, the differences can be partially explained by the difference 
between the experiment having isoscentre above the spine, and PCXMC-heart simulation 
having the heart at isocentre, which can be done since the location of the heart is explicitly 
known to the simulation.  
To test whether this offset was the cause of the dose difference, another simulation 
(PCXMC-experimental) was performed with the mathematical phantom aligned as the 
phantom was in the experiment.  
Results show that this was the dominant factor in the LAO/RAO 10 tube 
angulations, as the new simulated dose (PCXMC-experimental) resembled those measured. 
However at 30º, the PCXMC-experimental simulations overestimated the breast doses. 
 At 40º the two simulations predicted a similar dose to the measured dose, indicating 
that these doses are not very sensitive to the precise location of the beam centre. This makes 
sense for predominantly scattered dose. Interestingly at LAO 40, the PCXMC-heart 
simulation resembled those measured more than the PCXMC-experimental simulation. 
 
Figure 6-12: Breast dose conversion coefficients for Gafchromic® film and PCXMC simulations in the 
transverse plane.  
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One conspicuous case is the PA projection, where measured dose was 3 times higher 
than PCXMC calculation in either configuration. This indicates that the specific size and 
location of the breasts has a significant bearing on the fraction of each breast intersected by 
the beam. Clearly, in the simulations, the breasts are out of the beam, and receive less dose 
than even the 40º cases, indicating only scatter contribution. The figure depicting the breast 
size & shape in the MIRD formalism show how this is possible (figure 6-13). Although 
PCXMC does not show or describe its breast geometry specifically in its documentation, the 
schematic figures shown in figure 6-13 are presented in the software interface.  
 
Figure 6-13: Schematic of the mathematical phantom used in PCXMC showing the size and location of the 
breasts. The red square indicates the X-ray field entering from the posterior in a posterior-anterior (PA) tube 
angulation (adapted from PCXMC software).  
In contrast, all three methods follow the same trend but differ only in magnitude 
(figure 6-14). The CAU-CRA data in figure 6-14 show the consequence of all of these 
projections along the torso midline missing both breasts, and therefore the simulation 
underestimates the breast dose. This is the case regardless of whether the heart is positioned 
at isocentre, or the experimental arrangement is mimicked. In either case, the simulation 
underestimates the measured dose by a factor of 1.6 to 3 over the range of angles between 
CAU 40 to CRA 40. 
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Figure 6-14: Breast dose conversion coefficients for Gafchromic® film and PCXMC simulations in the sagittal  
plane. The breast dose is much lower in the PCXMC simulations than those measured.  
For the combined configurations, figure 6-15 shows the simulations always 
underestimated the measured dose. For the angle combinations involving a CRA tilt, this 
was independent of the isocentre modelled, for left and right or for small and large angles. 
For CAU combinations however, there was a substantial difference between using heart or 
midline isocentre. Interestingly, the heart-isocentre simulations were closer to the measured 
results.  
 
Figure 6 -15: Comparison of the breast dose conversion coefficients in the combined  tube angulations for 
Gafchromic® film and the two PCXMC simulations. The Gafchromic® film always measured a higher dose. 
The anatomical and geometrical differences between experiment and simulations can 
be easily understood with the aid of figures 6-16 and 6-17 respectively. The phantom used in 
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the experiment (RANDO®) does not contain proper, distinct organs, whereas the 
mathematical phantom in PCXMC does. In the experiment, the X-ray beam is attenuating 
through varying amounts of bone, soft tissue and lung tissue, whereas in the simulations the 
X-ray beam is intercepted by bone and various organs. Both RANDO® and the 
mathematical phantom in PCXMC are simplifications of real anatomy in a real patient, 
which is more complex.   
 
Figure 6-16: Human anatomy compared with PCXMC’s mathematical phantom and RANDO® phantom. The 
RANDO® phantom is a simplified version of the human anatomy consisting of a skeleton, soft tissue and lung  
tissue equivalent materials.  
Due to the differences in the phantom composition and distribution, the experiment 
measured almost twice as much dose to the breast than the simulations predicted in the 
sagittal plane. The PCXMC-experimental simulation was set up to replicate the experiment, 
thus the trends were similar, for example the breast dose decreases as the angle increases in 
the transverse plane, with the exception of the PA scenario. As demonstrated previously in 
figure 6-13, the X-ray beam misses both breasts in either simulation under certain conditions, 
which explains why the PCXMC simulations predict a much lower breast dose than the 
measurement from the experiment with RANDO®.   
Once again the experiment did not have a heart to use as the centre for the field of 
view as is the case of a real CA procedure, thus the experiment was set up in a PA position 
and then was not repositioned as the tube angulation changed. The PCXMC-experimental 
simulation replicated the experiment with no table movement after it was set up in the PA 
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position. Thus the X-ray beam paths for PCXMC-heart and PCXMC-experimental 
simulations are different.  
Figure 6-17 clearly demonstrates the differences between the two PCXMC 
simulations for a RAO 10 tube angulation with regards to the location of the heart and the 
surrounding organs in the simulated radiographs. The PCXMC-heart simulation emulates a 
real CA procedure where the floating patient tabletop can be manoeuvred to keep the heart 
in the centre of the field of view. The PCXMC-experimental simulation replicates the 
experiment where the patient table remained stationary for all tube angulations after the PA 
position was set up.  
 
 
 
Figure 6 -17: Radiographs simulated  from PCXMC software in RAO10 tube angulation. (a) The X-ray beam 
size entering the posterior and simulated radiograph for PCXMC-heart simulation. (b) PCXMC-experimental  
simulation. The far right radiographs are duplicates of the adjacent radiograph but with organs obstructing the 
heart removed from view. The blue, white, red, yellow and green organs are the lungs, skeleton, heart, esophagus 
and thymus respectively. 
 
(a) 
(b) 
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The largest influence on dose differences between the experiment and simulations 
appears to be the geometric variation between RANDO® and the mathematical phantom. 
The breasts in particular are quite different in shape and size and consequently also position 
relative to X-ray beams. Perhaps the differences between patients would yield similar 
variation as those seen between simulations and measured dose presented here in the thesis. 
As real patients are unlikely to be exactly the same, the dose to the breast would vary 
accordingly. The differences observed here, may be useful as estimates of uncertainties 
among patients. 
Discrepancies between patients can vary greatly in terms of asymmetry anatomy, 
different breast sizes and even in the position of the breasts with respect to the midline when 
lying supine. Figure 6-18 highlights these variations in real patients with CT images of 8 
female patients aged between 34 – 90 years old, showing very different breast sizes and 
position when lying spine. The 9th CT image is of RANDO®, placed here for comparison. 
The breasts tend to spread out to the patient’s side rather than remain rigid in an upright 
position like on the RANDO® phantom.  
Although the RANDO® breast slices are upright and rigid, they were selected to 
represent the equivalent thickness overlying the chest for a patient with large breasts lying 
supine, which is approximately 5 – 7 cm. This also allowed an experimental setup with the 
SID similar to that used clinically in terms of proximity to patient’s chest. It is anticipated 
that due to gravity, majority of the breast tissue would fall to the patient’s side regardless of 
additional breast size. Thus the experiment with RANDO® is intended to be indicative of a 
typical patient while recognising that considerable variation will exist within the patient 
population.   
The PCXMC simulation is practical for providing estimates because it can simulate 
processes that cannot be easily measured empirically. However a simulation is normally a 
simplified version of real life scenarios, thus a discrepancy between prediction and actual 
measurements appear and a user should have a sense of the uncertainties in an estimated 
dose arising from geometric variation. In this case, the differences presented here could be 
interpreted as uncertainties in the patient population. 
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Figure 6-18: Variations in breast size and breast positions on female patients lying spine. Discrepancies between 
patients can vary greatly and is very  different compared to the RANDO® phantom as well. Patients with small 
breast size tend to have the breast tissue lying close to the rib cage. Patients with large breast size tend to have 
the breast tissue spread out to the sides. Whereas RANDO®’s breasts are very rigid and upright in position.  6.3. BREAST DOSE FROM MOCK CA COMPARED TO EXPERIMENT & PCXMC SIMULATIONS 
The mock CA procedure consists of 9 acquisitions similar to that of a routine CA 
procedure and was performed by an experienced cardiology resident. The breast dose 
extracted from the mock CA procedure was compared with the normalised breast dose 
conversion coefficients developed from the single and combined tube angulation 
experiments. This was also modelled in the simulation.  
The breast dose distributions from the experiment (figure 5-6) and the mock CA 
procedure (figure 5-10) were compared and they yield different results in terms of left-right 
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asymmetric breast dose distribution. Contrary to the finding from the combined tube 
angulation experiment, the mock CA procedure produced a higher dose in the left breast 
instead of the right. This was attributed to the table translation in the mock CA procedure. 
The floating tabletop allows the operator to move the patient such that the heart is always in 
the field of view for the tube angulation selected. The mock CA procedure included tabletop 
movements whereas experiment did not. This was because the mock CA procedure was 
performed by an experienced cardiology resident who was confident in estimating the 
location of the heart in the RANDO® phantom and moved the floating tabletop according to 
his judgement.  
Since the heart is slightly situated to the left and as a result of this floating tabletop 
motion, the left breast would be exposed to relatively more primary beam than the right 
breast, elevating the left breast dose. 
The experiment was performed under controlled conditions by the author who felt 
that it was more practical and reproducible to align the RANDO® phantom in a fixed 
position rather than rely on estimating the location of the heart inside RANDO®, which is 
relatively more subjective. By keeping the tabletop stationary for the controlled experiment 
it removed the table movement uncertainty during these experiments. In addition, the 
author relied on external markers to align RANDO® with respect to a PA tube angulation 
rather than fluoroscopy to align an anatomical landmark (i.e. spine) in the centre of the field 
of view because once the Gafchromic® film was placed inside RANDO®, any exposure 
would affect the actual breast dose measurements recorded on the film.  
In the experiment, the patient table was stationary, thus the left-right asymmetry 
observed in the experiment would be intrinsic to the RANDO® anthropomorphic anatomy. 
A typical patient would exhibit similar asymmetric traits, indicating that breast dose 
distribution is very likely to also be asymmetric in patients. Unfortunately the simulation 
does not provide a distinction between left and right breast dose and it is unclear whether 
such asymmetry is also inherent in the PCXMC mathematical phantom.  
To compare the results from the experiment, mock CA procedure and simulations, 
the normalised breast dose conversion coefficients were applied to the DAP for each 
acquisition as outlined in table 4-5 and summed to calculate the net breast dose . 
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 Compared with the experiment, the mock CA procedure had an acquisition 
(RAO33/ CRA4) performed with a 23 cm FOV. This was because a view of the left 
ventricular is routinely viewed at the end of a CA procedure, which involves changing to a 
larger FOV to observe the full left ventricular function (LV view). It was not possible to 
subtract this acquisition from the mock CA procedure because it has already been recorded 
on the film as part of the breast dose. The experiment did not perform any tube angulations 
with a 23 cm FOV. To overcome this issue, the normalised breast dose from the experiment 
of the equivalent tube angulation on a 15 cm FOV was used instead. In the case of the 
simulations, this additional 23 cm FOV acquisition can be easily simulated and was 
performed. Thus, two values are given for the simulations and the experiment; one 
excluding the 23 cm FOV (8 acquisitions) and one including a 15 cm FOV instead of the 23 
cm FOV (9 acquisitions).  
The PCXMC-heart simulation more closely resembles the mock CA procedure, 
because the operator allowed for floating tabletop movement where he would estimate the 
position of the heart to be at the centre of the field of view. The PCXMC-heart simulation 
calculated a breast dose of 0.95 mGy compared with the measured value from the 
Gafchromic® XR-QA2 film of 1.7 mGy. Table 6-1 summarises the dose measurements from 
the mock CA procedure, PCXMC simulations and the experiment. 
 
Table 6-1: Summary of breast dose from mock CA procedure, PCXMC simulations and the experiment. Values 
in the “8 acquisition”  column represent calculations made without the LV view, whereas values form the “9 
acquisition” column contains the 23 cm LV view. 
Breast dose 8 acquisitions 9 acquisitions  Normalised breast 
dose (mGy/Gy.cm2) 
Mock CA procedure  1.7 ± 0.11 mGy  0.12 
PCXMC-heart simulation 0.64 mGy 0.95 mGy 0.05, 0.07 
PCXMC-experimental 
simulation 
0.56 mGy 0.82 mGy 0.04, 0.06 
Experiment using clinically 
relevant tube angulations  
1.02 ± 0.09 mGy 1.7± 0.15 mGy* 0.07, 0.12 
*The 23 cm FOV was replaced with a 15 cm FOV 
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The PCXMC-heart simulation underestimated the breast dose when compared with 
the mock CA procedure even though it was a better representation of the procedure.  
Interestingly, the normalised breast dose from the mock CA procedure (0.12 mGy/ 
Gy.cm2) is the same as the experiment and twice the PCXMC-experimental simulation (0.06 
mGy/ Gy.cm2). This suggests that the experiment was a close approximation in terms of the 
amount of dose delivered to the breast for the mock CA procedure.  
It also shows the normalised breast dose per procedure is a reasonable coefficient to 
use for breast dose estimates when limited information is available, given that the procedure 
closely resembles the experiment or the mock CA procedure described in this study. When 
the DAP and tube angulations are available per acquisition, the breast dose conversion 
coefficients can be fully utilised. The example prescribed above provides a breast dose 
estimate per CA procedure.  
The range of the breast dose (0.6 – 3.8 mGy) measured and calculated in this study is 
comparatively small and typical of that from scatter radiation. Breast dose reported from the 
literature [76, 81] are in the range of 1.5– 4.2 mGy. Although in 1989, Mustafa and Janeczek 
[82] reported a right breast dose of 0.6 mGy for a cardiac digital subtraction angiography 
(DSA) procedure. Their conclusion was that the left breast and left lung would receive the 
highest doses, which is consistent with the greater left breast dose received from in this 
study (mock CA). From table 5-4 the measured right breast dose from the mock CA 
procedure was 1.17 mGy. The measurement from this study is almost twice that of Mustafa 
and Janeczek’s work, most likely due to technological differences.  
Table translation movement from a clinical setting was difficult to quantify and 
replicate into the simulation. Users of simulation need to be cautious, because the 
mathematical phantom used in PCXMC is somewhat different to a RANDO® phantom. The 
relatively small range of breast dose predicted by the simulation and the measurements give 
credit to both methods.  6.4. EFFECTIVE DOSE ESTIMATED USING PCXMC SIMULATIONS 
The PCXMC simulation featured calculations of the effective dose and risk estimate. 
These were investigated and compared with the mock CA procedure.  
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The measured breast dose from the mock CA procedure was 1.7 mGy. Because dose 
measurements were only made in the breast organ, a whole body effective dose (E) was not 
possible, but a tissue-weighted breast dose (TWBD) can be calculated and compared against 
prediction from PCXMC. The tissue-weighted breast dose is the breast tissue equivalent 
dose multiplied by the breast tissue weighting factor.  
The predicted breast dose from the simulation was 0.95 mGy and the predicted 
whole body effective dose was 2.9 mSv. Thus the percentage contribution of breast dose to 
the whole body effective dose is very small, only 4%, while the heart is a major contributor 
to the effective dose, ranging from 30 – 70% depending on the tube angulation. Table 6-2 is a 
summary of the breast dose, tissue-weighted breast dose, whole body effective dose and 
percentage contribution of tissue-weighted breast dose to the effective dose from the mock 
CA procedure and PCXMC simulations. 
 
Table 6-2: Summary of breast dose, tissue-weighted breast dose, whole body effective dose and  the percentage 
contribution of breast dose to the effective dose from mock CA procedure and simulation. 
 Absorbed 
breast dose 
(mGy) 
TWBD – tissue-weighted 
breast dose (mSv)* 
E (mSv) % contribution 
of TWBD to the 
effective dose 
Mock CA procedure 1.7  0.2 Not 
available 
 
PCXMC-heart simulation 0.9 0.1 2.9  4 
PCXMC-experimental 
simulation 
0.8 0.1 2.3 4 
*Tissue-weighted breast dose = equivalent dose (breast) × wT (breast)  
 
Comparing the TWBD in the individual clinical tube angulation, a similar 
contribution is observed between the two PCXMC simulations. This shows that the TWBD 
contribution to the effective dose is approximately 5-11% only. As expected, the dose to the 
heart is the primary contributor to the effective dose since it is in the X-ray beam for the 
duration of a procedure. The breasts are not always intersected by the X-ray beam during 
clinical tube angulations, and even when they are, in some cases the doses are still only in 
the order of measured scattered dose.  
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Usually the effective dose is not broken down in terms of tube angulations. Figure 
6-19 is a histogram of the normalised effective dose for the simulations in the transverse 
plane for single tube angulations. The effective dose is shown to have an angular 
dependence, where at small angles, little difference is observed between the simulations. At 
large angles, however, their differences start to increase. This angular dependence is 
attributed to the organ dose contributions in the simulation. The effective dose for the 
remaining single and combined tube angulations can be found in appendix D. 
 
Figure 6-19: Effective dose conversion coefficients form the two PCXMC simulations in the transverse plane for 
single tube angulations. The uncertainty is 0.8% (heart) and 0.7 %( experimental).  
Figures 6-20 and 6-21 show the effective dose contribution from the breast, heart and 
other organs from the simulations. The heart contribution is much greater in the PCXMC-
heart simulation than the PCXMC-experimental simulation.  
In the sagittal plane and combined tube angulations, the two simulations yielded a 
similar effective dose. This was because both yielded a similar breast dose (figure 5-8 and 
figure 5-9) and most of the sensitive organs are not in the primary X-ray beam.  
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Figure 6-20: Effective dose contribution from breast, heart and other organs for the PCXMC-heart simulation.  
 
Figure 6-21: Effective dose contributions from breast, heart and other organs for the PCXMC-experimental  
simulation. 
An additional feature of the PCXMC software is calculating risk estimates based on 
the simulation. The typical age of patients who undergo CA procedures is 60 years old or 
over [83,87], thus the input data for risk estimates was entered for a range of age group for 
males and females using the Euro-American mortality data. The simulation data from 
section 6.3 was used to compute the risk estimate. These risk estimates have been 
renormalised to represent a typical CA procedure performed with 9 acquisitions. This was 
done by dividing the effective dose by the DAP from the mock CA procedure (14.06 
mGy.cm2), then multiplying it with a DAP retrieved from patient data (82 mGy.cm2). Table 
6-3 shows the risk of exposure-induced death (REID) for males and females aged 30 – 80 
years old for the PCXMC-heart simulation and table 6-4 is for PCXMC-experimental 
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simulation. The REID is extremely low both for males and females in either simulation. As 
the age group increases, the REID and cancer risks decrease. The probability of breast cancer 
is extremely low, which is consistent with conventional understanding. Lung cancer was the 
highest of the possible cancer risks listed in PCXMC risk estimates, but is still a very low risk 
factor. Even for patients undergoing multiple CA procedures during their lifetime, the 
cancer risk associated directly from a CA procedure is low.  
Table 6-3: REID, breast cancer and  lung  cancer table for males and females in different age groups for an 
effective dose of 16.9 mSv (PCXMC-heart simulation). Quanti ties given by PCXMC are given here to 2  
significant figures. 
 REID Breast cancer Lung cancer 
Age group Male Female Female Male Female 
30 years old 0.09% 0.17% 0.00% 0.06% 0.12% 
40 years old 0.09% 0.17% 0.00% 0.06% 0.12% 
50 years old 0.09% 0.16% 0.00% 0.06% 0.12% 
60 years old 0.09% 0.15% 0.00% 0.05% 0.11% 
70 years old 0.08% 0.12% 0.00% 0.05% 0.09% 
80 years old 0.06% 0.09% 0.00% 0.04% 0.07% 
 
Table 6-4: REID, breast cancer and  lung  cancer table for males and females in different age groups for an 
effective dose of 13.6 mSv (PCXMC-experimental simulation). Quantities given by PCXMC are given here to 2  
significant figures. 
 REID Breast cancer Lung cancer 
Age group Male Female Female Male Female 
30 years old 0.08% 0.13% 0.00% 0.04% 0.09% 
40 years old 0.08% 0.13% 0.00% 0.04% 0.09% 
50 years old 0.07% 0.12% 0.00% 0.04% 0.09% 
60 years old 0.07% 0.11% 0.00% 0.04% 0.08% 
70 years old 0.06% 0.10% 0.00% 0.04% 0.07% 
80 years old 0.05% 0.07% 0.00% 0.03% 0.05% 
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6.5. COMPARISON WITH OTHER WORKS & CLINICAL APPLICATION 
Most of the research conducted in the field of interventional cardiology involves 
assessing radiation-induced skin injuries or stochastic effects. TLDs and DAP are popular 
dosimeter combinations used to assess the correlation between entrance skin dose (ESD) or 
maximum entrance skin dose (MESD) and DAP or effective dose (E) and DAP. Radiographic 
film, radiochromic film and software simulations have also been used in some investigations.  
DAP has the useful property that it is approximately invariant with distance from the 
X-ray tube, so long as the planes of measurement and calculation are not so close to the 
patient or phantom that there is a significant contribution from backscattered radiation. It 
provides an integral of the air kerma over the area of the X-ray beam in a plane 
perpendicular to the beam axis [66]. TLDs have been placed on patient’s posterior skin to 
measure ESD or MESD and inside an anthropomorphic phantom to measure organ dose and 
derive an effective dose. TLDs provide a dose point measurement as oppose to film which 
can provide dose distribution as well.  
Radiographic and radiochromic film as an area dosimeter has the advantage of 
providing dose measurement and dose distribution and is usually used for ESD or MESD 
measurements. Simulations have been used to determine E from DAP measurements using 
various Monte Carlo transport codes and mathematical phantom models.  
Table 6-5 summarises the dose measurements from the literature and compares them 
with this study. This table shows the wide range of DAP and MESD values reported in the 
literature and the relatively smaller range of values reported for E. While there are a 
reasonable number of studies, not every study reports the same information. Therefore there 
are significant gaps in our knowledge.  
Table 6-6 summaries those studies with effective dose conversion coefficients from 
the literature and those that show an angular dependence on E.  Table 6-7 summarises those 
studies with a more detailed breakdown of breast dose as a function of tube angulations.  
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Table 6-5: Summary of DAP, MESD, effective dose and breast dose measurements from interventional cardiology literature. 
Reference Year Method Mean DAP 
(Gy.cm2) 
MESD 
(mGy) 
Mean E (mSv) Breast Dose (mGy) 
Leung and Martin [78] 1996 DAP-patient data 14 - 3.11 - 
Betsou et al [79] 1998 DAP, TLD in phantom & on patient’s skin 30.42 , 54.63 - 5.65  4.25 
Neofotistou et al [80] 1998 DAP-patient data, TLD on patient’s skin 23-79 - 4.6-15.81  - 
Harrison et al [86] 1998 DAP-patient data, XDOSE 20.6 - 3.4 - 
Hansson et al [69] 2000 DAP-patient data, TLD inside & outside 
phantom 
73 277.4 16.8 - 
Van de Putte [70] 2000 DAP-patient data, TLD on patient’s skin, 
MCNP4b2, BodyBuilder 
60.64 267 - - 
Lobotessi et al [81] 2001 DAP-patient data 58.3 - 12.941, 13.416 - 
Vano et al (a) [71] 2001 DAP- patient data, TLD, film  27.3–370.6  107–711  - - 
Vano et al (b) [72] 2001 DAP-patient data, film 46 194-2407 - - 
Delichas et al [87] 2003 DAP-patient data, ODS 60  80.8 - 20.9 - 
Karambatsakidou et al 
[74] 
2005 Film 49 191.17 - - 
Iqeilan [75] 2006 DAP-patient data, XR-R film 78.4 577.57 - - 
Bozkurt and Bor[90]  2007 DAP, MNCP4v2, VIP phantom  - - Refer to table 6-7 Refer to table 6-6 
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Reference Year Method Mean DAP 
(Gy.cm2) 
MESD 
(mGy) 
Mean E (mSv) Breast Dose (mGy) 
Domienik et al [76] 2008 DAP-patient data, TLD, film 16–317  43–1507  - - 
Morrish et al [82] 2008 DAP-patient data 28 – 39.3  - 5.1 – 6.61  - 
Bogaert et al (a) [88] 2008 PCXMC - - Refer to table 6-7 - 
Bogaert et al (b) [77] 2009 DAP-patient data, TLD 55.7 3107 - - 
Compagnone et al [83] 2011 DAP-patient data, MCNP4c2, VIP phantom 45.5 - 8.71, 4.88,  - 
Struelens et al [133] 2011 MCNP-X (v2.5.0), VIP phantom - - Refer to table 6-7 Refer to table 6-6 
Seierstad et al [84] 2012 DAP-patient data, TLD inside phantom 252, 173 53 52, 3.43  1.5 
This thesis 2013 DAP, XR-QA2 film, PCXMC 2.0 143 80 2.99, 2.310  1.7, 0.959, 0.8210  
This thesis 2013 DAP-patient data (50 patients) 82 - - - 
1 NRPB R262 dose conversion coefficients 
2 DAP from patient data 
3 DAP from phantom procedure 
4 Spine – location of TLD on patient’s skin  
5 ICRP 60 
6 FDA model 
7 Mean 
8 Bozkurt model 
9 PCXMC-heart simulation 
10 PCXMC-experimental simulation 
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Table 6-6: Summary of normalised effective dose per CA procedure and as a function of tube angulations. Only the tube angulations that closely matched with those 
measured in this study were compared. Quantities are shown here to 2 significant figures. 
Reference Year Method E/DAP (mSv/Gy.cm2) 
Overall LAO40 LAO30 LAO10 PA RAO10 RAO30 LAO45/CAUD30 RAO30/CAU25 
Betsou et al [79] 1998  0.18         
Delichas et al [87] 2003 ODS-60 0.26 - - - - - - - - 
Schultz and 
Zoetelief [59] 
2005  - 0.441 - 0.422 0.452 0.432 - - - 
Bozkurt and Bor 
[90] 
2007 VIP-
man 
0.13 0.08 
(LAO45) 
- - 0.15 - 0.15 0.12 - 
Bogaert et al [88] 2008 PCXMC 0.19 - - - - - - - - 
Struelens et al [133] 2011  - - 0.26 0.25 - - 0.32 0.228 
(LAO45/CAU25) 
0.22 
Seierstad et al [84] 2012 TLD 0.2 - - - - - - - - 
This study (heart 
sim) 
2013 PCXMC 
2.0 
0.21 0.27 0.24 0.18 0.18 0.21 0.26 0.20 
(LAO42/CAU27) 
0.21 
(RAO31/CAU28) 
This study 
(experimental sim) 
2013 PCXMC 
2.0 
0.16 0.18 0.22 0.2 0.17 0.21 0.22 0.17 
(LAO42/CAU27) 
0.17 
(RAO31/CAU28) 
1 84 kV  
2 75 kV 
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Table 6-7: Summary of normalised breast dose as a function of  tube angulations. Only the tube angulations that closely matched with those measured  in this study were 
compared. Quantities are shown here to 2 significant figures. 
Reference Year Method Normalised equivalent1 breast dose (mSv/Gy.cm2) 
LAO45 LAO30 PA RAO30 LAO45/CAUD30 RAO30/CAU25 
Bozkurt and Bor 
[87] 
2007 Monte Carlo – MCNP4c2 , 
VIP-man, 80 kV  
0.02 - 0.04 0.04 0.03 - 
Struelens et al [130] 2011 Monte Carlo – MCNP-X 
(v 2.5.0), voxel-based 
anthropomorphic phantom 
 0.13 0.12 0.14 0.11 
(LAO45/CAU25) 
0.11 
This study  2013 XR-QA2 film, phantom 0.11  ^ 0.13 0.21 0.14 0.1* 0.12** 
This study 
(simulations) 
2013 PCXMC 0.112,  ^
0.073,  ^
0.092 
0.143 
0.072, 3 0.102 
0.163 
0.072,*  
0.043,*  
0.082, ** 
0.053, ** 
1 Equivalent dose is the absorbed organ dose multiply by the radiation weighting factor of 1 (photons). Refer to section 2.2.2 
2 PCXMC-heart 
3 PCXMC-experimental 
^  LAO40 
* LAO42 / CAU27 
** RAO31 / CAU 28 
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A range of DAP (14 – 370 Gy.cm2) for a CA procedure has been reported from the 
published papers. This reflects on the variability of a CA procedure, which depends on the 
size of patients and experience of the physician. Those studies with a relatively lower DAP 
value were performed on a phantom (this study and [84]) or has been corrected to give the 
equivalent DAP for a standard man [78]. The standard man here is referring to the concept 
of the reference man from ICRP publication 23 [134], which defined a reference individual for 
estimation of radiation dose in health physics. The reference man is defined as being 
between 20 – 30 years of age, weighing 70 kg, is 170 cm in height, and lives in a climate with 
an average temperature of from 10º – 20ºC. He is a Caucasian and is a Western European or 
North American in habitat and custom. The information from ICRP 23 is still considered 
valid and appropriate for radiation protection purposes, but it has been supplemented and 
amended by the ICRP publication 89 [17].  
The MESD range was 39 – 1507 mGy, where the lowest value was reported from this 
study. Domineik et al [76] reported a MESD range of 43 – 1507 mGy illustrating the spread 
of MESD for a CA procedure. Their relatively high MESD is attributed to a higher DAP 
reported (43 – 317 Gy.cm2). A greater MESD may be a result of longer procedure time or 
repeated use of the same tube angulation over the same skin surface.   
Effective dose was reported in the literature, reflecting its importance to the medical 
community and ranged between 2.3 – 20.9 mSv. This study reported the lowest effective 
dose and one of the few studies to provide a breakdown of contributions from individual 
angulations. Table 6-6 showed the overall normalised effective dose conversion factor (mSv/ 
Gy.cm2) from this study is in agreement with published papers [59, 79, 84, 87, 88, 90, 133]. 
Schultz and Zoetelieft [59], Bozkurt and Bor [90] and Struelens et al [133] showed that dose 
conversion coefficient from DAP to E is dependent on exposure conditions, including tube 
voltage and tube angulation.  
The breast dose from this study sampled 3 planes in the breast as opposed to at one 
or a few discrete locations similar to those found in the literature [79] where authors placed 
four TLDs in the breast to derive breast dose. Betsou [79] measured breast dose with 4 TLDs 
in RANDO. The representative cardiac catheterization procedure on the phantom was 54.6 
Gy.cm2. Mustafa and Janeczek [85] also used 4 TLDs to measure the scatter radiation to the 
right breast from a cardiac angiography with just a RAO 30º tube angulation.  
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Bozkurt and Bor [90] used a voxel-based mathematical phantom (VIP-man) to 
compute normalised breast dose as a function of kilovoltage for a selection of tube 
angulations. Their VIP phantom is an improvement over the modified MIRD phantom used 
by PCXMC in terms of being more representative of patients. Thus one expects their 
simulation predictions to most closely match the experiment. However, four of those tube 
angulations were compared with results from this study in table 6-7. Their study predicted 
much lower normalised breast dose than the present study experimental and simulation 
results. Struelens et al [133] also utilised a VIP phantom and Monte Carlo transport codes to 
simulate breast dose for various tube angulations. Five of their tube angulations are 
compared with this study in table 6-7, and were in close agreement with the present study.   
Seierstad et al [84] measured breast dose using TLDs loaded in an Alderson phantom 
and the CA procedure was performed by an experienced cardiac interventionist similar to 
the simulated CA examination in this study (mock CA). So, that procedure most resembles 
this study, and the similarity of results in DAP, MESD, E and breast dose shown in table 6-5 
reflects this in their relatively close agreement. 
This study offers a breast dose normalised to DAP for a set of clinically relevant tube 
angulations. To apply this, simply take the DAP from each acquisition at the end of a 
procedure and match it with the tube angulation used in the procedure and multiply by the 
dose conversion coefficient. For example, assuming a routine CA procedure consists of 8 
tube angulations as described here with the clinical tube angulations, the breast dose 
conversion coefficient is 0.12 mGy /Gy.cm2. The national reference dose in UK [135] for a 
CA procedure is 29 Gy.cm2 from a 2005 review; the breast dose would be 3.48 mGy.  
At the Austin Hospital, Melbourne Australia, the typical DAP for a CA is 82 Gy.cm2 
as determined from the records of 50 patients in 2013. The breast dose corresponding to this 
DAP is 9.84 mGy. For a more detailed analysis, if the DAP is known for each tube 
angulation used in the CA procedure, choosing the breast dose conversion coefficient (or 
closest approximation) and then summing would yield a breast dose for that particular CA 
procedure.   
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6.6. LIMITATIONS AND ADVANTAGES 
Radiochromic film dosimetry 
The measurements made in this experiment were a sample of breast dose collected at 
three different planes in the RANDO® detachable breasts. While only 3 planes represent 
coarse sampling of depth, it exceeds previous studies using a few dose points and therefore 
provides better approximation. 
On the other hand, the radiochromic film is able to capture the two-dimensional dose 
distribution in the breast at the depth where the film was placed in the breast. This is not 
possible with TLDs which can only provide a single dose point measurement. The primary 
beam radiation and scattered beam radiation deposited to the breast can be clearly seen in 
the Gafchromic® film and can be quantified. 
RANDO® 
The RANDO® is an anthropomorphic phantom with detachable breast slices. 
Although it is not an especially accurate representation of a typical female CA patient, it is 
an acceptable approximation. It is available and permits film dosimetry to be performed 
internally. There are however some important differences between RANDO® typical 
patients. As shown in figure 4-1, the detachable breasts on RANDO® sit upright on the chest 
and are very rigid compared to human breasts in figure 4-2, which are more elastic and tend 
to fall to the side when the person is lying supine. 
Breast size variations exist within the patient population as demonstrated in figure 
6-18, where not only the breast size is different but the position of the breasts on the patient’s 
chest can vary. Breast asymmetry also exists in the patient population and it was difficult to 
account for using the RANDO® phantom. The anterior-posterior thickness of breast chosen 
in this study was similar to a real patient with large breasts lying supine. Breast sizes larger 
than B size used on RANDO® would have been unrealistic in comparison to real patients 
lying supine.  
Lastly, RANDO® doesn’t contain any organs. It is comprised of a natural skeleton 
and tissue-simulating material for the lung tissue and soft tissue. A mass of soft tissue that 
appears to imitate the heart can be seen in the axial CT images of RANDO® (figure 4-3) and 
in the comparison diagram between human anatomy and RANDO® anatomy (figure 6-16). 
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Potentially this meant the alignment of the heart was not reproducible, as it was 
subjective to individual operator’s judgement on a less well defined organ. Subsequently, 
this will affect the X-ray beam intersecting the breasts slightly, depending on the position of 
the X-ray beam relative to the heart. Hence the radiological beam path difference will result.   
Overall, the RANDO® phantom is still a useful tool as a reference for dosimetry 
purpose, and is one of the best available for performing direct measurements of internal 
dosimetry. Given the increasing prevalence in obesity, perhaps a more representative 
phantom of an older, larger female person would be useful and could be considered by 
manufacturers.   
PCXMC 
The PCXMC uses the Monte Carlo method to calculate absorbed organ dose and 
effective dose. The process involves tracking photon interactions such as photoelectric effect 
and Compton scattering in a mathematical phantom as described in chapter 2. The 
mathematical phantom is only a reference person and is not necessarily indicative of patient 
population, but it allows for user adjustable weight and height. Compared to the RANDO® 
phantom, the mathematical phantom contains organs and is not restricted by the number of 
breast slices where dose measurements can be obtained. 
Unlike the radiochromic film, PCXMC does not provide information on the dose 
contribution from each breast or of the distribution of the dose within each breast. This 
information is useful for interpreting the contribution from scatter or direct X-ray beam 
intersection with breast tissue. The absorbed breast organ dose calculated in PCXMC only 
provides a single absorbed breast dose value thus asymmetry of dose distribution for an 
organ with a left and right component will not be revealed in the PCXMC software. 
A difference in breast size and location is the main cause of difference between the 
PCXMC estimates and measured doses. From a radiation protection perspective, these 
differences are not significant, but are of interest from a dosimetry viewpoint. However the 
PCXMC does provide effective dose, organ dose and risk estimate without having to make 
any physical measurements, making it a convenient tool in clinical applications. 
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Breast dose from experiments performed in this thesis 
The breast dose derived from this thesis is for single tube angulations and a selection 
of combined tube angulations. When tube angulation and DAP information is gathered from 
a CA procedure, the breast dose can be estimated using table 5-2. 
The experiment was not identical to a real CA procedure because the patient floating 
top table was not utilised to maintain the heart centralised in the field of view. This was 
because it was difficult to visualise the heart in the RANDO® phantom when it does not 
contain any organs. In a real CA procedure, there is free movement of the patient table and 
the heart is kept in the centre of the field of view. This limits the direct correlation between 
this experimental work and a real CA procedure, but it offers an approximation. The two 
simulations indicate the degree that breast doses vary with table translation. The geometric 
set up quantifies their differences. 
Another limitation of this thesis is there are more tube angulations that can be used 
clinically which were not measured. The combined tube angulations were chosen in the 
experiment based on the sequence of acquisition from the mock CA procedure. The mock 
CA procedure was an attempt to replicate a real CA procedure using RANDO® where a 
resident cardiologist performed the examination and patient table movements were allowed 
to estimate the location of the heart. The mock CA procedure may vary slightly to a real CA 
procedure and was used to gauge how well the experimental outcomes compared to a 
relatively more realistic examination.   
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7. SUMMARY & CONCLUSION 7.1. SUMMARY 
 In this thesis the breast dose was measured using Gafchromic® XR-QA2 film for a set 
of single and combined tube angulations and a mock diagnostic coronary angiogram. 
Gafchromic® film was used as a dosimeter to provide spatial distribution of dose deposited 
in the breasts. This builds upon the limited information which has been provided previously 
by point measurements only. Measurements were conducted in an anthropomorphic 
phantom to investigate asymmetric breast dose distribution and geometric variations. The 
breast size was selected based on the approximate anterior-posterior thickness of the breast 
overlying the chest of a patient lying supine. The experimental results were compared with 
an established Monte Carlo simulation, PCXMC. The results achieved indicate the XR-QA2 
film is a suitable method for measuring breast dose provided the accumulated dose is above 
the minimum measurable dose for the XR-QA2 film. 
The experiments showed the two contributing factors to breast dose were 1) the 
fraction of breast intercepted by the primary X-ray beam and 2) the radiological beam path 
encompassing attenuation and scatter from the X-ray beam to the breasts. Thus, solely 
relying on beam geometry is not enough as the experiment has shown by investigating 
breast dose as a function of tube angulation. 
At small angles, the fraction of breast intercepted by the primary X-ray beam can be 
offset by the radiological path length, resulting in a reduced breast dose in the direction of 
the beam.  At large angles, where the physical path length and radiological path are greatest, 
the radiation dose from a direct beam is similar to that from scattered radiation. The 
distinction of breast dose behaviour between LAO-RAO axis and CAU-CRA axis can be 
explained by the differences in radiological path length and anatomy of RANDO®. 
For combined tube angulations, this study showed that one component would 
dominate the other. For a combined tube angulation with a CRA component, the breast dose 
is independent of LAO-RAO component. Whereas for those with a CAU component, the 
breast dose trend is dominated by the LAO-RAO component.  This is due to the difference in 
radiological path lengths between CRA and CAU tube angulations. 
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PCXMC simulation is commonly used to estimate doses from radiological imaging 
procedures. Predictions from the simulation showed that in about 50% of cases it 
underestimates the breast dose compared to measured dose. Predictions are convenient but 
differences in geometry can lead to dose differences. Users of simulation software need to 
take care of geometry differences to avoid gross underestimates or overestimates. 
This investigation also showed the complexity of dose contribution to the breasts and 
the posterior skin in the Gafchromic® film analysis for a mock CA procedure. The 
Gafchromic® film was able to provide spatial distribution and demonstrate the asymmetric 
dose distribution to the breasts. This was an advantage over TLDs, which only provide a 
single data point used to infer breast dose as per other experiments from the literature. 
PCXMC simulation also gives no spatial dose information, assigning a breast dose with no 
distinction from left and right breast. The mock CA procedure provided a net dose to the 
breasts and was used to verify the suitability of the normalised breast dose coefficients from 
the experimental results for the clinical tube angulations.  
The variations in breast dose from the experiment, simulations and mock CA 
procedure can be interpreted as possible variations in real patients. Large variations in 
physical size and location of the breasts exist in patient population, as demonstrated in the 
CT images in figure 6-18. Thus the geometric differences between these three give an 
indication of these variations. 
In summary, the normalised breast dose from the experiment and mock CA 
procedure were the same (0.12 mGy/ Gy.cm2 per procedure). The asymmetry of breast dose 
distribution depends on the geometry of the setup. For the experiment, the right breast dose 
was always greater than the left, whereas for the mock CA procedure it was vice versa. This 
highlights the importance of the fraction of breast intercepted by the X-ray beam in relation 
to the patient setup relative to the heart. 
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7.2. CONCLUSION, OUTCOMES & SIGNIFICANCE 
Gafchromic® XR-QA2 Film  
The characteristics of Gafchromic® XR-QA2 have been reviewed in the literature as a 
suitable medium for measuring dose at diagnostic energies. The scanning protocols used on 
a flatbed document scanner gave an uncertainty of 6.4% in digitising the film to pixel values 
before conversion into dose. To the author’s knowledge, there has been no literature on 
using Gafchromic® XR-QA2 to investigate doses coronary angiography at the time of 
writing.  
For clinical use, it is suggested that the calibration curve consists of a combined fit of 
several calibration curves at different energies as portrayed in chapter 3. This model enables 
easier and more practical conversion of pixel values from the Gafchromic® XR-QA2 film 
into dose for clinical applications. The results achieved in this study indicate the XR-QA2 
film is a suitable method for measuring breast dose provided the accumulated dose is above 
the minimum measurable dose for the XR-QA2 film. As an area dosimeter, it is able to 
evaluate dose distribution which is an advantage over point measurements from TLDs.  
PCXMC estimated breast dose 
 A simulation was performed for a typical CA procedure to be compared with the 
mock CA procedure. However the experiments with the single and combined tube 
angulations were setup slightly different to the typical CA procedure because there was no 
table translation. Hence predictions for a more accurate representation of the experiment 
were performed.  
PCXMC estimates tend to underestimate the breast dose 50% of cases when 
compared with measured dose. By doing both measurements and simulation, we have 
learnt that geometry setup is important to breast dose and is a contributor to the variations 
observed in this study.  
The normalised breast dose per procedure from the PCXMC-heart simulation was 
0.07 mGy/ Gy.cm2 compared to 0.12 mGy/ Gy.cm2 for the mock CA procedure. For the 
PCXMC-experimental simulation the normalised breast dose was 0.04 mGy/ Gy.cm2 
compared to 0.12 mGy/ Gy.cm2 for the clinical tube angulations.  
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PCXMC is an easily available and convenient method for estimating breast dose. 
Limitations include no distinction between left and right breast, hence breast dose 
asymmetry is not observable. But this study has shown breast dose asymmetry does exist. 
Users of such simulations to predict dose need to bear in mind the importance of the 
geometry setup and the asymmetry of breast dose distribution.  
Measured breast Dose 
Normalised breast dose conversion coefficients were determined in a series of single 
and combined tube angulations. A mock CA procedure was performed to validate the 
coefficients yielded from the experiment. These normalised breast dose conversions are 
tabulated as a function of tube angulations in table 5-2.  The normalised breast dose from the 
experiment and mock CA procedure were the same 0.12 mGy/ Gy.cm2 per procedure. 
Breast dose reported in the literature ranges from 0.6 to 4.2 mGy per CA procedure. 
For this experiment, a mock CA procedure performed by an experienced cardiologist, the 
breast dose was measured to be 1.7 ± 0.11 mGy and differed by 44% compared with PCXMC 
simulation for an equivalent arrangement. This is comparable to the mean glandular dose of 
2 mGy from a mammogram. Although this is not exactly an equivalent dose unit for 
comparison, the mean glandular dose is the closest comparator for the breast dose measured 
experimentally in this study.  
Significance  
At this dose level, stochastic risk such as breast cancer from a single CA is unlikely to 
impact the patient and even multiple CA procedures do not show a significant increase in 
breast cancer incidence. This was shown using PCXMC software to generate risk estimates 
for breast cancer to females ranging from 30 to 60 years old using Euro-American mortality 
data with parameters from the mock CA procedures. Incidentally, lung cancer was shown to 
be a greater risk factor for both males and females.  
Novel aspects of this work include providing analysis and distribution of breast dose 
as a function of tube angulations and a mock CA procedure including breakdown between 
left and right breasts. Other authors have used TLDs to measure breast dose, but these are 
only a dose point measurements as opposed to area measurements by film. Various authors 
have also used simulations to model breast dose, but they only provide a single dose value, 
thus the asymmetric breast dose distribution was not observed.  
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Recommendations 
Conventional understanding that breast dose in CA is low remains true. From a 
radiation protection perspective there is an intrinsic association between radiation dose and 
risk. This also reassures patients and staff that although the perceived risk to breasts is now 
greater, the actual risk from breast dose is very small.  
This study provides a method to assess breast dose in CA for a given tube angulation. 
Staff can simply apply the normalised breast dose conversion coefficients from this study 
and multiply by the DAP to estimate breast dose. A simple model was developed that can be 
used to convert measurements from the Gafchromic® XR-QA2 film into absorbed dose for 
clinical applications. Institutional medical physicists could adopt the process described in 
this study to investigate breast dose or other organs of interest.  
Further work can investigate the doses received from a range of cardiac procedures 
performed in interventional cardiology. As a result from the study, the lung and heart might 
be the next organs of interest for this type of detailed study of dose distribution. 
It is hoped that this study will promotes awareness to clinicians in relation to the 
effects of geometric variations to breast dose and help those interested in breast dose in the 
cardiac catheterisation laboratory use this method to assess radiation dose.  
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APPENDIX A A1  X-RAY INTERACTIONS WITH MATTER  
An X-ray is a type of electromagnetic radiation that can transport energy through space as a 
combination of electric and magnetic fields. X-rays can be produced from either electron 
interactions (see section A1.1) or photon interactions (see section A1.2) between the target anode 
material and a stream of energetic electrons emitted from the filament in the cathode inside the X-
ray tube assembly. Figure A-1 is a simple schematic of the X-ray tube. The two electrodes, the anode 
and the cathode, are sealed in a vacuum envelope where the filament produces electrons via 
thermionic emission and the HV circuit controls the potential difference between the cathode and 
anode. This ensures control over the number and speed of the accelerated electrons originating 
from the cathode.  
 
Figure A-1:  Schematic of the X-ray tube. Electrons are produced via thermionic emission at the filament, the HV 
circuit controls the potential difference between the cathode and anode, the electrons produced at the cathode 
are abruptly stopped at the anode causing X-rays to be emitted in all directions, but only those that emerge in 
the cone of the primary beam defined by collimators are useful for imaging [5]. 
A1.1 ELECTRON INTERACTIONS 
X-rays can be produced by a process called Bremsstrahlung radiation, where energetic 
electrons interact with the coulomb field of the nucleus. This results in the electrons being deflected 
from their original direction and energy is loss as depicted in figure A-2.  
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Figure A-2:  Production of Bremsstrahlung radiation. Incident electron is deflected by the positively charged 
nucleus, resulting in energy lost in the form of a photon. 
A1.2  PHOTON INTERACTIONS 
Photons are packets of energy with no mass. They can be attenuated either by absorption or 
scatter from the incident beam. The number of photons removed from the incident beam (∆B) is 
proportional to the thickness of the material (∆x) they pass through, the linear attenuation 
coefficient (μ) and the initial photon number (B): 
 (24). 
The linear attenuation coefficient is the fraction of photons attenuated per thickness of 
material (cm-1). It is dependent on the incident energy and the atomic number of the absorber 
material. Upon integrating equation 24, the number of photons deposited at a certain distance (x) is: 
xeBB µ−= 0  (25). 
The linear attenuation coefficient is also related to the probability of interaction per atom 
that is the cross-section (a), density (ρ), the mass number (A) and the Avogadro’s number (NA=6.022 
x 1023 mol-1) and is given by 
ρ
µσ
×
×
=
A
a N
A
 (26). 
In the energy range used for medical applications, interactions between photons and matter 
are mainly due to four processes, photoelectric effect, coherent scattering, Compton scattering and 
pair production. The total attenuation co-efficient or cross-section is the sum of all interactions such 
that, 
  μ = τ (photoelectric) + σcoh (coherent) + σinc (Compton) + κ (pair production) 
At diagnostic energy levels, photoelectric effect and Compton scattering are the main 
processes involved with X-ray production and scattered radiation. The photoelectric effect is where 
all the energy from an incident photon is transferred to one of the inner shell electrons as kinetic 
energy by relating the linear attenuation coefficient (µ), density (ρ), atomic number (Z) and energy 
(E) with Einstein's photoelectric equation:  
xBB ∆−=∆ µ
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ρ
µ
 (27), 
This only takes place if the incoming photon has sufficient energy to overcome the binding 
energy of the electron.  As a result of the ejected electron, the atom is left in an excited state. The 
resultant vacancy is subsequently filled by an electron from a different energy shell. As the electron 
drops into the vacancy, energy is released in the form of a photon that is characteristic of that 
energy difference between the energy shells, thus these photons are also known as “characteristic 
X-rays” (figure A-3). The energy deposited in a photoelectric event in tissue can be assumed to be 
absorbed at the point of photon interaction [5,136]. Most of the X-rays from the X-ray tube are 
produced by Bremsstrahlung and less than 10% of the X-ray beam is due to characteristic X-rays. 
Figure A-4 is a 90 kVp spectrum of a Tungsten target with added filtration material, where 
the maximum photon energy produced is 90 keV.  The broad spectrum represents the range of 
energies produced by the Bremsstrahlung process and the peaks represent the characteristic X-rays. 
The effect of the added filtration material is to absorb the lower energy photons, therefore 
decreasing the amount of photons from below 35 keV. 
 
Figure A-3:  Photoelectric Effect. This only takes place when the incident photon energy is just above the 
electron binding energy of the atom. 
155 | P a g e  
 
 
Figure A-4:  X-ray spectrum with 4 mm Aluminum filter at 90 kVp. The peaks represent the K-shell characteristic 
X-rays from the Tungsten anode. The broad spectrum is a result of the Bremsstrahlung process and the drop in 
photon fluence from 30 – 15 keV is due to the Aluminum filtering the low energy photons. [121]  
Coherent scattering is a process whereby the photon undergoes a change in direction and 
no energy is converted into kinetic energy. The process occurs mainly at low energies and is always a 
small percentage of the total number of interactions. Compton scattering is when an incident 
photon strikes an outer shell electron, ejecting it from its orbit. Part of the energy is transferred to 
the recoil electron as kinetic energy; the photon is deflected from its original direction with the 
residual energy. The angle of deflection governs the amount of residual energy of the scattered 
photon (figure A-5). The kinetic energy (T) for the recoil electron is given by the following equation 
where (θ) is the angle of scattering for the photon and (α) is the ratio of the energy of the photon to 
the rest energy of the electron [5, 133]. 
)cos1(1
)cos1(
θα
θα
−+
−
= hvT  (28), 
It is independent of atomic number and on average, the fraction of the energy transferred to 
kinetic energy per collision increases with increase in photon energy. In soft tissue the Compton 
process is much more important than either the photoelectric or pair process for photons in the 
range 100 keV to 10 MeV. 
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Figure A-5: Compton scattering. The energy of the recoil  electron is dependent on the scattered angle of the 
scattered photon.  
The probability of each interaction process occurring varies with the incident photon energy 
(hν), and the atomic number (Z) of the absorber material. The relative proportion of the main 
interaction processes in water is plotted against energy in table A-1. For interactions with low energy 
photons or in materials with a high atomic number, the photoelectric process dominates. It is 
important to differentiate between the types of interaction taking place because it will have an 
impact on the energy absorbed per unit material. For example, Compton scattering produces 
scattered radiation, where the cascading effect may deposit a secondary amount of energy outside 
the organ of interest. Whereas compared to photoelectric process, the energy deposited will be 
localised in a very condensed area. Thus the percentage of contribution from each process will have 
an impact on the absorbed dose to the tissue. It is the deposition of energy from these energetic 
electrons resulting from either of these processes that can cause damage to cells.  
Table A-1: Types of photon interactions in water, adapted from source [136] 
 %  interactions by each process 
Energy (keV) Photoelectric 
effect 
Compton 
scattering 
Coherent 
scattering 
20 65.1 23.3 11.6 
40 19.4 69.9 11 
60 6.6 86.6 6.8 
80 2.9 92.6 4.5 
100 1.5 95.3 3.1 
150 0.5 97.9 1.6 
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A2 IMAGE INTENSIFIERS  
Early fluoroscopy produced images that were very dim and required dark adaptation of the 
radiologist's eyes before commencing the examination. Dark adaptation is a technique used to 
enhance the radiologist’s eyes to scotopic (rod) vision by wearing red goggles for 20 to 30 minutes 
prior to the examination. This was because the dim light emitted by the fluoroscopic screens could 
only be interpreted using rod vision [137]. In the 1950s, the image intensifier improved this situation 
by producing an image bright enough to be viewed under normal viewing conditions. Essentially the 
image intensifier is a very large vacuum tube that allowed X-ray photons transmitted through the 
patient to be converted into a light image of sufficient brightness to be displayed on the television 
camera.   
The X-ray photons entering the input phosphor are converted into light photons via 
photoelectric absorption. The light photons are then absorbed by the photo-cathode and converted 
into electrons. The amount of emitted electrons is proportional to the intensity of the light collected 
at the photo-cathode. These electrons gain kinetic energy as they are accelerated by a high potential 
difference between the input phosphor and the output phosphor. Focusing lens is used to direct the 
electrons towards the output phosphor, which has a much smaller surface area compared to the 
input phosphor. At the output phosphor the kinetic energy of the electrons are converted back to a 
light image that is captured through a video camera, and can be viewed under normal conditions by 
the radiologist or further recorded in digital format. The increase in brightness is a result of the 
minification gain, because the initial electron flux from a large input surface area is amplifed when it 
is concentrated onto a much smaller output surface area. In effect, the light image that emerges 
from the output phosphor is much brighter than it would be at the input phosphor layer. In addition, 
the kinetic energy gained by the electrons from the high voltage applied across the image intensifier 
also increases the emitted light from the output phosphor (flux gain) [137]. 
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A3 COMMON VIEWS FOR CORONARY ANGIOGRAM 
Table A-2: Common views for left coronary artery, adapted from [50] 
 Angulations 
1 Posterior-anterior (PA) or mild RAO views with caudal rotation (left main artery) 
2 Frontal PA view with severe cranial angulation (proximal LAD artery) 
3 RAO (20 º -30º) view (LAD & left circumflex (LCX) arteries); 
4 RAO view with caudal angulation (LCX artery, d istal LAD artery, and orig ins of the d iagonal 
arteries 
5 RAO view with cranial angulation (distal LCX, proximal LAD, & proximal diagonal arteries 
6 LAO (60 º) view (LAD, LCX, & diagonal arteries) 
7 LAO view with caudal angulations (proximal LAD artery  & posterolateral branches of LCX 
artery) 
8 LAO v iew with cranial angulation (proximal LAD artery & posterolateral branches of LCX 
artery) 
9 Lateral view (middle & distal LAD & LCX arteries); and 
10 Lateral view with cranial angulation (proximal LAD artery) 
 
 
Table A-3: Common views for right coronary artery, adapted from source [50] 
 Angulations 
1 LAO (60 º) view with cranial angulation (origin , middle & distal branches); 
2 Lateral view (proximal, middle & distal portions); 
3 RAO (30 º) view, (middle portion & acute marginal branches); and 
4 RAO (shallow) view with cranial angulation (origin & distal branches) 
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APPENDIX B B1 RADIOGRAPHIC FILM 
Radiographic film comprises a base coated with a very thin adhesive sub-coating that binds 
gelatine emulsion to the base. Dispersed in the gelatine emulsion are silver halide crystals which 
comprise the active material that absorbs the energy from X-rays and light photons to produce a 
latent image [137]. Figure B-1 illustrates the composition of radiographic film. 
 
Figure B-1 : Cross section of radiographic X-ray film. (a) Schematic of film. (b) A microphotograph of an X-ray 
film. The insert in (b) shows the silver halide crystals in the emulsion [137].  
An intensifying screen is often placed before the film to maximise the conversion of X-rays 
into light photons, because light photons interact more efficiently with the silver halide crystals to 
produce free electrons. The silver halide crystals are normally doped with impurities that form 
“traps” within the crystals. The mechanism behind this process is that a light photon removes an 
electron from a halogen atom in the silver halide crystal. This “free” electron can drift inside the 
crystal and eventually is caught by a “trap”. This effectively holds the electron at least temporarily in 
the trap. Silver ions are attracted to these trap sites from the negatively charged electrons, and 
neutral silver atoms will form, creating a latent image. The chemical process is described in the 
following equations: 
AgBr + photons → Ag+ + Br- + e-  (29) 
Ag+ + e- → Ag   (30) 
A film processor and other chemicals are required for the latent image to become 
permanent on the film and visible. The development process involves a complex series of chemical 
reactions, many of which occur simultaneously inside a film processor. An automated film processor 
transports exposed film through a series of four sections, to perform the following four functions (1) 
development, (2) fixing, (3) washing and (4) drying. 
In the developer the invisible latent image is converted into a visible image composed of 
minute clusters of metallic silver and the fixer removes undeveloped silver halide from the emulsion 
and prepares the film for the remaining steps in the processing cycle. Then the wash removes excess 
chemicals from the processed film and the dryer prepares the film for viewing and storage [137, 
138]. Figures B-2 and B-3 illustrate the activation process of the silver halide crystals and the 
subsequent film development process inside a film processor. 
 
 
(a) (b) 
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Figure B-2: Processing action in radiographic X-ray film emulsion. (a) Schematic showing the distribution of 
silver halide grains with  the gray areas indicating the latent image produced by the exposure. (b) During the 
development process, metallic silver (black) is produced in the exposed grains. (c) In the fixing process, the 
unexposed silver halide grains are removed [137].  
 
 
 
 
Figure B-3: The film processor. The film enters at the feed tray then goes through the four sections, developer, 
fixer, wash and dryer before exiting the film processor to produce a visible radiograph on the film [137]. 
 
 
  
(a) (c) (b) 
161 | P a g e  
 
B2 EXTRACT FROM RTI MANUAL & PIRANHA DOSE PROBE CERTIFICATE 
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The Piranha is manufactured by RTI and was last calibrated in August 2012.  
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B3 CROSS CALIBRATION OF RTI PIRANHA SYSTEMS – RESULTS   
Date tested: 07/02/2012 
Test location: ARPANSA equipment, Toshiba X-ray tube 
General setup: SID @ 100cm, 100mAs, collimated X-ray beam, detectors suspended on a plastic 
holder on a stand 
Table B-1: Cross calibration of RTI piranha systems. 
 kVp ARPANSA dosimeter  (mGy) Austin dosimeter (mGy) %  difference 
1 70 4.248 4.252 0.1 
2 70 4.279 4.286 0.2 
3 70 4.245 4.252 0.2 
4 80 5.608 5.618 0.2 
5 90 7.07 7.082 0.2 
6 100 8.674 8.687 0.1 
 B4 CROSS CHECK BETWEEN TWO BOXES OF GAFCHROMIC® FILM – BATCH A10121203  
X-rayed date: 02/06/2013 Box 2 = from Mr. Anthony Wallace (ARPANSA) 
Films scanned date: 06/06/2013 Box 3 = from Mr. Paul U (Austin Health) 
Films analyzed date: 07/06/2013 Correction factor (f)= 0.9 
 Corrected MPV for box 3 = MPV from Box 3 × f 
 
Figure B-4: Cross check between box 2 and box 3 of XR-QA2 film. At doses greater than 100 mGy, the two 
curves measured almost the same mean pixel value.   
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Table B-2: Cross check with two boxes of XR-QA2 film with batch number A10121203 
 Dose 
(mGy) 
Box 2 Box 3 
 MPV StdDev MPV StdDev 
71 kV 4.043 42923.91 483.772 48033.47 553.801 
 9.739 38043.26 638.076 41757.29 390.175 
 58.359 24158.51 530.278 24350.3 375.862 
 109.599 20201.56 552.952 19620.94 392.855 
84 kV 0 48020.79 554.059 54011.71 477.554 
 4.648 42076.49 461.862 46796.59 564.548 
 10.6 37586.7 395.215 41324.76 499.013 
 64.86 23305.86 485.088 24251.91 367.008 
 119.63 19428.6 480.076 19721.42 406.424 
100kV 6.025 40927.83 407.184 45432.88 419.135 
 8.987 38807.27 506.06 42932 416.582 
 55.705 24541.22 710.027 25440.7 356.071 
 115.868 19471.37 510.536 19516.54 456.438 
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B5 CALIBRATION DATA  
Table B-3: ABC enabled calibrations for 71 and 84 kV. 
71 DA, Filter=7mm Al, dose rate = 0.2104 mGy/s          84 DA, Filter=1mm Cu, dose rate = 0.6368 mGy/s 
mGy Area MGV StdDev  mGy Area MGV StdDev  
67.207 0.17 20032.45 624.309 3.116489 64.265 0.17 20499.3 605.023 2.951433 
67.83 0.17 19771.12 592.443 2.996507 65.52 0.17 20065.42 642.711 3.203077 
68.433 0.17 19559.16 422.153 2.158339 66.8347 0.17 19756.99 408.028 2.065233 
34.186 0.17 24969.93 681.186 *  2.728025 33.328 0.17 25515.88 517.959 2.029947 
34.361 0.17 24710.96 619.444 2.506759 33.7947 0.17 25165.84 586.198 2.329341 
34.072 0.17 24514.35 506.418 2.065802 33.04 0.17 24956.63 471.411 1.888921 
16.9 0.17 31693.11 518.058 1.634608 13.742 0.17 33229.67 512.999 1.543798 
14.737 0.17 31700.49 679.746 2.144276 14.099 0.17 32961.17 621.407 1.88527 
16.43 0.17 31399.52 417.394 1.329301 13.836 0.17 33444.16 633.887 1.895359 
8.249 0.17 38213.89 583.678 1.527398 7.887 0.17 38166.34 544.205 1.425877 
8.23 0.17 37937.2 617.883 1.628699 8.12 0.17 37863.5 617.512 1.63089 
8.2 0.17 37594.25 493.617 1.313012 8.244 0.17 37583.24 627.113 1.668597 
4.094 0.17 42685.61 553.104 1.295762 4.078 0.17 43091.6 478.444 1.110295 
4.11 0.17 42829.78 631.116 1.473545 4.265 0.17 42516.23 429.534 1.010282 
4.105 0.17 42224.73 406.908 0.963672 4.794 0.17 41998.07 509.101 1.212201 
2.049 0.17 45293.29 618.095 1.36465 2.062 0.17 46251.51 513.47 1.110169 
2.062 0.17 45778.72 543.836 1.187967 2.099 0.17 45999.56 526.831 1.145296 
2.059 0.17 45067.23 379.014 0.840997 2.02 0.17 45672.12 520.678 1.140035 
1.008 0.17 49019.67 504.541 1.029262 1.73 0.17 46604.37 534.784 1.147498 
1.122 0.17 48801.6 654.804 1.341768 1.05 0.17 47617.18 531.488 1.116169 
1.042 0.17 48309.4 414.489 0.857988 1.011 0.17 47287.28 321.955 0.680849 
*(polygon tool used) 
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Table B-4: ABC enabled calibrations for 71 and 84 kV. 
97DA, Filter=1mm Cu + 3mm Al + 0.5mm Cu, dose rate=0.928mGy/s 
mGy Area MGV StdDev   
64.874 0.17 20652.78 648.606 3.140526 
64.616 0.17 20345.2 665.825 3.272639 
64.627 0.17 20172.52 514.274 2.549379 
34.023 0.17 25607.03 602.678 2.353565 
29.257 0.17 26939.78 654.246 2.42855 
29.005 0.17 26555.14 477.223 1.797102 
15.922 0.17 32498.21 651.657 2.005209 
14.049 0.17 33599.35 585.481 1.742537 
14.956 0.17 32445.41 542.631 1.672443 
7.122 0.17 39880.36 583.718 1.463673 
8.134 0.17 38975.51 663.632 1.70269 
7.446 0.17 39198.77 422.177 1.077016 
3.93 0.17 43394.67 584.494 1.346926 
4.161 0.17 42504.4 665.961 1.566805 
3.571 0.17 42863.54 470.318 1.097245 
2.364 0.17 45853 544.533 1.187562 
1.898 0.17 46118.42 498.553 1.081028 
2.003 0.17 45371.71 483.884 1.066488 
0.9957 0.17 48305.73 511.996 1.059907 
1.229 0.17 47308.84 462.627 0.977887 
1.57 0.17 46149.99 464.54*  1.006587 
*(polygon tool used) 
 
 
 
 
168 | P a g e  
 
Table B-5: ABC disabled calibration results for 71 kV. 
Film # MPV 1 (L) MPV 2 (R) MPV 3 AVG Piranha – Dose (mGy) 
71_36 46261.26   46261.26 0 
71_31   43733.85 43733.85 1.647 
1, 4 44546.75 44790.05  44668.4 1.91 
71_33   42617.66 42617.66 3.37 
2, 5 42413.25 42683.59  42548.42 4.00 
71_37   39882.51 39882.51 5.11 
3, 6 39416.05 39833.01  39624.53 7.72 
71_28   38733.33 38733.33 8.57 
7, 10 36695.79 37223.79  36959.79 11.72 
71_29   35393.12 35393.12 13.10 
8, 11 34273.4 34814.48  34543.94 16.25 
71_30   33653.74 33653.74 17.64 
9, 12 32343.52 32660  32501.76 20.73 
71_25   31836.61 31836.61 21.68 
13, 16 26558.9 26939.23  26749.07 41.62 
71_26   26921.16 26921.16 41.66 
14, 17 21365.83 21535.46  21450.65 83.48 
71_27   21450.72 21450.72 84.98 
15, 18 19868.18 20150.34  20009.26 104.39 
71_32   19626.89 19626.89 117.04 
19, 22 18822.82 19148.72  18985.77 126.38 
71_33   18823.23 18823.23 138.76 
20, 23 18191.09 18314.23  18252.66 147.48 
71_34   18258.05 18258.05 157.29 
21, 24 17566.28 17752.86  17659.57 168.56 
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Table B-6: ABC disabled calibration data for 84 kV. 
Film # MPV 1 (L) MPV 2 (R) MPV 3 AVG Piranha - Dose (mGy) 
84_25 47544.23   47544.23 0.00 
84_25_1   46277.33 46277.33 1.26 
1, 4 45193.72 44505.57  44849.65 1.33 
84_26   45100.95 45100.95 2.45 
2, 5 43709.67 43645.36  43677.52 2.65 
3, 6 40568.11 40503.01  40535.56 6.22 
84_27_1   41102.61 41102.61 7.01 
84_30   36294.92 36294.92 14.17 
7, 10 35379.08 35643.01  35511.04 14.30 
84_29   31578.72 31578.72 24.94 
8, 11 30759.13 31039.13  30899.13 25.02 
84_28_1   30616.01 30616.01 28.53 
9, 12 29701.35 30081.72  29891.54 28.60 
84_33   27507.21 27507.21 42.73 
13, 16 26267.81 26773.58  26520.7 42.77 
84_32   24227.7 24227.7 64.13 
14, 17 23055.85 23506.99  23281.42 64.17 
84_31   22149.59 22149.59 85.61 
15, 18 19894.11 20062.41  19978.26 106.97 
84_36   19304.54 19304.54 128.62 
19, 22 18805.91 18974.41  18890.16 129.21 
20, 23 18099.68 18251.3  18175.49 150.86 
84_35   17946.67 17946.67 171.85 
21, 24 17493.38 17574.34  17533.86 172.48 
84_34   17065.72 17065.72 215.09 
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Table B-7: ABC disabled calibration data for 97 kV. 
Film # MPV 1 (L) MPV 2 (R) MPV 3 AVG Piranha - Dose (mGy) 
97_28 48124.53   48124.53 0.00 
97_19   45068.43 45068.43 2.64 
1, 4 43320.04 43132.19  43226.11 2.65 
2, 5 41142.83 41632.59  41387.71 4.83 
97_20   42602.81 42602.81 5.24 
97_21   40426.61 40426.61 8.20 
3, 6 37928.09 38325.57  38126.83 9.26 
97_22   37143.64 37143.64 13.17 
7, 10 33734.93 34139.58  33937.25 17.45 
34, 35, 36 32122.93 32038.36 31871.16 32010.81 23.25 
8, 11 28336.76 28761.48  28549.12 33.87 
97_23   29143.6 29143.6 34.88 
9, 12 26179.41 26421.92  26300.67 45.53 
97_24   26576.87 26576.87 46.56 
13, 16 23381.84 23971.47  23676.66 63.62 
97_25   23329.97 23329.97 69.95 
26, 27 21649.35 21782.19  21715.77 90.28 
97_29   21658.09 21658.09 91.12 
97_30   20794.41 20794.41 98.04 
97_32   20375.9 20375.9 110.15 
14, 17 19758.23 19987.62  19872.92 112.15 
39, 40 19733.23 19770.28  19751.76 118.54 
97_31   19476.93 19476.93 126.38 
15, 18 18176.29 18392.38  18284.33 150.62 
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APPENDIX C C1 ANATOMICAL LANDMARKS  
Table C-1: Measured dimensions for each slice of the RANDO torso. Slice 12 and 13 were found stuck together 
because of the age of the phantom, the internal material were stuck together. 
Slice 
number 
Approx. corres ponding  
anatomical landmark 
Length 
(cm) 
Width 
(cm) 
Thickness 
(cm) 
Measured 
Weight 
(kg) 
Calculated 
Volume 
(cm3) 
11 C8 18 40 2.5 1.1 1800 
12 T1 Stuck to slice 13 2.5 2.7 - 
13 T2 21 39.5 2.5 2073.8 
14 T3 20.1 39.5 2.5 1.4 1984.9 
15 T4 21.2 39 2.5 1.35 2067 
16 T5 22.1 34.8 2.5 1.3 1922.7 
17 T6 22.5 32.5 2.5 1.25 1828.1 
18 T7 21.9 31.4 2.5 1.25 1719.2 
19 T8 21.8 30.7 2.5 1.35 1673.2 
20 T9 21.6 30.2 2.5 1.35 1630.8 
21 T10 21.4 29.4 2.5 1.35 1572.9 
22 T11 21 28.7 2.5 1.35 1506.8 
23 T12 20.9 28.1 2.5 1.3 1468.2 
24 L1 20.9 27.5 2.5 1.25 1436.9 
25 L2 21 26.9 2.5 1.25 1412.3 
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C2  MATLAB INTERPOLATION  
Interpolation example for film “A3” 
%interpolation for gaps. Dated 20130613 
 
%A3 
t=[1 2 4 5]; p=[A3(2,1),A3(2,2),A3(2,4),A3(2,5)]; A3(2,3)=interp1(t,p,3); 
t=[1 2 4 5]; p=[A3(3,1),A3(3,2),A3(3,4),A3(3,5)]; A3(3,3)=interp1(t,p,3); 
t=[1 2 4 5]; p=[A3(4,1),A3(4,2),A3(4,4),A3(4,5)]; A3(4,3)=interp1(t,p,3); 
 
Extrapolation example for left top edge of film “L1Left_13”  
%Date: 22/06/2013. extrapolate edges. Left top edge 
m=[1 3];p=[L1Left_13(5,4),L1Left_13(4,5)]; L1Left_13(4,4)=interp1(m,p,2); 
m=[1 4];p=[L1Left_13(5,2),L1Left_13(2,5)]; L1Left_13(4,3)=interp1(m,p,2);L1Left_13(3,4)=interp1(m,p,3); 
m=[1 5];p=[L1Left_13(5,1),L1Left_13(1,5)]; L1Left_13(4,2)=interp1(m,p,2);L1Left_13(3,3)=interp1(m,p,3); 
L1Left_13(2,4)=interp1(m,p,4); 
 
m=[1 3]; p=[L1Left_13(5,1),L1Left_13(4,2)]; L1Left_13(4,1)=interp1(m,p,2); 
p=[L1Left_13(4,2),L1Left_13(3,3)]; L1Left_13(3,2)=interp1(m,p,2); 
p=[L1Left_13(3,3),L1Left_13(2,4)]; L1Left_13(2,3)=interp1(m,p,2); 
p=[L1Left_13(2,4),L1Left_13(1,5)]; L1Left_13(1,4)=interp1(m,p,2); 
 
p=[L1Left_13(4,1),L1Left_13(3,2)]; %L1Left_13(3,1)=interp1(m,p,2); 
p=[L1Left_13(3,2),L1Left_13(2,3)]; L1Left_13(2,2)=interp1(m,p,2); 
p=[L1Left_13(2,3),L1Left_13(1,4)]; L1Left_13(1,3)=interp1(m,p,2); 
 
p=[L1Left_13(3,1),L1Left_13(2,2)]; L1Left_13(2,1)=interp1(m,p,2); 
p=[L1Left_13(2,2),L1Left_13(1,3)]; L1Left_13(1,2)=interp1(m,p,2); 
p=[L1Left_13(2,1),L1Left_13(1,2)]; L1Left_13(1,1)=interp1(m,p,2); 
 
m=[1 3];p=[L1Left_13_flip2(5,1),L1Left_13_flip2(4,2)]; L1Left_13_flip2(4,1)=interp1(m,p,2); 
m=[1 3];p=[L1Left_13_flip2(4,1),L1Left_13_flip2(3,2)]; L1Left_13_flip2(3,1)=interp1(m,p,2); 
m=[1 3];p=[L1Left_13_flip2(3,1),L1Left_13_flip2(2,2)]; L1Left_13_flip2(2,1)=interp1(m,p,2); 
m=[1 3];p=[L1Left_13_flip2(2,1),L1Left_13_flip2(1,2)]; L1Left_13_flip2(1,1)=interp1(m,p,2); 
 
m=[1 3];p=[L1Left_13_flip2(4,14),L1Left_13_flip2(5,15)]; L1Left_13_flip2(4,15)=interp1(m,p,2); 
m=[1 3];p=[L1Left_13_flip2(3,14),L1Left_13_flip2(4,15)]; L1Left_13_flip2(3,15)=interp1(m,p,2); 
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m=[1 3];p=[L1Left_13_flip2(2,14),L1Left_13_flip2(3,15)]; L1Left_13_flip2(2,15)=interp1(m,p,2); 
m=[1 3];p=[L1Left_13_flip2(1,14),L1Left_13_flip2(2,15)]; L1Left_13_flip2(1,15)=interp1(m,p,2); 
 
Two-dimensional dose plot of skin posterior  
%% Load image data 
%==================================================% 
FILE = 'H:\THESIS\Matlab Works\SkinDose\Head L002.tif'; im = imread(FILE); 
FILE2 = 'H:\THESIS\Matlab Works\SkinDose\Head R001.tif'; im2 = imread(FILE2); 
FILE3 = 'H:\THESIS\Matlab Works\SkinDose\End L004.tif'; im3 = imread(FILE3); 
FILE4 = 'H:\THESIS\Matlab Works\SkinDose\End R003.tif'; im4 = imread(FILE4); 
 
%% Get image info 
%==================================================% 
% imageinfo(FILE); 
 
%% Get red image 
%==================================================% 
im_red = im(:,:,1); im_red2 = im2(:,:,1); 
im_red3 = im3(:,:,1); im_red4 = im4(:,:,1); 
 
%% Apply the function 
%==================================================% 
% Try to convert to single so we can multiply by  
% a floating point numbers. e.g. exp() 
im_red = cast(im_red, 'single'); im_red2 = cast(im_red2, 'single'); 
im_red3 = cast(im_red3, 'single'); im_red4 = cast(im_red4, 'single'); 
 
a = -0.01551; b = 3.425; c = 9.783; d = -1.18; 
im_redn=(im_red-35670)/9681; im_redn2=(im_red2-35670)/9681; 
im_redn3=(im_red3-35670)/9681; im_redn4=(im_red4-35670)/9681; 
 
doseLeftHead = a*exp(b*(im_redn))+c*exp(d*(im_redn)); 
doseRightHead = a*exp(b*(im_redn2))+c*exp(d*(im_redn2)); 
doseLeftEnd = a*exp(b*(im_redn3))+c*exp(d*(im_redn3)); 
doseRightEnd = a*exp(b*(im_redn4))+c*exp(d*(im_redn4)); 
 
%% Show the result 
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%==================================================% 
M=max(max(doseLeftHead)); 
M2=max(max(doseRightHead)); 
M3=max(max(doseLeftEnd)); 
M4=max(max(doseRightEnd)); 
M5=[M;M2;M3;M4]; High=max(M5); 
cLow = 0.0; 
cHigh = High; 
 
imshow(doseLeftHead);colorbar;caxis([cLow cHigh]);colormap(jet);   
figure,imshow(doseRightHead);colorbar;caxis([cLow cHigh]);colormap(jet);   
figure,imshow(doseLeftEnd);colorbar;caxis([cLow cHigh]);colormap(jet);  
figure,imshow(doseRightEnd);colorbar;caxis([cLow cHigh]);colormap(jet); 
 
%Right click legend in each figure to use "interactive colormap shift" 
%to change colormap scale to match all four figures before saving as 
%.png for Gimp editing. 
%starting from 140, move to 40. 
%================================================% 
%another method for displaying the results 
%cmin = 0.0; 
%cmax = High; 
%clims = [cmin cmax] 
 
%figure,imagesc(doseLeftHead,clims);colormap(jet);colorbar; 
%figure,imagesc(doseRightHead,clims);colormap(jet);colorbar; 
%figure,imagesc(doseLeftEnd,clims);colormap(jet);colorbar; 
%figure,imagesc(doseRightEnd,clims);colormap(jet);colorbar; 
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C3  PCXMC SIMULATION PARAMETERS 
Table C-2: Summary of geometric parameters used in the PCXMC simulations. 
 Heart Spine 
 X ref Y ref Z ref FSD Beam 
size 
X ref Y ref Z ref FSD Beam 
size 
LAO 40º -3.75 1.5 48.47 62.56 9.53 -6.71 6 48.61 62.56 9.53 
LAO 30º -2.35 1.5 48.47 63.76 9.72 -4.62 6 48.61 63.76 9.72 
LAO 10º 0.15 1.5 48.47 64.88 9.89 -1.41 6 48.61 64.88 9.89 
PA 1.35 1.5 48.47 65 9.91 0 6 48.61 65 9.91 
RAO 10º 2.27 1.5 48.47 64.88 9.89 1.41 6 48.61 64.88 9.89 
RAO 30º 4.05 1.5 48.47 63.76 9.72 4.62 6 48.61 63.76 9.72 
RAO 40º 5.35 1.5 48.47 62.56 9.53 6.71 6 48.61 62.56 9.53 
CAUD 40º 1.12 1.5 51.95 62.56 9.53 0 6 55.33 62.56 9.53 
CAUD 30º 1.12 1.5 50.95 63.76 9.72 0 6 53.23 63.76 9.72 
CAUD 10º 1.12 1.5 49.25 64.88 9.89 0 6 50.02 64.88 9.89 
PA 1.35 1.5 48.47 65 9.91 0 6 48.61 65 9.91 
CRAN 10º 1.12 1.5 47.65 64.88 9.89 0 6 47.2 64.88 9.89 
CRAN 30º 1.22 1.5 45.65 63.76 9.72 0 6 43.99 63.76 9.72 
CRAN 40º 1.22 1.5 44.35 62.56 9.53 0 6 41.9 62.56 9.53 
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APPENDIX D D1  EFFECTIVE DOSE FROM PCXMC SIMULATIONS 
Table D-1: Effective dose conversion coefficients calculated from two PCXMC simulations for single and 
combined tube angulations. PA is shaded in gray. 
Effective dose conversion coefficients (mSv / Gy.cm2) 
Tube angulation Heart as the target organ Experimental set up 
LAO 40º 0.265 0.18 
LAO 30º 0.24 0.215 
LAO 10º 0.175 0.167 
PA 0.181 0.174 
RAO 10º 0.206 0.206 
RAO 30º 0.26 0.217 
RAO 40º 0.271 0.183 
CAUD 40º 0.144 0.142 
CAUD 30º 0.159 0.156 
CAUD 10º 0.175 0.171 
PA 0.181 0.174 
CRAN 10º 0.178 0.174 
CRAN 30º 0.2 0.192 
CRAN 40º 0.192 0.191 
RAO 6º / CRA 40º 0.19 0.152 
RAO 2º / CRA 30º 0.198 0.159 
LAO 35º / CRA 31º 0.214 0.162 
RAO 33º / CRA 4º 0.264 0.184 
LAO 34º / CAU 6º 0.246 0.18 
LAO 42º / CAU 27º 0.202 0.17 
RAO 31º / CAU 28º 0.208 0.17 
 
